Sentence,class,file
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/e8/rrw059.PMC5321179.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/92/3b/rrw062.PMC5321180.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/39/40/rrw065.PMC5321181.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a7/9f/rrw069.PMC5321182.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/61/rrw071.PMC5321183.pdf
NCCN Clinical Practice Guidelines in Oncology https://www.nccn.org/professionals/ physician_gls/f_guidelines.asp .,Non-OADS,/arxiv_data1/oa_pdf/6b/61/rrw071.PMC5321183.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/4e/rrw074.PMC5321184.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the originalwork is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/76/8f/rrw076.PMC5321185.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/41/rrw078.PMC5321186.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/02/5d/rrw081.PMC5321187.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/e7/rrw082.PMC5321188.pdf
ACKNOWLEDGEMENTS The authors are grateful to all members of the Arimura Laboratory( http://www.shs.kyushu-u.ac.jp/~arimura ) for their valuable com- ments and helpful discussion.,Non-OADS,/arxiv_data1/oa_pdf/c4/e7/rrw082.PMC5321188.pdf
"Cornell University, 2008. http://svmlight.joachims.org/ 19.",Non-OADS,/arxiv_data1/oa_pdf/c4/e7/rrw082.PMC5321188.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/46/94/rrw083.PMC5321189.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/77/rrw085.PMC5321190.pdf
"http://ec.europa.eu/health/ scienti ﬁc_committees/emerging/docs/scenihr_o_041.pdf (9 May 2016, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/5d/77/rrw085.PMC5321190.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/6d/rrw086.PMC5321191.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4a/ae/rrw087.PMC5321192.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/01/22/rrw089.PMC5321193.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/67/a0/rrw091.PMC5321194.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/56/21/rrw096.PMC5321195.pdf
"See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.ONLINE LETTERS TO THE EDITOR diabetes.diabetesjournals.org DIABETES, VOL.",Non-OADS,/arxiv_data1/oa_pdf/44/c4/zdbe3.PMC5321248.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3f/62/emss-71567.PMC5321284.pdf
Ethical Note Our study was approved by the scientific committee of the ‘Nouragues Ecological Research  Station’ where fieldwork was conducted ( http://www.nouragues.cnrs.fr ).,Non-OADS,/arxiv_data1/oa_pdf/3f/62/emss-71567.PMC5321284.pdf
"Available at: http://www.spatialecology.com/ htools Brown JL, Morales V , Summers K. Divergence in parental care, habitat selection and larval life history  between two species of Peruvian poison frogs: an experimental analysis.",Non-OADS,/arxiv_data1/oa_pdf/3f/62/emss-71567.PMC5321284.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjgh-2015-000007).,Non-OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
http://apps.who.int/ebola/current-situation/ebola-situation-report-5-august-2015 (accessed 10 Aug2015).,Non-OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
http://www.who.int/csr/resources/publications/ebola/ health-worker-infections/en/ (accessed 29 May 2015).,Non-OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
http://www.worldbank.org/en/topic/poverty/publication/socio-economic-impacts-ebola-sierra-leone (accessed 24 Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
https://data.hdx.rwlabs.,OADS,/arxiv_data1/oa_pdf/be/1b/bmjgh-2015-000007.PMC5321298.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
http://www.irp.wisc.edu/publications/focus/pdfs/foc142e.pdf (accessed 2 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
https://www2.deloitte.com/content/dam/Deloitte/global/ Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-south-africa.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
http://www.who.int/ mediacentre/news/releases/2015/caesarean-sections/en/ 8.,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
2015. http://allafrica.com/stories/201507170479.html 10.,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
http://ewn.co.za/2015/02/18/ Are-private-hospitals-pushing-pregnant-women-to-have-C-Sections 11.,Non-OADS,/arxiv_data1/oa_pdf/18/c8/bmjgh-2015-000013.PMC5321299.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
1980. http://www.who.int/ surgery/strategies/Mahler1980speech.pdf?ua=1 2.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. https://sustainabledevelopment.un.org/content/documents/7891TRANSFORMING%20OUR%20WORLD.pdf 15.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. http://www.royalcollege.ca/portal/page/portal/rc/about 22.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2012. http://www.cosecsa.org/test/ uploads/COSECSA%20Strategic%20Plan%20(IX)2012-2014.pdf 24.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. https://www.rcsi.ie/cosecsa 25.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2014. https://www.aamc.org/download/397432/data/2014gqallschoolssummaryreport.pdf 30.,OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2014. http://ifmsa.org/wp-content/uploads/2015/05/2014MMPS_02_Access-to-Safe-Surgery-and-Anaesthesia-for-All.pdf 43.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2002. http://www.oecd.org/dac/stats/45539274.pdf63.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. http://www.oecd.org/dac/stats/documentupload/ODA%202014%20Tables%20and%20Charts.pdf 64.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. https://www.imf.org/external/np/exr/contacts/contacts.aspx 66.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2014. http://www.designthatmatters.org/blog/?tag=Lemelson20th 81.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
"Medical devices: analysis of results of the baseline country survey, 2013update 2013. http://www.who.int/gho/health_technologies/medical_devices/en/ 87.",OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2012. http://www.lessonsfromhaiti.org/download/Report_Center/accompaniment-in-aid-deliverycon 96.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. http://www.surgeons.org/news/surgical-colleges-support-the-lancet-commission-on-global-surgery/ 97.,Non-OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
2015. http://www.who.int/healthinfo/indicators/2015/en/ 99.,OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
"2015. http://www.lancetglobalsurgery.org/#!indicators/o217z Ng-Kamstra JS, et al.BMJ Glob Health 2016; 1:e000011.",OADS,/arxiv_data1/oa_pdf/45/49/bmjgh-2015-000011.PMC5321301.pdf
http://www.ncbi.nlm.nih.gov/pubmed/9328501#cm9328501_142 5.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
https://www.icc-cpi.int/NR/rdonlyres/8FF91A2C-5274-4DCB-9CCE-37273C5E9AB4/282477/160910VPRSBookletEnglish.pdf 9.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
http://www.ohchr.org/Documents/Publications/training8Rev1en.pdf 10.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
https://www.hrw.org/about-our-research#4 11.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
http://www.codesria.org/spip.php?article586 13.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
http://apps.who.int/iris/bitstream/10665/89966/1/9789241506021_eng.pdf 16.,OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
https://www.scribd.com/doc/65051634/Courting-Conflict-Justice-Peace-and-the-Icc-in-Africa 22.,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/bmjgh-2015-000001.PMC5321303.pdf
Data from 2001 and 2010 available44 *Global Health Observatory Data Repository; http://apps.who.int/gho/data/node.main.488?lang=en.,OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"†European health for all database (HFA-DB), WHO Regional Office for Europe, http://data.euro.who.int/hfadb/.",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
‡http://www.who.int/tb/country/en/.,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"As for measuring, estimating and monitoring risk factors, the WHO ’s STEPwise approach to non- communicable disease risk factor surveillance (STEPS, see http://www.who.int/chp/steps/riskfactor/en/) is awell-established instrument for obtaining core data on risk factors that determine the burden of disease.",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"New York: United Nations Independent Expert Advisory Group Secretariat, 2014. http://www.undatarevolution.org/wp-content/uploads/2014/11/A-World-That-Counts.pdf (accessed 8 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"Geneva: Word Health Organization, 2009. http://www.who.int/healthinfo/HSS_MandE_framework_Nov_2009.pdf (accessed 8 Feb 2016).4. WHO.",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"Geneva: World Health Organization, 2010. http://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf (accessed 8 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"Geneva: The World Health Organization and The World Bank, 2014. http://apps.who.int/iris/bitstream/10665/112824/1/WHO_HIS_HIA_14.1_eng.pdf (accessed 8 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
Converging health systems frameworks: towards a concepts-to-actions roadmap forhealth systems strengthening in low and middle income countries.Global Health Governance 2010;3. http://blogs.shu.edu/ghg/files/ 2011/11/Shakarishvili-et-al_Converging-Health-Systems-Frameworks_Spring-2010.pdf (accessed 1 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"Geneva: World Health Organization, 2007. http://who.int/healthsystems/strategy/everybodys_business.pdf (accessed 8 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://www.who.int/bulletin/volumes/91/8/ 12-113985/en/ (accessed 1 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://www.inform.kz/eng/article/2346141 (accessed 1 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"The Heritage Foundation, 2014. http://www.heritage.org/index/country/kazakhstan(accessed 6 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://www.euro.,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://strategy2050.kz/en/news/1131(accessed 15 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"President of Kazakhstan Nursultan Nazarbayev at the opening of the fourth session of the Kazakh Parliament of the fifth convocation, 2September 2014. http://www.akorda.kz/ru/speeches/internal_political_affairs/in_speeches_and_addresses/page_217780_vystuplenie-prezidenta-kazakhstana-n-nazarbaeva-na-otkrytii- chetvertoi-sessii-parlamenta-rk-pyatogo-s (accessed 15 Jan 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
Eschborn 2014. http://health.bmz.de/ good-practices/GHPC/A_Quiet_Revolution/HIS_Bangladesh_long_EN.pdf (accessed 6 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
17 November 2015. https://www.imf.org/external/np/ms/2015/112515.htm (accessed 9 Feb 2016).37.,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://www1.worldbank.org/publicsector/anticorrupt/Corruption%20WP_78.pdf (accessed 15 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
"Perception of corruption in Kazakhstan, UNDPKAZ 04, Almaty 2003. http://unpan1.un.org/intradoc/groups/public/documents/ undp/unpan011504.pdf (accessed 15 Jan 2016).",Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://data.worldbank.org/ (accessed 6 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
http://www.ssc.upenn.edu/~garba/sharygin_rmkaz_v08.pdf (accessed 6 Feb 2016).,OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
doi:http://dx.doi.org/10.1016/j.puhe.2015.11.026.,OADS,/arxiv_data1/oa_pdf/48/a0/bmjgh-2015-000003.PMC5321304.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ BMJ Global Health 2016; 1:e000022.,Non-OADS,/arxiv_data1/oa_pdf/67/a6/bmjgh-2015-000022corr1.PMC5321306.pdf
2003. http://www.jhpiego.org/files/MNHPolComp.pdf 13.,Non-OADS,/arxiv_data1/oa_pdf/2c/30/bmjgh-2015-000022.PMC5321307.pdf
2000. http://www.ncss.com 20.,Non-OADS,/arxiv_data1/oa_pdf/2c/30/bmjgh-2015-000022.PMC5321307.pdf
2014. http://www.atlasti.com/product.html 28.,Non-OADS,/arxiv_data1/oa_pdf/2c/30/bmjgh-2015-000022.PMC5321307.pdf
http://www.ponseti.info/index.html 21.,Non-OADS,/arxiv_data1/oa_pdf/47/0c/bmjgh-2015-000023.PMC5321308.pdf
https://cure.org/clubfoot/ 22.,Non-OADS,/arxiv_data1/oa_pdf/47/0c/bmjgh-2015-000023.PMC5321308.pdf
https://cure.org/about/28.,Non-OADS,/arxiv_data1/oa_pdf/47/0c/bmjgh-2015-000023.PMC5321308.pdf
http://apps.who.int/gho/data/view.main.690?lang=en 32.,OADS,/arxiv_data1/oa_pdf/47/0c/bmjgh-2015-000023.PMC5321308.pdf
http://www.who.int/ healthinfo/global_burden_disease/tools_national/en/.,Non-OADS,/arxiv_data1/oa_pdf/47/0c/bmjgh-2015-000023.PMC5321308.pdf
http://nrhm.gov.in/nrhm-in-state/ state-wise-information/assam.html 4. International Institute for Population Sciences (IIPS) and Macro International.,Non-OADS,/arxiv_data1/oa_pdf/b4/dd/bmjgh-2015-000024.PMC5321309.pdf
http://medind.nic.in/haa/t04/i1/haat04i1c.shtml (accessed 24 Mar2013).,OADS,/arxiv_data1/oa_pdf/b4/dd/bmjgh-2015-000024.PMC5321309.pdf
http://nrhm.gov.in/nrhm-components/rmnch-a/maternal-health/janani-suraksha-yojana/background.html 7.,Non-OADS,/arxiv_data1/oa_pdf/b4/dd/bmjgh-2015-000024.PMC5321309.pdf
http://nrhmassam.in/index.php 9.,Non-OADS,/arxiv_data1/oa_pdf/b4/dd/bmjgh-2015-000024.PMC5321309.pdf
http://watson.brown.edu/files/watson/imce/ events/2015/Voena%20Bride%20Price%20and%20the%20Returns% 20to%20Education%20for%20Women.pdf (accessed 21 July 2015).,Non-OADS,/arxiv_data1/oa_pdf/21/95/bmjgh-2015-000025.PMC5321310.pdf
2011;5. http://www.cicr-columbia.org/wp-content/uploads/2011/02/Policy-Brief-5-Culture-and-its-Impact-on-Social-and-Community-Life.pdf 13.,Non-OADS,/arxiv_data1/oa_pdf/21/95/bmjgh-2015-000025.PMC5321310.pdf
2001.http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/WHO_NHD_01.3/en/index.html (accessed11 Apr 2014).,Non-OADS,/arxiv_data1/oa_pdf/96/1c/bmjgh-2015-000026.PMC5321311.pdf
https://intergrowth21.tghn.org/global-perinatal-package/intergrowth-21st-comparison-application/ 20.,Non-OADS,/arxiv_data1/oa_pdf/96/1c/bmjgh-2015-000026.PMC5321311.pdf
"Our perspectives on Global Health emanate from our personal and collectiveexperiences as health policy and system researchers and practitioners based in low and middle-income health systems, including, but not limited to our engagementswith, respectively, an intern ational membership organisa- tion (http://www.healthsyste msglobal.org) and a series of global conferences (http://h ealthsystemsresearch.org/ hsr2016/), African Health Policy and Systems Research(HPSR) ﬁeld-building initiatives (http://www.hpsa-africa.",Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
"org, http://www.chesai.org,), and national-level research training and policy collaboratives in India (http://www.phﬁ.org/keystone), and an emerging West African collab- oration of institutions and individuals to support and promote health policy and systems research and practicein the subregion.",Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
"equinetafrica.org), and the People ’s Health Movement (http://www.phmovement.org), for example, are playing important roles in inculcating a universal outlook and global leadership for health equity.",Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
"Its partnersinclude some linked to CHEPSAA, and its West African Network of Emerging Leaders draws in both CHEPSAA ’s Emerging Leaders and the Emerging Voices for GlobalHealth network (http://www.ev4gh.net).",Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
http://www.theguardian.com/health-revolution/2016/mar/22/millions-saved-book-healthcare-global-aid-policy (accessed25 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
http://www.who.int/social_ determinants/thecommission/finalreport/en/ (accessed 25 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
http://www.who.int/entity/alliance-hpsr/resources/alliancehpsr_abridgedversionreaderonline.pdf?ua=1 15.,OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
2012. http://www.who.int/alliance-hpsr/resources/publications/9789241504409/en/ 17.,Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
"Participatory action research in health systems: a methods reader, TARSC, AHPSR,WHO, IDRC Canada, EQUINET, Harare, 2014. http://www.equinetafrica.org/sites/default/files/uploads/documents/PAR%20Methods%20Reader2014%20for%20web.pdf (accessed 24 May2016).",Non-OADS,/arxiv_data1/oa_pdf/1f/ca/bmjgh-2016-000058.PMC5321314.pdf
To view please visit the journal online (http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/e6/7a/bmjgh-2016-000070.PMC5321315.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e6/7a/bmjgh-2016-000070.PMC5321315.pdf
http://www.who.int/mediacentre/news/ebola/25-august-2014/en/ 5.,Non-OADS,/arxiv_data1/oa_pdf/e6/7a/bmjgh-2016-000070.PMC5321315.pdf
http://www.fiercemedicaldevices.com/story/fda- nod-lifewatch-wireless-patch-based-vital-signs-monitoring-system/2016-02-09 18.,Non-OADS,/arxiv_data1/oa_pdf/e6/7a/bmjgh-2016-000070.PMC5321315.pdf
"DIPNOTE, 2016. https://blogs.state.gov/stories/2016/04/13/why-internet-access-key-development Steinhubl SR, et al.BMJ Glob Health 2016; 1:e000070.",Non-OADS,/arxiv_data1/oa_pdf/e6/7a/bmjgh-2016-000070.PMC5321315.pdf
"Geneva, Switzerland: International Statistical Classification of Diseases and Health Related Problems TenthRevision: Instruction Manual, 1993. http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf (retrieved 2 February 2016).",Non-OADS,/arxiv_data1/oa_pdf/58/06/bmjgh-2015-000014.PMC5321316.pdf
"Geneva: World Health Organisation, 2014; http://www.who.int/entity/gho/countries/vnm/enhttp://www.who.int/entity/gho/countries/vnm/en 10.",Non-OADS,/arxiv_data1/oa_pdf/58/06/bmjgh-2015-000014.PMC5321316.pdf
"Hanoi :Vietnamese Government ,2012 [December 2014]; http://www.gso.gov.vn/default_en.aspx?tabid=503&time=&kw=mortality 13.",Non-OADS,/arxiv_data1/oa_pdf/58/06/bmjgh-2015-000014.PMC5321316.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://apps.who.int/gb/ebwha/pdf_files/WHA58-REC1/english/A58_2005_REC1-en.pdf (accessed 15 Jun 2016) 2.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.un.org/ga/search/view_doc.asp?symbol=A/67/L.36&referer=http://www.un.org/en/ga/info/draft/index.shtml&Lang=E (accessed 15 Jun 2016) 3.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
https://sustainabledevelopment.un.org/?menu=1300 5.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.who.int/whr/2010/10_summary_en.pdf?ua=1 6.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.un.org/millenniumgoals/2014%20MDG%20report/MDG%202014%20English%20web.pdf (accessed 15 Jun 2016) 7.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Geneva: WHO, 2014. http://apps.who.int/iris/bitstream/10665/112824/1/WHO_HIS_HIA_14.1_eng.pdf (accessed 19 Feb 2016).8.",OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://data.worldbank.org/indicator/SH.STA.BRTC.ZS(accessed 4 Jun 2016).,OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2016. http://data.worldbank.org/indicator/SH.STA.BFED.ZS (accessed 4 Jun 2016).,OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2015. http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html (accessed 4 Jun2016).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2016.http://apps.who.int/gho/data/node.main.38?lang=en (accessed 4 Jun 2016).,OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Economic status, data by country [Data set]; 2015b.Retrieved 19 February 2016 from http://apps.who.int/gho/data/view.main.94030 (accessed 4 Jun 2016).",OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://data.unicef.org/maternal-health/delivery-care.html(accessed 4 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Global Health Observatory Data Repository, DTP3 immunization Data by urban wealth quintile [Data set].http://apps.who.int/gho/data/view.main.100210?lang=en (accessed 4 Jun 2016).",OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
Available from: Countdown to 2015. http://www.countdown2015mnch.org/documents/2014Report/ Pakistan_Country_Profile_2014.pdf (accessed 15 Jun 2016) 18.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.unicef.org/publications/files/ SOWC_2015_Summary_and_Tables.pdf (accessed 28 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Dhaka: UNICEF, 2010. http://www.unicef.org/bangladesh/Urban_paper_lowres.pdf(accessed 19 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.health.gov.mv/publications/13_1395305886_ Maldives_Health_Profile_2014_final_final.pdf (accessed 15 Jun 2016) 32.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Washington DC: The World Bank, 2013. http://documents.worldbank.org/curated/en/2013/01/17207220/expanding-health-coverage-vulnerable-groups-india 34. International Institute for Population Sciences (IIPS) and Macro International.",Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://planningcommission.nic.in/reports/genrep/rep_uhc0812.pdf (accessed 15 Jun 2016) 35.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://jointlearningnetwork.org/news/how-and-why-india-must-introduce-universal-healthcare-coverage 36.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
Available from the World Health Organization.http://apps.who.int/medicinedocs/documents/s19416en/s19416en.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.unicef.org/about/annualreport/files/Bhutan_COAR_2013.pdf (accessed 3 Nov 2014).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2006. http://www.searo.who.int/entity/health_situation_trends/documents/10-Point_Regional_Strategy_for_ HIS_SEA-HS-226.pdf (accessed 19 Feb 2016).,OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Data: health expenditure, public (% of GDP) [Data set]; 2015c http://data.worldbank.org/indicator/SH.XPD.PUBL.ZS (accessed 4 Jun 2016).",OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.jointlearningnetwork.org/resources/bangladesh-health-watch-report-2011-moving-towards-universal-health-coverag (accessed 15 Jun 2016) 49.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.thehindu.com/news/national/other-states/hospital-detains-newborn-as-parents-fail-to-pay-bill/article7653045.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
https://www.nice.org.uk/about/what-we-do/nice-international/nice-international-projects/nice-international-in-india(accessed 15 Jun 2016) 52.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2014. http://www.health.gov.mv/publications/13_1395305886_Maldives_Health_Profile_2014_final_final.pdf (accessed 25 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2014. http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_mdv_en.pdf?ua=1 (accessed 24 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
2014. http://www.searo.who.int/mediacentre/releases/2014/pr1567/en/ (accessed 25 Sep 2014).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Delhi: Public Health Foundation of India, 2011. http://planningcommission.nic.in/reports/genrep/rep_uhc0812.pdf (accessed 15 Jun 2016) 61.",Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.savethechildren.org.uk/sites/default/files/docs/Universal_health_coverage_summary.pdf (accessed 15 Jun 2016) 64.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2013/09/26/000333037_20130926111127/Rendered/PDF/812480BRI0P12100Box037933B00PUBLIC0.pdf (accessed 15 Jun 2016) 65.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.nhssp.org.np/health_policy/Consolidated%20NHSP-2%20IP%20092812%20QA.pdf (accessed 14 Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
http://www.dawn.com/news/1110761 68.,Non-OADS,/arxiv_data1/oa_pdf/7e/5d/bmjgh-2015-000017.PMC5321317.pdf
"Deaths, Australia 2014. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3302.0Main%20Features12014?opendocument&tabname=Summary&prodno=3302.0&issue=2014&num=&view= (accessed 1 Mar 2016).",Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Universal Periodic Review Australia recommendations from UPR 2011. http://nationalcongress.com.au/wp-content/uploads/2015/09/UPR-Australia-Congress-Shadow-Report-and-Factsheets-Final.pdf (accessed 1 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
https://www.humanrights.gov.au/sites/default/files/document/publication/WEB_Australias_Second_UPR_Review_2015.pdf(accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Statistics of UPR recommendations 2016. http://www.upr-info.org/database/statistics/index.php(accessed 1 Mar 2016).,OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
National report submitted in accordancewith paragraph 5 of the annex to Human Rights Council resolution16/21 Canada 2013. http://daccess-dds-ny.un.org/doc/UNDOC/GEN/G13/108/44/PDF/G1310844.pdf?OpenElement (accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
National report submitted in accordancewith paragraph 5 of the annex to Human Rights Council resolution16/21 New Zealand 2013. http://daccess-dds-ny.un.org/doc/UNDOC/GEN/G13/184/80/PDF/G1318480.pdf?OpenElement (accessed 24Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
National report submitted in accordancewith paragraph 5 of the annex to Human Rights Council resolution16/21 United States of America 2015. http://daccess-dds-ny.un.org/doc/UNDOC/GEN/G15/024/66/PDF/G1502466.pdf?OpenElement(accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Report of the Working Group on the Universal Periodic Review 2015. https://documents-dds-ny.un.org/ doc/UNDOC/GEN/G16/004/89/PDF/G1600489.pdf?OpenElement(accessed 15 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
https://documents-dds-ny.un.org/doc/UNDOC/GEN/G15/180/84/PDF/G1518084.pdf?OpenElement (accessed 15 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Access to Justice Arrangements Productivity Commission Inquiry Report 2014. http://www.pc.gov.au/inquiries/completed/access-justice/report/ access-justice-volume1.pdf (accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Prisoners in Australia 2014. http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4517.0~2014~Main%20Features~Aboriginal%20&%20Torres%20Strait%20Islander%20prisoner%20characteristics~10007 (accessed 24 Nov2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
http://www.austlii.edu.au/au/other/IndigLRes/rciadic/rciadic_summary/rcsumk06.html (accessed 24 Nov 2015).,OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
Policy Discussion Paper on Mandatory Sentencing 2014. http://www.aph.gov.au/DocumentStore.ashx?id=c05f81ff-d005-4738-8e1b-28469555b76a&subId=298819(accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
"Social Justice Report 2009 Nov 24, 2015. https://www.humanrights.gov.au/our-work/aboriginal-and-torres-strait-islander-social-justice/publications/social-justice-report-0 (accessed 24 Nov 2015).",Non-OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
https://www.humanrights.gov.au/sites/default/files/ document/publication/SJNTR%20FINAL.pdf (accessed 1 Mar 2016).,OADS,/arxiv_data1/oa_pdf/91/40/bmjgh-2015-000018.PMC5321319.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjgh-2015-000019).,Non-OADS,/arxiv_data1/oa_pdf/33/0b/bmjgh-2015-000019.PMC5321320.pdf
Health in 2015: from MDGs to SDGs: 2015. http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/33/0b/bmjgh-2015-000019.PMC5321320.pdf
"IndianCensus Bureau, 2011. http://pib.nic.in/prs/2011/latest31mar.pdf(accessed Jan 2016).",Non-OADS,/arxiv_data1/oa_pdf/33/0b/bmjgh-2015-000019.PMC5321320.pdf
"http://ses2002.guj.nic.in/ (accessed 15 Feb 2016, available on request).",OADS,/arxiv_data1/oa_pdf/33/0b/bmjgh-2015-000019.PMC5321320.pdf
2013. http://www.fogsi.org/wp-content/uploads/2015/05/pdf/FOGSI_Annual_Report_2012_13.pdf (accessed 15 Jun 2015).,Non-OADS,/arxiv_data1/oa_pdf/33/0b/bmjgh-2015-000019.PMC5321320.pdf
http://www.jabfm.org/ content/25/Suppl_1.toc (accessed 28 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
"Utrecht, : University of Utrecht, 2012. http://www.nivel.nl/sites/default/files/ bestanden/Proefschrift-Dionne-Kringos-The-strength-of-primary-care.pdf (accessed 28 Jan 2016).",Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.globalfamilydoctor.com/groups/WorkingParties/Research/plenarypanelprojectresourcedocuments.aspx (accessed28 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
"Resolution SEA/RC68/R6 Community-based health services andtheir contributions to universal health coverage, 2015. http://apps.who.int/iris/bitstream/10665/204455/3/RC68_Report%20.pdf(accessed 28 Aug 2016).",Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
2015. http://www.ridanepal.org/downloaded/EHCS%20briefing%20paper.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.who.int/countries/ind/en/ (accessed 15 Mar 2016).,OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.who.int/countries/bgd/ en/ (accessed 11 May 2016).,OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.who.int/gho/countries/pak.,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
17. http://worldpopulationreview.com/countries/pakistan-population/ Health Systems Profile- Pakistan Regional Health SystemsObservatory- EMRO http://www.who.int/countries/pak/en/ (accessed3 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://heartfile.org/pdf/phpf-GWP.pdf (accessed 3 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.who.int/nmh/countries/pak_en.pdf?ua=1 (accessed 3 Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
2009. http://apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf (accessed 1Mar 2016).,OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
Lancet 2015;386:737. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61532-X/abstract 25.,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
http://www.thelancet.com/journals/lancet/article/ PIIS0140-6736(15)00949-6/fulltext?rss%3Dyes 26.,Non-OADS,/arxiv_data1/oa_pdf/a2/09/bmjgh-2016-000057.PMC5321321.pdf
To view please visit the journalonline (http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/d1/95/bmjgh-2016-000030.PMC5321322.pdf
http://www.cdc.gov/vhf/ebola/resources/outbreak-table.html (accessed 4 Nov 2015).,OADS,/arxiv_data1/oa_pdf/d1/95/bmjgh-2016-000030.PMC5321322.pdf
"Sustaining Human Progress: Reducing Vulnerabilities and Building Resilience.New York: United Nations Development Programme, 2014.http://hdr.undp.org/sites/default/files/hdr14-report-en-1.pdf (accessed17 Feb 2015).",Non-OADS,/arxiv_data1/oa_pdf/34/ba/bmjgh-2016-000056.PMC5321324.pdf
"Brussels: EC, 2014. http://ec.europa.eu/health/healthcare/ docs/com2014_215_final_en.pdf (accessed 23 Mar 2016).",Non-OADS,/arxiv_data1/oa_pdf/34/ba/bmjgh-2016-000056.PMC5321324.pdf
"Ouagadougou: Ministère de la Santé, Direction générale del’information et des statistiques sanitaires, 2011. http://www.cns.bf/ IMG/pdf/dgiss_annuaire_serie_longue.pdf (accessed 23 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/34/ba/bmjgh-2016-000056.PMC5321324.pdf
"Ouagadougou: Ministère de la Recherche Scientifique et de l ’Innovation, 2011. http://planificationfamiliale-burkinafaso.net/ docs/information/Evaluation%20de%20SONU%20UNFPA.pdf(accessed 23 Mar 2016).",Non-OADS,/arxiv_data1/oa_pdf/34/ba/bmjgh-2016-000056.PMC5321324.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000066).,Non-OADS,/arxiv_data1/oa_pdf/e9/35/bmjgh-2016-000066.PMC5321325.pdf
"EED is a putative underlying cause of chronic malnutrition and stunting, which affects 26% of children under 5 years of age in the developing world and is associated with 21%of deaths in this age group (http://www.un.org/ millenniumgoals).",Non-OADS,/arxiv_data1/oa_pdf/e9/35/bmjgh-2016-000066.PMC5321325.pdf
2015. https://www.foreignaffairs.com/articles/west-africa/2015-08-18/ ebola-s-lessons 4.,Non-OADS,/arxiv_data1/oa_pdf/bb/51/bmjgh-2016-000047.PMC5321326.pdf
http://www.who.int/contracting/en/ 17.,OADS,/arxiv_data1/oa_pdf/bb/51/bmjgh-2016-000047.PMC5321326.pdf
http://www.who.int/hiv/aboutdept/relateddepts/en/ 23.,Non-OADS,/arxiv_data1/oa_pdf/bb/51/bmjgh-2016-000047.PMC5321326.pdf
2013. https://hbr.org/2009/06/collaborate-with-your-contract.,Non-OADS,/arxiv_data1/oa_pdf/bb/51/bmjgh-2016-000047.PMC5321326.pdf
2015. http://www.msf.org/article/remarks-international-president-msf-dr-joanne-liu-gates-foundation-global-partner-forum 29.,Non-OADS,/arxiv_data1/oa_pdf/bb/51/bmjgh-2016-000047.PMC5321326.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. WHO.,Non-OADS,/arxiv_data1/oa_pdf/dc/1b/bmjgh-2016-000064.PMC5321327.pdf
2015. http://data.worldbank.,Non-OADS,/arxiv_data1/oa_pdf/dc/1b/bmjgh-2016-000064.PMC5321327.pdf
http://www.bls.,Non-OADS,/arxiv_data1/oa_pdf/dc/1b/bmjgh-2016-000064.PMC5321327.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/56/e4/bmjgh-2016-000036.PMC5321329.pdf
http://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E 2.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.un.org/en/zerohunger/challenge.shtml 3.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.un.org/en/documents/udhr 8.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www2.ohchr.org/english/law/pdf/cescr.pdf 9.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.unhchr.ch/tbs/doc.nsf/(Symbol)/ 3d02758c707031d58025677f003b73b9?Opendocument 10.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.fao.org/3/a-i3892e.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.srfood.org/images/stories/pdf/officialreports/20140310_finalreport_en.pdf 14.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"Washington: International Food Policy Research Institute, 2007. http://www.ifpri.org/publication/human-right-food-us-nutrition-concern-1976-2006 17.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"Oakland: Food First and Institute for Food and Development Policy, 2002.http://www.mindfully.org/Food/Right-To-Food30jun02.htm 22.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.fao.org/docrep/meeting/005/y7106e/y7106e03.htm#P192_62571 23.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
17 March 2009. http://www.un.org/en/ga/ search/view_doc.asp?symbol=A/RES/63/187 24.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://daccess-dds-ny.un.org/doc/UNDOC/GEN/N14/600/94/PDF/N1460094.pdf?OpenElement This draft proposal was notapproved (as it can be seen in the official UN website http://www.un.org/en/ga/70/resolutions.shtml) 25.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
25November 2014. http://usun.state.gov/remarks/6295 26.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"[Column] Website of the World Public Health Nutrition Association, August 2011. http://www.wphna.org/htdocs/2011_aug_col_claudio.htm 28.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"European Union, 9 May 2008. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2008:115:TOC 30.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"Rome: Food and Agriculture Organisation of United Nations, 2011. http://www.fao.org/docrep/016/ap554e/ap554e.pdf 33.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"European Union, 2009. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:12012P/TXT&from=EN 35.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"Council of Europe, 2010. http://www.echr.coe.int/Documents/Convention_ENG.pdf 36.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
http://www.worldhunger.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
2015. http://www.idlo.int/sites/default/files/pdfs/publications/Realizing%20the%20Right%20to% 20Food_Legal%20Strategies%20and%20Approaches_full-report.pdf 42.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
Right to Food and Nutrition Watch 7.http://www.rtfn-watch.org 45.,Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"The Charter of this network can be found at: http://www.fian.org/ fileadmin/media/publications/GMRtFN_-_formatted_charter.pdf Vivero Pol JL, Schuftan C. BMJ Glob Health 2016; 1:e000040.",Non-OADS,/arxiv_data1/oa_pdf/fa/0b/bmjgh-2016-000040.PMC5321330.pdf
"The sample size was calculated using the sample size calculator for a proportion or descriptive study at http://www.openepi.com (OpenEpi V .3), 11keeping 90% CI.",OADS,/arxiv_data1/oa_pdf/2a/cc/bmjgh-2015-000009.PMC5321331.pdf
http://www.openepi.com/SampleSize/SSPropor.htm (accessed 13Mar 2016).,OADS,/arxiv_data1/oa_pdf/2a/cc/bmjgh-2015-000009.PMC5321331.pdf
"In addition, UpToDate created a link on the company website (http://www.uptodate.com) informing visitors of theexistence of this programme for health professionals in RLS and a promotional video that was also posted on the UpToDate website.",Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
"Ebola data : To compare the search behaviour of GHD UTD programme participants to that of the general public, we retrieved global Google search data from Google Trends on 11/28/2015 (https://http://www.google.com/trends/explore#q=ebola) and data on the number of con ﬁrmed Ebola cases from the US Centers for Disease Control website (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/cumulative-cases- graphs.html).",Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
https://www.clinicaltrials.gov/ 2.,Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
http://data.worldbank.org/indicator/SH.XPD.PCAP 16.,Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
http://www.boston.com/business/healthcare/articles/2010/03/01/collaboration_links_doctors_in_developing_countries_with_digital_colleagues/ 17.,Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
http://apps.who.int/gho/data/node.main.A1443?,OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
"http://www.newyorker.com/magazine/2013/07/29/slow-ideas Valtis YK, et al.BMJ Glob Health 2016; 1:e000041.",Non-OADS,/arxiv_data1/oa_pdf/38/27/bmjgh-2016-000041.PMC5321332.pdf
http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf 12.,Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
http://www.unaids.,Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
"Vital Signs: HIV Diagnosis, Care, and Treatment Among Persons Living with HIV —United States, 2011 Weekly November 28, 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6347a5.htm 19.",Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
2014. http://www.hiv-monitoring.nl/files/8914/1527/1076/SHM_Monitoring_report_2014.pdf23.,Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
http://dx.doi.org/10.4102/ phcfm.v7i1.807 http://www.,Non-OADS,/arxiv_data1/oa_pdf/d3/36/bmjgh-2015-000010.PMC5321333.pdf
29 July 2016. http://money.cnn.com/ 2016/05/13/news/alcohol-sales-fall/ 7.,Non-OADS,/arxiv_data1/oa_pdf/08/fb/bmjgh-2016-000099.PMC5321335.pdf
8 July 2016. http://www.ab-inbev.com/social- responsibility/smart-drinking/global-goals/_jcr_content/contentPar/download/file.res/Global%20Smart%20Drinking%20Goals 18.,Non-OADS,/arxiv_data1/oa_pdf/08/fb/bmjgh-2016-000099.PMC5321335.pdf
8 August 2016. https://en.wikipedia.,Non-OADS,/arxiv_data1/oa_pdf/08/fb/bmjgh-2016-000099.PMC5321335.pdf
"6There is a movement away from implementation research, which is centred on analysing the way interventions consider evidence, a ﬁeld that is close to knowledge transfer, which is also not fully developed in low and middle income countries (LMICs).7 However, we do agree with the fact that ‘research in both ﬁelds deals with the chal- lenges of translating intentions into desired changes ’.8A meeting of major journal editors has been organized by the Canadian Institutes of Health Research Institute of Population and Public Health and theCanadian Journal of Public Health in April 2016 (http://sparkingsolutions.ca).",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/bmjgh-2016-000115.PMC5321336.pdf
"Geneva, World Health Organization, 2008. http://apps.who.int/iris/bitstream/10665/43943/1/9789241563703_eng.pdf 3.",Non-OADS,/arxiv_data1/oa_pdf/6e/9c/bmjgh-2016-000115.PMC5321336.pdf
2014. http://www.who.int/classifications/ichi/en/ (accessedDec 2015).,OADS,/arxiv_data1/oa_pdf/fa/76/bmjgh-2016-000034.PMC5321337.pdf
http://www.ihtsdo.org/snomed-ct/ (accessed Dec 2015).,OADS,/arxiv_data1/oa_pdf/fa/76/bmjgh-2016-000034.PMC5321337.pdf
2015. http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R15-en.pdf(accessed 15 Jan 2016).,OADS,/arxiv_data1/oa_pdf/fa/76/bmjgh-2016-000034.PMC5321337.pdf
"Geneva: World Health Organization, 1978. http://www.who.int/hpr/NPH/docs/declaration_almaata.pdf 3.",Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
https://sustainabledevelopment.un.org/topics 5.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
"Geneva: World Health Organization, 2015. http://www.who.int/tb/publications/digitalhealth-TB-agenda/en/ 6.",Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
http://www.worldbank.org/en/publication/wdr2016 8.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
http://www.mckinsey.com/insights/high_tech_telecoms_internet/the_internet_of_things 9.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
https://uidai.gov.in/ 11.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
http://www.weforum.org/reports/ personal-data-emergence-new-asset-class 12.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
http://www.huffingtonpost.com/james-barrat/hawking-gates-artificial-intelligence_b_7008706.html 13.,Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
"Geneva: World Health Organization, 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf Falzon D, Raviglione M. BMJ Glob Health 2016; 1:e000038.",Non-OADS,/arxiv_data1/oa_pdf/6a/6a/bmjgh-2016-000038.PMC5321338.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/e3/78/bmjgh-2016-000043.PMC5321339.pdf
"New Delhi, India: Ministry of Health and Family Welfare, 2006. http://nrhm.gov.in/images/pdf/programmes/jsy/guidelines/jsy_ guidelines_2006.pdf 13.",Non-OADS,/arxiv_data1/oa_pdf/e3/78/bmjgh-2016-000043.PMC5321339.pdf
http://www.healthphone.org/ammaji/early-initiation-and-colostrum-feeding.htm (accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/e3/78/bmjgh-2016-000043.PMC5321339.pdf
http://www.youtube.com/watch?v=cIcWdwpT3tw (accessed 24 Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/e3/78/bmjgh-2016-000043.PMC5321339.pdf
"Factsheets.MWCD, 2015. http://wcd.nic.in/ (accessed 25 Oct 2015).",OADS,/arxiv_data1/oa_pdf/e3/78/bmjgh-2016-000043.PMC5321339.pdf
2015. http://www.unaids.org/en/ regionscountries/countries/southafrica 2.,Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"Joint United Nations Programme on HIV/AIDS, 2013. http://www.unaids.org 3.",Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"Pretoria, South Africa: Statistics South Africa; 2013. http://www.statssa.gov.za/publications/SAStatistics 19.",Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"The Joint United Nations Programme on HIV/AIDS (UNAIDS) HIV Estimates, 2013. http://allintoendadolescentaids.org/wp-content/uploads/2015/02/South-Africa.pdf.",Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"Pretoria, South Africa: Statistics South Africa, 2013. http://www.statssa.gov.za/publications/SAStatistics 24.",Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
Page 9. http://www.statssa.gov.za/ publications/P0305/P03052013.pdf 25.,OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"Pretoria, South Africa: Statistics South Africa, 2012. http://www.statssa.gov.za/ publications/SAStatistics 32.",Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdoles2015 53.,Non-OADS,/arxiv_data1/oa_pdf/32/93/bmjgh-2015-000004.PMC5321340.pdf
"Funding This study was supported by the Center for Community Health Care, Research and Development, Nigeria (CCHARD) http://www.cchrad.org.",Non-OADS,/arxiv_data1/oa_pdf/a9/d5/bmjgh-2015-000006.PMC5321341.pdf
2009. http://www.niaid.nih.gov/topics/tuberculosis/understanding/whatistb/pages/tbdefinitions.aspx (accessed 21 Jul 2015).,Non-OADS,/arxiv_data1/oa_pdf/a9/d5/bmjgh-2015-000006.PMC5321341.pdf
"Media centre, 2015. http://www.who.int/ mediacentre/factsheets/fs275/en/ (accessed 26 Mar 2015).",Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
"Background document on counterfeit medicines in Asia, 2011. http://www.whpa.org/Background_document_Counterfeit_Medicines_in_Asia.pdf (accessed 2 Aug 2016).",Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
"Guidelines on the conduct of surveys of the quality of medicines, June 2015. http://www.who.int/medicines/areas/quality_safety/quality_assurance/Guidelines-on-medicines-quality-surveys-QAS15-630_30062015.pdf (accessed 29 Jun 2016).",Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
http://www.nationsencyclopedia.,Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
"Nigeria: WHO statistical profile, last updated 2015. http://www.who.int/gho/countries/nga.pdf?ua=1(accessed 29 Jun 2016).",OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
"National Agency for Food and Drug, 2015. http://www.nafdac.gov.ng/ (accessed 26 Mar 2015).",Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
http://www.drugfuture.com/pharmacopoeia/usp35/ data/v35300/usp35nf30s0_m3575.html (accessed 2 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
http://www.pharmacopeia.cn/v29240/usp29nf24s0_m45568.html (accessed 2 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/cd/47/bmjgh-2016-000086.PMC5321342.pdf
http://www.unocha.org/syria (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Needs and Population Monitoring Report POPULATION BASELINE ROUND IV OCTOBER 2015. https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/assessments/npm_report_round_iv_october_2015_1.pdf (accessed 19 Dec 2015).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
21 Aug 09. https://iwpr.net/global-voices/cholera-epidemic-fears-rise (accessedMar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Epidemic preparedness and response plan for cholera in Syria 30 November 2015. http://www.emro.who.int/images/stories/syria/Epidemic_preparedness_cholera_plan_of_Syria.1_November_2015.pdf?ua=1 (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
The Syria Institute: Siege Watch First Quarterly Report on Besieged Areas in Syria —February 2016. http://siegewatch.org/wp-content/ uploads/2015/10/PAX-RAPPORT-SIEGE-WATCH-FINAL-SINGLE-PAGES-DEF.pdf (accessed Mar 2016) 7.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
http://www.acu-sy.org/en/suspected-case-of-cholera-in-n-syria/(accessed Oct Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
https://www.humanitarianresponse.info/en/operations/whole-of-syria/assessment/needs-and-population-monitoring-npm-mobility-dynamic-report-3 (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Weekly Epidemiological Monitor Volume 8 Issue 14 & 15 12 April 2015 Published by World HealthOrganization (WHO) Eastern Mediterranean Regional Office(EMRO) http://applications.emro.who.int/dsaf/epi/2015/Epi_Monitor_2015_8_14-15.pdf?ua=1 (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Water-borne Disease Assessment in Idleb week 26 2015 Brief Epidemiological review of Waterborne Diseases in Idleb Governoratebetween June 2014 and June 2015. http://www.acu-sy.org/en/wp-content/uploads/2015/07/Ext13-Week26-WBD_Assessment_Idleb.pdf 16.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
"Sparrow A. Syria the Other Threat New York Review of Books Blog August 12, 2014. http://www.nybooks.com/daily/2014/08/12/syria-threat-polio/ (accessed Oct 2015).",Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
http://www.icrcproject.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
http://www.reachresourcecentre.info/system/files/resource-documents/reach_syr_profile_easternaleppo_watersecurity_aug2015.pdf (accessed Mar 2016).,OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
May 7 2015 http://www.nybooks.com/articles/2015/05/07/syria-death-assads-chlorine/ (accessed Oct 2015).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
"Report of the Secretary-General on the implementation of Security Council resolutions 2139 (2014), 2165 (2014) and 2191 (2014)December 15 2015. http://www.un.org/en/ga/search/view_doc.asp?symbol=S/2015/962 (accessed Dec 2015).",Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Triebert C. Syria ’s Bombed Water Infrastructure: an OSINT Inquiry December 11 2015 https://www.bellingcat.com/news/mena/2015/12/ 11/syrias-bombed-water-infrastructure/ 23.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
World Health Organization 2005. http://apps.who.int/iris/bitstream/10665/96340/1/9241546166_eng.pdf 24.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
http://www.acu-sy.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
November Quarterly DLOs Training Extension- Syria EWARN- Epi week 47- 2015. http://www.acu-sy.org/en/wp-content/uploads/2015/12/Ext-47-November-Quarterly-DLOS-training-EN.pdf 29.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
2 2014 http://www.moh.gov.sy/pages/EpidemicBulletin/201304/indexe.html (accessed Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
June 2015. http://www.emro.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
"Geneva: World Health Organization, 2012. http://www.who.int/diseasecontrol_emergencies/ publications/who_hse_epr_dce_2012.1/en/ 35.",Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
https://en.wikipedia.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
2014. http://www.strategicforesight.com/publication_pdf/63948150123-web.pdf (accessed Mar 2016) 37.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
https://en.wikipedia.org/wiki/Second_Battle_ of_Idlib (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
http://www.who.int/wer/ 2015/wer9040.pdf (accessed 30 Dec 2015).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Sixty-fourth World Health Assembly WHA 64.15 Agenda item 13.9 24 May 2011. http://www.who.int/cholera/technical/Resolution_CholeraA64_R15-en.pdf (accessed Nov 2015).,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
Advisory Group On Reform Of WHO ’s Work In Outbreaks and Emergencies First Report November 15th 2015. http://www.who.int/about/who_reform/emergency-capacities/first-report-advisory-group.,Non-OADS,/arxiv_data1/oa_pdf/78/d7/bmjgh-2016-000029.PMC5321343.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000101).,Non-OADS,/arxiv_data1/oa_pdf/e9/12/bmjgh-2016-000101.PMC5321344.pdf
"Competing interests All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: all authors had financial support from the National Institute of Allergy andTable 4 Linear probability model estimates* of the effect of RDT and ACT subsidies on ACT consumption among study participants who were tested for malaria, stratified by test results (N=267) Estimated effects Malaria negative Malaria positive UnadjustedAdjusted (parsimonious) UnadjustedAdjusted (parsimonious) Comparisons of interest (% differences) RDT subsidy (irrespective of ACT subsidy group)13.4% (2.4% to 24.4%)12.8% (1.7% to 23.9%)2.9% (−13.6% to 19.4%)4.2% (−1.2% to 20.4%) ACT subsidy (irrespective of RDT subsidy group)6.4% (−4.7% to 17.6%)8.2% (−3.3% to 19.6%)17.8% (0.4% to 35.1%)19.5% (2.2% to 36.8%) Covariate effects (% differences) Wealth: poorest 40th centile 2.9% (−9.0% to 14.8%)4.2% (−12.2% to 20.6%) Reference level % (Group D —no subsidies)7.0% (−1.5% to 15.6%)5.6% (−3.4% to 14.6%)63.2% (47.4% to 79.0%)60.8% (43.3% to 78.2%) *LPM models specified as a generalised linear model for a binomial outcome with an identity link function.",Non-OADS,/arxiv_data1/oa_pdf/e9/12/bmjgh-2016-000101.PMC5321344.pdf
The Hindu Centre for Politics and Public Policy 30 June 2016. http://www.thehinducentre.com/multimedia/archive/02922/109__India_and_Nep_2922002a.pdf (accessed 31 Jul 2016).,Non-OADS,/arxiv_data1/oa_pdf/2a/53/bmjgh-2016-000116.PMC5321345.pdf
"Remembering the 1989 blockade, Nagarik 05 October 2015. http://nepalitimes.com/article/from-nepali-press/Remembering- the-1989-blockade,2651 (accessed 31 Jul 2016).",Non-OADS,/arxiv_data1/oa_pdf/2a/53/bmjgh-2016-000116.PMC5321345.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d2/68/bmjgh-2016-000096.PMC5321346.pdf
"2013. http://www.oecd.org/dac/peer-reviews/Evidence-RBF-maternal-health.pdf Long Q, et al.BMJ Glob Health 2016; 1:e000096.",Non-OADS,/arxiv_data1/oa_pdf/d2/68/bmjgh-2016-000096.PMC5321346.pdf
2013. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf 18.,OADS,/arxiv_data1/oa_pdf/d2/68/bmjgh-2016-000096.PMC5321346.pdf
2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 19.,Non-OADS,/arxiv_data1/oa_pdf/d2/68/bmjgh-2016-000096.PMC5321346.pdf
"Dhaka: Ministry of finance, Government of the People Republic ofBangladesh, 2015. http://www.mof.gov.bd/en/index.php?option=com_content&view=article&id=340&Itemid=1 (accessed 3Mar 2016).",Non-OADS,/arxiv_data1/oa_pdf/90/ee/bmjgh-2016-000052.PMC5321348.pdf
"Transforming Our World: the 2030 Agenda for SustainableDevelopment, 2016. http://bit.ly/1P1zfHH (accessed 5 Mar 2016).",Non-OADS,/arxiv_data1/oa_pdf/90/ee/bmjgh-2016-000052.PMC5321348.pdf
"Department of cooperatives, LGRD, Dhaka, Bangladesh: 2015. http://www.coop.gov.bd/site/page/ 77e5c950-c266-474c-9752-49738a216dfa/At-a-glance (accessed 3 Feb 2016).",Non-OADS,/arxiv_data1/oa_pdf/90/ee/bmjgh-2016-000052.PMC5321348.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjgh-2016-000072).,Non-OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2007. http://www.itu.int/osg/spu/publications/ worldinformationsociety/2007/ (accessed 19 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2009. http://www.cdc.gov/violenceprevention/pdf/electronic_aggression_researcher_brief-a.pdf(accessed 5 Jul 2016).,OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2013. http://www.actforyouth.net/ resources/rf/rf_gender1_1213.cfm (accessed 9 Oct 2016).,OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2013. http://www.actforyouth.net/resources/rf/rf_gender2_1213.pdf (accessed 9 Oct 2016).,OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2015. http://www.internetworldstats.com/africa.htm#ng 41.,Non-OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2014. http://www.oyostate.gov.ng/ 46.,Non-OADS,/arxiv_data1/oa_pdf/b2/ab/bmjgh-2016-000072.PMC5321349.pdf
2015. http://apps.who.int/iris/bitstream/10665/200009/1/9789241565110_eng.pdf?ua=1 (accessed 22 Apr 2016).,OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
2014. http://www.who.int/healthinfo/global_burden_disease/ estimates/en/index1.html (accessed 22 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
2013. http://vizhub.healthdata.org/gbd-compare/#(accessed 18 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
http://www.un.org/sustainabledevelopment/sustainable-development-goals/ (accessed 22 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
"UN Secretary-General Announces $25 Billion in Initial Commitments to End Preventable Deaths of Women, Childrenand Adolescents by 2030. http://www.un.org/sustainabledevelopment/blog/2015/09/un-secretary-general-announces-25-billion-in-initial-commitments-to-end-preventable-deaths-of-women-children-and-adolescents-by-2030/ (accessed 22 Apr 2016).",Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
http://www.gao.gov/new.items/d01286r.pdf 15.,Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
1995. http://www.unwomen.org/~/media/headquarters/attachments/sections/csw/pfa_e_final_web.pdf (accessed 22 Apr 2016).,Non-OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
2016. https://www.medscinet.com/GI/Uploads/SDG_Report_FINAL.Jan13%20(1).pdf (accessed 22 Apr2016).,OADS,/arxiv_data1/oa_pdf/03/c2/bmjgh-2016-000080.PMC5321350.pdf
Source: adapted from http://www.inuitfirstcanadians.com/2014/02/28/250/.,Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
"Ottawa: The Expert Panel on the State of Knowledge of Food Security inNorthern Canada, Council of Canadian Academies, 2014. http://www.scienceadvice.ca/en/assessments/completed/food-security.aspx (accessed 29 Jan 2015).",Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
"Prince George, BC: National Collaborating Centre for Aboriginal Health, NCCAH 2011.http://www.nccah-ccnsa.ca/docs/social%20determinates/1828_NCCAH_mini_diets_health_final.pdf 7.",Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
Geneva: 2002. http://www.who.int/ dietphysicalactivity/publications/trs916/en/ (accessed 12 Apr 2015).,Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
Aboriginal Affairs and NorthernDevelopment Canada 2013. http://www.aadnc-aandc.gc.ca/eng/1395347953550/1395348287432 (accessed 8 Aug 2015).,Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
"Harare: EQUINET, 2008. http://www.equinetafrica.org/bibl/ docs/PRAequitygauge2008.pdf (accessed 17 Nov 2015).",Non-OADS,/arxiv_data1/oa_pdf/43/b5/bmjgh-2016-000093.PMC5321351.pdf
http://www.who.int/emergencies/zika-virus/situation-report/7-april-2016/en/ (accessed 21 July 2016).,Non-OADS,/arxiv_data1/oa_pdf/d6/9d/bmjgh-2016-000087.PMC5321352.pdf
Map displaying infected countries from 1947-2016. http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/d6/9d/bmjgh-2016-000087.PMC5321352.pdf
http://www.cdc.gov/zika/pdfs/denvchikvzikv-testing-algorithm.pdf (accessed 31Mar 2016).,OADS,/arxiv_data1/oa_pdf/d6/9d/bmjgh-2016-000087.PMC5321352.pdf
http://www.cdc.gov/media/releases/2016/s0226-laboratory-test-for-zika-virus.html (accessed 22 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/d6/9d/bmjgh-2016-000087.PMC5321352.pdf
1 –25 May 2015. https://sustainabledevelopment.un.org/ content/documents/1684SF_-_SDG_Universality_Report_-_May_2015.pdf (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://www.un.org/ga/search/ view_doc.asp?symbol=A/70/L.1&Lang=E (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
2015. http://www.undp.org/content/undp/en/home/mdgoverview.html (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
2015. http://www.undp.org/content/undp/en/home/mdgoverview/post-2015-development-agenda/ (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://apps.who.int/iris/bitstream/10665/200009/1/9789241565110_eng.pdf?ua=1 (cited 2 August 2016).,OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
WHO discussion paper .1–4 October 2012. http://www.who.int/topics/millennium_development_goals/post2015/WHOdiscussionpaper_October2012.pdf?ua=1 (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://www.un.org/millenniumgoals/2015_ MDG_Report/pdf/MDG%202015%20rev%20( July%201).pdf (cited 2August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3877943/ (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
https://www.oecd.org/migration/ Is-this-refugee-crisis-different.pdf (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://www.who.int/ mediacentre/events/meetings/2015/MDGs-SDGs-Summary.pdf?,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
2014.https://www.newsecuritybeat.org/2014/11/whats-international-development-debates-include-sustainable-development-goals/ (cited2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
2013. http://www.cdc.gov/hrqol/wellbeing.htm (cited 2 August 2016).,OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
3-14 June 1992. http://www.unep.org/Documents.Multilingual/Default.asp?documentid=78&articleid=1163 (cited 2 August 2016).,OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
1 –2 September 2012. http://www.who.int/topics/millennium_development_goals/post2015/healthinthepost_ briefing_20120921.pdf?ua=1 (cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
25 –27 September 2015. http://www.who.int/mediacentre/ events/meetings/2015/un-sustainable-development-summit/en/ (cited2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
"Department of Economic and Social Affairs, United Nations Statistics Division, 4 March 2016. http://unstats.un.org/sdgs/iaeg-sdgs/metadata-compilation/ (cited 2 August 2016).",OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
2015. http://apps.who.int/iris/handle/10665/180807 (cited 2 August 2016).,OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
http://www.euro.who.int/__ data/assets/pdf_file/0007/188809/Health-in-All-Policies-final.pdf(cited 2 August 2016).,Non-OADS,/arxiv_data1/oa_pdf/37/a2/bmjgh-2016-000068.PMC5321355.pdf
"Secondary Health Education and Relief Through Teaching, 2015.http://www.hearttfoundation.org/ (accessed 30 Nov 2015).",Non-OADS,/arxiv_data1/oa_pdf/1d/5e/bmjgh-2016-000097.PMC5321356.pdf
http://www.ipala.org/index.html (accessed 23 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/1d/5e/bmjgh-2016-000097.PMC5321356.pdf
"2006 September, 2006. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.543.2630&rep=rep1&type=pdf (accessed 8 Jul 2016).",OADS,/arxiv_data1/oa_pdf/1d/5e/bmjgh-2016-000097.PMC5321356.pdf
1998. http://www.kfpe.ch/key_activities/publications/guidelines/guidelines_e.php 36.,Non-OADS,/arxiv_data1/oa_pdf/1d/5e/bmjgh-2016-000097.PMC5321356.pdf
"2009 December, 2009. http://www.ccghr.ca/docs/PAT_Interactive_e.pdf (accessed Jul 2015).",Non-OADS,/arxiv_data1/oa_pdf/1d/5e/bmjgh-2016-000097.PMC5321356.pdf
Toview please visit the journal online (http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/38/49/bmjgh-2016-000077.PMC5321358.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000104).,Non-OADS,/arxiv_data1/oa_pdf/44/89/bmjgh-2016-000104.PMC5321359.pdf
http://www.redcross.org/humanityinwar/summary-of-the-geneva-conventions-of-1949-and-theiradditional-protocols (accessed 19 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
http://www.msf.,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
2015. https://www.hrw.org/sites/default/files/related_material/HHR%20Attacks%20on%20Hospitals%20brochure%200515%20LOWRES.pdf (accessed 19 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
Attacks on Health Care Dashboard: 2016 Quarter 1. http://www.who.int/hac/techguidance/attacks_dashboard_2016_q1.pdf?ua=1 (accessed 6 Oct 2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
Attacks on Health Care Dashboard: 2016 Quarter 2. http://www.who.int/hac/techguidance/Attacks_Dashboard_2016_Q2.pdf?ua=1 (accessed 6 Oct 2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
http://edition.cnn.com/2016/04/28/middleeast/syria-aleppo-hospitalairstrike/HospitalstargetedacrossSouth (accessed 19Jun2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
http://edition.cnn.com/2016/04/29/politics/ u-s-airstrike-hospitalafghanistan-investigation/ (accessed 19 Jun2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
2015. https://www.samsusa.net/foundation/images/PDFs/Syrian%20Medical%20Voices%20from%20the%20Ground_F.pdf (accessed 19 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
"2016. http://www.who.int/hac/techguidance/attacksreport.pdf (accessed 6 Oct 2016).Table 1 WHO reported deaths and injuries by country in 2014 and 201511 2014 –2015 Countries and territoriesNumber of attacksrecordedTotal deathsTotal injuries Afghanistan 19 69 50 Central African Republic30 30 17 Colombia 7 5 19 Democratic Republic of the Congo10 35 11 Guinea 11 8 80 Iraq 43 114 198Liberia 5 0 0Libya 33 55 65Myanmar 1 0 0Nigeria 10 23 20Pakistan 43 102 66Sierra Leone 3 2 10Somalia 6 11 6South Sudan 18 52 3Sudan 20 0 31Syrian Arab Republic 228 352 668Ukraine 32 17 28West Bank and Gaza Strip53 14 188 Yemen 22 70 101 Totals 594 959 1561 2 Bhuyan SS, et al.BMJ Glob Health 2016; 1:e000109.",Non-OADS,/arxiv_data1/oa_pdf/7c/7c/bmjgh-2016-000109.PMC5321360.pdf
"Kirkpatrick Partners, 2016. http://kirkpatrickpartners.com/OurPhilosophy/TheKirkpatrickModel/ tabid/302/Default.aspx (accessed 7 Apr 2016).",Non-OADS,/arxiv_data1/oa_pdf/ce/cb/bmjgh-2016-000102.PMC5321362.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000112).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
http://www.nobelprize.org/educational/medicine/insulin/discovery-insulin.html 2.,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
http://haiweb.org/what-we-do/acciss/ 7. International Diabetes Federation.,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
"Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org (accessed 12 May 2016).",Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf(accessed 15 Feb 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
"The essential medicine list .N e w Delhi: Government of NCT of Delhi, 2013. http://dshm.delhi.gov.in/ pdf%5CQAC%5CSoPs%5CEssential%20Drug%20List%20Delhi%202013.pdf (accessed 5 Jan 2016).",Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
Hindustan Times 2014. http://www.hindustantimes.com/ punjab/no-medicines-at-bathinda-cancer-centre-patients-left-in-thelurch/story-Coj5xudmHmYlBPI4hBGUOL.html (accessed 25 May2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
Greater Kashmir 2012. http://www.greaterkashmir.com/news/kashmir/vital- health-programme-a-damp-squib-in-jk/122767.html (accessed 25May 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2007. http://apps.who.int/medicinedocs/documents/s19208en/s19208en.pdf (accessed 25 May 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf (accessed 5 Sep 2014).,OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
https://www.seair.,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
"New Delhi: Nirman Bhawan, Government of India, 2010. https://accountscadrecsir.wordpress.com/category/cghs/(accessed 25 May 2016).",Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2013.http://www.nppaindia.nic.in/ceiling/press10june13/so1540e-14-6-13.html (accessed 25 May 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
Rediff Business 2013. http://www.rediff.com/business/slide-show/ slide-show-1-why-govt-lets-mncs-sell-insulin-at-a-higher-price/20130208.htm (accessed 25 May 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2003. http://www.rediff.com/money/2003/aug/04wockhardt.,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2016. https://www.propublica.org/article/doctors- who-take-company-cash-tend-to-prescribe-more-brand-name-drugs (accessed 6 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
http://www.makeinindia.com/ about (accessed 6 Jun 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
"Amsterdam: Health Action International, 2016. http://haiweb.org/wp-content/uploads/2016/06/ACCISS-TradeReport_FINAL_2.pdf(accessed 6 May 2016) 36.",Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2015. http://articles.economictimes.indiatimes.com/ 2015-04-09/news/60979360_1_biotechnology-major-biocon-biocon-today-insulin-glargine (accessed 6 May 2016).,Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
"2016. http://www.business-standard.com/ content/b2b-pharma/biocon-receives-regulatory-approval-for-insulin-glargine-in-japan-116033000194_1.html (accessed 6 Jun 2016) Sharma A, Kaplan WA.",Non-OADS,/arxiv_data1/oa_pdf/5c/8b/bmjgh-2016-000112.PMC5321364.pdf
2015. http://who.int/reproductivehealth/projects/13-MCS-ABO.pdf(accessed 22 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/b1/d6/bmjgh-2016-000113.PMC5321365.pdf
"Secondary World Abortion Policies 2013, 2013. http://www.un.org/en/development/desa/population/publications/policy/ world-abortion-policies-2013.shtml 42.",Non-OADS,/arxiv_data1/oa_pdf/b1/d6/bmjgh-2016-000113.PMC5321365.pdf
"The ICH-GCP code is currently under revision,23but the revision ’s limited scope has been questioned by leading academic groups (http://moretrials.net/).",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
Accessed on 14th June 2016 at http://moretrials.net/).,Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://oig.hhs.gov/oei/reports/oei-01-00-00190.pdf (accessed14 Sep 2015).,OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"Opinion on theEthical Aspects of Clinical research in Developing Countries.Opinion N° 17, 4th February 2003. http://europa.eu/rapid/ press-release_IP-03-193_en.htm?locale=en (accessed 14 Sep 2015).",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"Geneva, Switzerland, 2002. http://www.cioms.ch/ publications/layout_guide2002.pdf (accessed 14 Jun 2016).",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"KCE Report 246c, 2015. https://kce.fgov.be/publication/report/publicly-funded-practice-oriented-clinical-trials (accessed 14 Sep2015).",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"ICH Tripartite Guideline for Good Clinical Practices E6 (R1), 10th June 1996.http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 14 Jun2016).20.",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf (accessed 14 Jun 2016).,OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"London, UK: Nuffield Council on Bioethics, 2002. http://nuffieldbioethics.org/wp-content/uploads/2014/07/Ethics-of-research-related-to-healthcare-in-developing-countries-I.",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://www.who.int/csr/disease/ebola/ebola-new-interventions-02-sep-2014.pdf (accessed 19 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://apps.who.int/iris/bitstream/10665/43622/1/9789241563383_eng.pdf (accessed 19 Sep 2015).,OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf(accessed 19 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
"Geneva & Pietermaritzburg: Council in Health Research for Development (COHRED), 2013. http://www.cohred.org/wp-content/uploads/2012/04/Fair-Research-Contracting-Guidance-Booklet-e-version.pdf (accessed 19 Sep 2015).",Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
2009. http://www.who.int/tdr/publications/documents/gclp-web.pdf (accessed 14 Jun 2016).,OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
http://www.mhra.gov.uk/home/groups/comms-ic/ documents/websiteresources/con123239.pdf (accessed 18 Sep 2015).,Non-OADS,/arxiv_data1/oa_pdf/0d/17/bmjgh-2016-000122.PMC5321366.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000114).,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.globalpedendo.org/index.htm 3.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.slep.com.br/slep.php?f=contenido&id=homepage_en&g=homepage&lang=en 4.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
https://www.pedsendo.org/research_awards/international_scholars/index.cfm 5.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
"http://www.clanchildhealth.org/ Rowlands A, et al.BMJ Glob Health 2016; 1:e000114.",Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.idf.org/lifeforachild 8.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.who.int/ medicines/publications/essentialmedicines/EMLc_2015_FINAL_amended_AUG2015.pdf?ua=1 12.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_ AUG2015.pdf?ua=1 13.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.who.int/selection_medicines/country_lists/en/ 15.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://apps.who.int/medicinedocs/en/q/ 16.,OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
Seattle: PATH; 2006. http://www.who.int/medicines/publications/EssMeds_RHealth.pdf (accessed 19 Oct 2016).,OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm 20.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
2008.http://www.who.int/selection_medicines/committees/subcommittee/2/ FLUDRO.pdf (accessed 19 Oct 2016).,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://data.worldbank.org/indicator/NY.GNP.,OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
http://www.who.int/universal_health_coverage/en/ 38.,Non-OADS,/arxiv_data1/oa_pdf/2e/50/bmjgh-2016-000114.PMC5321367.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000128).,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2013. http://apps.who.int/ iris/bitstream/10665/94384/1/9789241506236_eng.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2011. http://www.who.int/nmh/events/2011/ncds_brazzaville_declaration.pdf 3.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2015. http://www.ncdalliance.org 4.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2010. http://www.cgdev.org/publication/where-have-all-donors-gone-scarce- donor-funding-non-communicable-diseases-working-paper 7.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2012. http://www.hsph.harvard.edu/program-on-the-global-demography-of-aging/WorkingPapers/2012/PGDA_WP_87.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2011. http://econpapers.repec.org/paper/esswpaper/id_3a3595.htm 18. International Diabetes Federation.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2014. http://www.idf.org/diabetesatlas/update-2014 19.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
Secondary The Interagency Emergency Health Kit 2011.2011. http://www.who.int/medicines/publications/emergencyhealthkit2011/en/ 20.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
"2014. http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1 22. van Ommeren M, Barbui C, de Jong K, et al.",OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2010. http://apps.who.int/iris/bitstream/10665/44260/1/9789241598996_eng.pdf 24.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2015. http://www.healthdata.org/gbd 25.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2015.http://esa.un.org/unpd/wpp/Download/Standard/Population/ 28.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2011. http://www.ifrc.org/ PageFiles/95530/The-Sphere-Project-Handbook-20111.pdf 35.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2015. http://f1000research.com/slides/1000061 36.,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
2010.http://www.who.int/chp/steps/2010_STEPS_Report_Bangladesh.pdf?ua=1 37. .,Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
Secondary Chronic Non-CommunicableDiseases Risk Factors Survey in Iraq 2006. http://www.who.int/chp/steps/IraqSTEPSReport2006.pdf?ua=1 38.,OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
"2010. http://www.who.int/chp/steps/2008_STEPS_Lebanon.pdf?ua=1 Tonelli M, et al.BMJ Glob Health 2016; 1:e000128.",Non-OADS,/arxiv_data1/oa_pdf/db/ea/bmjgh-2016-000128.PMC5321368.pdf
4 December 2014. http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=471 (accessed 5 Sep 2016).,Non-OADS,/arxiv_data1/oa_pdf/23/09/bmjgh-2016-000180.PMC5321369.pdf
Sci Data 2015;2:150019 http://dx.doi.,OADS,/arxiv_data1/oa_pdf/23/09/bmjgh-2016-000180.PMC5321369.pdf
http://www.croiconference.org/sessions/prevail-ii-randomized-controlled-trial-zmapp%E2%84%A2-acute-ebola-virus-infection (accessed 5Sep 2016).,Non-OADS,/arxiv_data1/oa_pdf/23/09/bmjgh-2016-000180.PMC5321369.pdf
"Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease.21 October 2015. http://www.businesswire.com/news/home/20151021005958/en/ (accessed 5 Sep 2016).",Non-OADS,/arxiv_data1/oa_pdf/23/09/bmjgh-2016-000180.PMC5321369.pdf
Ethical considerations for use of unregistered interventions for Ebola virus disease (EVD).http://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/ (accessed 5 Sep 2016).,Non-OADS,/arxiv_data1/oa_pdf/23/09/bmjgh-2016-000180.PMC5321369.pdf
Data sharing statement De-identified quantitative data are available at the Healthcare System Design Group ’s (Possible ’s Implementation Research Team) website (http://hsdg.partners.org/data/).,OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
"New York: UNICEF, 2012. http://www.who.int/maternal_child_adolescent/documents/levels_trends_child_mortality_2012.pdf.",Non-OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
https://data.humdata.org/dataset/hmis-estimated-population-data-2014-2015 18.,OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
http://www.surveycto.com/ index.html (accessed 8 Sep 2015).,OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
http://www.simprints.com (accessed31 Jan 2016).,Non-OADS,/arxiv_data1/oa_pdf/bf/0d/bmjgh-2016-000050.PMC5321370.pdf
2014. http://data.worldbank.org/ (accessed 15 Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/fe/95/bmjgh-2016-000059.PMC5321371.pdf
http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf (accessed 18 Jul2012).,Non-OADS,/arxiv_data1/oa_pdf/fe/95/bmjgh-2016-000059.PMC5321371.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://data.worldbank.org/indicator/SH.XPD.PCAP 2. WHO.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.who.int/healthinfo/global_burden_disease/estimates/en/ 3.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
2015. https://www.hcup-us.ahrq.gov/db/state/ costtocharge.jsp 16.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/medicare/the-medicare-physician-payment-schedule.page?,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.who.int/choice/onehealthtool/en/ 20. WHO.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.who.int/choice/onehealthtool/ OneHealth_Tool_Supporting_integrated_strategic_health_planning.pdf?ua=1 21.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.who.int/choice/cost-effectiveness/CHOICE_FAQ.pdf?ua=1 23.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD 35.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://data.worldbank.org/indicator/SP.DYN.,OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://data.worldbank.org/indicator/SH.DYN.MORT 37.,Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
"http://data.worldbank.org/indicator/SH.MMR.RISK McBain RK, et al.BMJ Glob Health 2016; 1:e000134.",Non-OADS,/arxiv_data1/oa_pdf/4e/d2/bmjgh-2016-000134.PMC5321372.pdf
http://www.who.int/macrohealth/action/sintesis15novingles.pdf 18.,Non-OADS,/arxiv_data1/oa_pdf/8f/c0/bmjgh-2016-000075.PMC5321373.pdf
"Washington DC: World Bank, 2015. https://openknowledge.worldbank.org/handle/10986/21568 License:CC BY 3.0 IGO.",Non-OADS,/arxiv_data1/oa_pdf/8f/c0/bmjgh-2016-000075.PMC5321373.pdf
http://www.who.int/mediacentre/factsheets/fs290/en/ 47.,Non-OADS,/arxiv_data1/oa_pdf/8f/c0/bmjgh-2016-000075.PMC5321373.pdf
We conducted a qualitativecontent analysis of the online discussion ‘Advancing Care Delivery: Driving Demand and Supply ofDiagnostics ’organised by the Global Health Delivery Project (GHD) (http://www.ghdonline.org/) at HarvardUniversity.,Non-OADS,/arxiv_data1/oa_pdf/be/84/bmjgh-2016-000132.PMC5321377.pdf
"Health system strengthening as propagated by the WHO focuses on speciﬁc building blocks (see the WHO framework, http://www.who.int/healthsystems/strategy/everybodys_ business.pdf), but an understanding of how aspects such as human resources, available technologies, ﬁnances, governance, routines and infrastructure interact is lacking from these building blocks.",Non-OADS,/arxiv_data1/oa_pdf/be/84/bmjgh-2016-000132.PMC5321377.pdf
"The capacity needed to create functioning diagnostic services runs somewhat contrary to what most POC tests promise, namely to work where there is insuf ﬁcient laboratory infrastructure, limited human resources, andprolonged turn-around on laboratory-based test results.Box 1 Characteristics of the online discussion and data analysis Global Health Delivery Online (GHDonline) hosted a 2-week Expert Panel focusing on diagnostic solutions for global health (archived and available at http://www.ghdonline.org/global-diagnostics/discussion/driving-demand-and-supply-of-diagnostics/).",Non-OADS,/arxiv_data1/oa_pdf/be/84/bmjgh-2016-000132.PMC5321377.pdf
"In the private sector, special pricing agreements initiatives (eg, the Initiativefor Promoting Affordable and Quality TB Tests (IPAQT) (http://www.ipaqt.org) model in India) need to be established to make tests more accessible (#75).",Non-OADS,/arxiv_data1/oa_pdf/be/84/bmjgh-2016-000132.PMC5321377.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/be/84/bmjgh-2016-000132.PMC5321377.pdf
2016. http://www.unaids.org/en/ resources/documents/2016/Global-AIDS-update-2016 2.,Non-OADS,/arxiv_data1/oa_pdf/3f/e5/bmjgh-2016-000125.PMC5321378.pdf
http://eprints.whiterose.ac.uk/65834/ 15.,Non-OADS,/arxiv_data1/oa_pdf/3f/e5/bmjgh-2016-000125.PMC5321378.pdf
This paper has appeared in an earlier form as a dissertation available at https://edoc.ub.uni-muenchen.de/19148/1/Shariful_Islam_Sheikh_ Mohammed.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b9/1b/bmjgh-2016-000033.PMC5321382.pdf
"LMU, 2015. https://edoc.ub.uni-muenchen.de/19148/1/Shariful_Islam_Sheikh_Mohammed.pdf (accessed 14 Apr 2016).",Non-OADS,/arxiv_data1/oa_pdf/b9/1b/bmjgh-2016-000033.PMC5321382.pdf
2014. http://www.who.int/substance_abuse/research_tools/translation/en/ 15.,Non-OADS,/arxiv_data1/oa_pdf/b9/1b/bmjgh-2016-000033.PMC5321382.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjgh-2016- 000129).,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://vizhub.healthdata.org/fgh/ 2.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://foreignpolicy.com/2014/01/21/the-case-for-aid/ 4.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
Available from: https://ideas.repec.org/p/mos/moswps/2010-54.html.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.rollbackmalaria.org/files/files/countries/malawi2011-2015.pdf 19.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.afdb.org/fileadmin/uploads/afdb/Documents/Project-and-Operations/Malawi —Support to The Health Sector Programme —Appraisal Report.pdf 20.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
Available from: http://siteresources.worldbank.org/AFRICAEXT/Resources/malawi.pdf 24.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
2012. http://aiddata.org/subnational-geospatial-research- datasets (access 1 May 2016).25.,OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.nsomalawi.mw/publications/integrated-household-survey.html 26.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.masdap.mw/layers/geonode:healthfac 27.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.nsomalawi.mw/2008-population-and-housing-census.html 28.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
https://www.kfw-entwicklungsbank.de/migration/Entwicklungsbank-Startseite/Development-Finance/Evaluation/Results-and-Publications/PDF-Dokumente-L-P/MalawiChitipa 2009.pdf 29.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
http://www.nyasatimes.com/2009/08/ 03/lomwe-becomes-buzz-word-for-malawis-employment-business/ 39.,Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
"http://www.irinnews.org/report/92877/ malawi-uk-aid-cuts-hit-health-care 12 Marty R, et al.BMJ Glob Health 2017; 2:e000129.",Non-OADS,/arxiv_data1/oa_pdf/83/7e/bmjgh-2016-000129.PMC5321384.pdf
Toview please visit the journal online (http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
27The WHO Anthro software was used for calculating WHZ (http://www.who.int/childgrowth/software/en/).,OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
Competing interests All authors have completed the Unified Competing Interest Form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that RB and SY are staff members of the WHO.,OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
http://apps.who.int/ gho/data/view.wrapper.nutrition-1-5?lang=en&showonly=nutrition 5.,Non-OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
http://nrhm.gov.in/nrhm-components/rmnch-a/child-health-immunization/child-health/guidelines.html 29.,Non-OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
http://nrhm.gov.in/communitisation/asha/about-asha.html 31.,Non-OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
http://icds-wcd.nic.,Non-OADS,/arxiv_data1/oa_pdf/27/77/bmjgh-2016-000144.PMC5321385.pdf
The question- naire and all related training materials will be made available here: https://sphcm.med.unsw.edu.au/project/ system-wide-analysis-health- ﬁnancing-equity-cambodia.,Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
Data management and quality assurance All research materials and data from this study will beheld and preserved in accordance with the University of New South Wales ’(UNSW) Research Data management guidelines: http://www.gs.,Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
2011.http://apps.who.int/gb/ebwha/pdf_fi les/WHA64/A64_R9-en.pdf(accessed 30 Aug 2011).,OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Geneva: WHO, 2010. http://apps.who.int/iris/ bitstream/10665/44371/1/9789241564021_eng.pdf 6.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"World Health Organization, 2016. http://apps.who.int/iris/handle/10665/204283 7.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Phnom Penh: Ministry of Health, 2008. http://www.wpro.who.int/health_services/cambodia_ nationalhealthplan.pdf 10.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
2012. http://ni.unimelb.edu.au/__data/assets/pdf_file/0009/623970/PB4_-_Cambodia_and_Laos.pdf 11.,Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Washington DC: The World Bank Group, 2013. http://documents.worldbank.org/curated/en/824341468017405577/Where-have-all-the-poor-gone-Cambodia-poverty-assessment-2013 12.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Manila: World Health Organization, Regional Office for the Western Pacific, 2012. http://www.wpro.who.int/asia_pacific_observatory/resources/policy_briefs/household_payments_health_services_asia_pacific.pdf 14.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Cambodian Demographic and Health Survey, 2014. https://dhsprogram.com/pubs/pdf/FR312/FR312.pdf 15.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"The World Bank, 2006. http://siteresources.worldbank.org/INTHSD/Resources/topics/Health-Financing/HFRFull.pdf.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Washington, DC: 1997. http://www1.worldbank.org/publicsector/pe/PEAMMarch2005/multi_page.pdf.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
2016. http://data.un.org/CountryProfile.aspx?,Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Cambodia: Health Service Delivery Profile Cambodia, 2012. http://www.wpro.who.int/health_services/service_delivery_profile_cambodia.pdf 26.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
"Washington DC: World Bank Group, 2014. http://documents.worldbank.org/curated/en/514181468213569828/Cambodias-rural-health-markets-and-the-quality-of-care 27.",Non-OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
2015. http://www.ilearnincambodia.net/uploads/3/1/0/9/31096741/ cses_2014_report.pdf.,OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.558.4225&rep=rep1&type=pdf 49.,OADS,/arxiv_data1/oa_pdf/8e/fc/bmjgh-2016-000153.PMC5321386.pdf
2012. https://www.usaid.gov/sites/default/files/documents/1864/CHW-Evidence-Summit-Final-Report.pdf 23.,Non-OADS,/arxiv_data1/oa_pdf/fc/45/bmjgh-2016-000141.PMC5321387.pdf
A review as part of ongoingresearch of International Consortium for Research on Equitable HealthSystems (CREHS) .2007. http://www.hrhresourcecenter.org/hosted_ docs/CHW_Prasad_Muraleedharan.pdf 30.,Non-OADS,/arxiv_data1/oa_pdf/fc/45/bmjgh-2016-000141.PMC5321387.pdf
http://www.cartercenter.org/news/publications/health/guinea_worm_publications/ghana-gets-results.html 45.,Non-OADS,/arxiv_data1/oa_pdf/fc/45/bmjgh-2016-000141.PMC5321387.pdf
2010. http://www.cdc.gov/breastfeeding/ pdf/breastfeedingreportcard2010.pdf (accessed Mar 2016).10.,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2012. http://www.hc-sc.gc.ca/fn-an/surveill/nutrition/commun/prenatal/initiation-eng.php#a3 (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2011. http://www.pewforum.org/ 2011/12/19/table-christian-population-as-percentages-of-total- population-by-country/ (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2016. http://www.who.int/nutrition/databases/infantfeeding/countries/en/ (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2016. http://www.oecd.org/els/family/database.htm (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2006. http://www.ifop.,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2001. http://web.ons.gov.uk/ons/datasets-and-tables/index.html (accessed Mar 2016).,OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
Secondary UK Breastfeeding Rates 2010. http://www.unicef.org.uk/BabyFriendly/About-Baby-Friendly/Breastfeeding-in-the-UK/UK-Breastfeeding-rates/ 35.,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
2014. http://ava.publicreligion.org/home (accessed Mar 2016).,Non-OADS,/arxiv_data1/oa_pdf/c3/15/bmjgh-2016-000151.PMC5321388.pdf
http://www.foretiafoundation.org/boko-haram-insurgency-health-and-social-implications-for-cameroon/(accessed 12 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/c9/77/bmjgh-2016-000193.PMC5321389.pdf
http://health.gov.ng/index.php/news-media/summary-of-media-reports/9-uncategorised/267-wild-polio-virus-outbreak-in-nigeria (accessed 27 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/c9/77/bmjgh-2016-000193.PMC5321389.pdf
http://www.afdb.org/en/news-and-events/article/lake-chad-a-living-example-of-the-devastation-climate-change-is-wreaking-on-africa-15129/ (accessed16 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/c9/77/bmjgh-2016-000193.PMC5321389.pdf
http://www.vanguardngr.com/2016/07/nigeria-in-recession-presently-in-tough-place-adeosun (accessed 22 Aug 2016).,Non-OADS,/arxiv_data1/oa_pdf/c9/77/bmjgh-2016-000193.PMC5321389.pdf
2016. https://www.gso.gov.vn/Default_en.aspx?tabid=766 (accessed 5 Jul 2016).,OADS,/arxiv_data1/oa_pdf/7a/22/bmjgh-2016-000162.PMC5321390.pdf
General Statistical Office of Viet Nam; 2013. http://english.thaibinh.gov.vn/Tin-Tuc/Socialconditions/278_Industry-sector(accessed 28 Dec 2016).,Non-OADS,/arxiv_data1/oa_pdf/7a/22/bmjgh-2016-000162.PMC5321390.pdf
"Groningen, NL, CDS, 2008. http://www.rug.nl/research/ portal/publications/economic-development-of-the-mekong-delta-in-vietnam(cb3bd4d7-c182-4c5c-8ab7-a97511d89e3e).html 27.",Non-OADS,/arxiv_data1/oa_pdf/7a/22/bmjgh-2016-000162.PMC5321390.pdf
2010. http://www.gso.gov.vn/default.aspx?,Non-OADS,/arxiv_data1/oa_pdf/7a/22/bmjgh-2016-000162.PMC5321390.pdf
"Geneva: UNAIDS, 2015. http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf 3.",Non-OADS,/arxiv_data1/oa_pdf/67/ea/bmjgh-2016-000179.PMC5321392.pdf
"Technical Report, University ofMinnesota, http://www.misrc.umn.edu/workingpapers/fullpapers/1996/9604_040100.pdf; accessed 11 Nov. 2016.",Non-OADS,/arxiv_data1/oa_pdf/67/ea/bmjgh-2016-000179.PMC5321392.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c9/fc/bmjgh-2016-000217.PMC5321394.pdf
2016. http://www.internationalhealthpartnership.net/fileadmin/uploads/ihp/Documents/About_IHP_/mgt_arrangemts___docs/UHC_Alliance/Consultation_Day_two_presentations/2._Session_6_second_deck__UHC2030__UHC_and_Health_ Security2__2_.pptx 4.,OADS,/arxiv_data1/oa_pdf/c9/fc/bmjgh-2016-000217.PMC5321394.pdf
2016. http://www.mofa.,Non-OADS,/arxiv_data1/oa_pdf/c9/fc/bmjgh-2016-000217.PMC5321394.pdf
"Geneva: World Health Organization, 2007. http://www.who.int/whr/2007/en/ 6.",Non-OADS,/arxiv_data1/oa_pdf/c9/fc/bmjgh-2016-000217.PMC5321394.pdf
"Geneva: World Health Organization, 2005. http://www.who.int/ihr/publications/9789241580496/en/ 13.",Non-OADS,/arxiv_data1/oa_pdf/c9/fc/bmjgh-2016-000217.PMC5321394.pdf
Therandomisation will be done by a computer software pro- gramme called Research Randomizer (available at https://www.randomizer.org/).,Non-OADS,/arxiv_data1/oa_pdf/30/f1/bmjgh-2015-000015.PMC5321396.pdf
Further information about the IPAQ-SF can be accessed at http://www.ipaq.ki.se/scoring.pdf.,Non-OADS,/arxiv_data1/oa_pdf/30/f1/bmjgh-2015-000015.PMC5321396.pdf
http://seer.cancer.gov/csr/1975_2009_pops09 (accessed 21 Aug 2012).2.,Non-OADS,/arxiv_data1/oa_pdf/30/f1/bmjgh-2015-000015.PMC5321396.pdf
http://canceradvocacy.org/resources/glossary.aspxtop (accessed 7 Mar 2015).,Non-OADS,/arxiv_data1/oa_pdf/30/f1/bmjgh-2015-000015.PMC5321396.pdf
http://www.tanita.,Non-OADS,/arxiv_data1/oa_pdf/30/f1/bmjgh-2015-000015.PMC5321396.pdf
"Washington, DC: WorldBank Group 2014. http://documents.worldbank.org/curated/en/ 524521468141287875/The-economic-impact-of-the-2014-Ebola- epidemic-short-and-medium-term-estimates-for-West-Africa 6.",Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2016. http://www.who.int/mediacentre/news/statements/2016/ emergency-committee-zika-microcephaly/en/ 10. WHO.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2016. http://apps.who.int/ebola/ current-situation/ebola-situation-report-2-march-2016 11.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2016. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/ distribution-map.html —areas 13.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
"World Health Organization, 2009. http://www.who.int/iris/handle/10665/137037 20.",Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2014. http://abcnews.go.com/Health/nigerian-ebola-hoax-results-deaths/story?id=25842191 27.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2015. http://www.independent.co.uk/news/world/millionaire-preacher-sends-4000-bottles-of-holy-water-as-ebola-cure-9674136.html 28.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2014. https://www.washingtonpost.com/news/worldviews/wp/2014/07/31/nigerian-official-warns-pastors-and-healers-to-stop-making-false-ebola-cure-claims/ 29.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2014. http://www.thisdaylive.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2014. http://www.bbc.com/news/uk-29048035 33.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
"Time, 2014. http://time.com/3490961/brussels-airlines-ebola/ 36.",Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
"The Guardian 2014 22 August, 2014. https://www.theguardian.com/ society/2014/aug/22/ebola-airlines-cancel-flights-guinea-liberia-sierra-leone 37. WHO.",Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2015. http://www.who.int 38.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2014. http://www.bloomberg.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2004. https://www.ncbi.nlm.nih.gov/books/NBK92473/ 54.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2016. http://www.cnbc.com/2016/02/01/zika-virus-worries-weigh-on-the-travel-industry.html 55.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
2016. http://latino.foxnews.com/latino/health/2016/02/02/rapidly-spreading-zika-virus-having-financial-impact-on-us-travel-industry/ 56.,Non-OADS,/arxiv_data1/oa_pdf/6a/12/bmjgh-2016-000111.PMC5321397.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/2/e1602289/DC1table S1.,Non-OADS,/arxiv_data1/oa_pdf/fb/58/1602289.PMC5321447.pdf
"P. J. Ersts, Geographic Distance Matrix Generator (American Museum of Natural History, Center for Biodiversity and Conservation); http://biodiversityinformatics.amnh.org/open_source/gdmg [accessed 20 January 2015].",OADS,/arxiv_data1/oa_pdf/fb/58/1602289.PMC5321447.pdf
Version 2.3-3 (2016); https://cran.r-project.org/web/packages/vegan/index.html.,Non-OADS,/arxiv_data1/oa_pdf/fb/58/1602289.PMC5321447.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/2/e1601198/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/f2/d6/1601198.PMC5321448.pdf
This information is hosted on the Spanish National Research Council[Consejo Superior de Investigaciones Científicas (CSIC)] digital repository (http://hdl.handle.net/10261/142056).,OADS,/arxiv_data1/oa_pdf/f2/d6/1601198.PMC5321448.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/2/e1602067/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/6e/35/1602067.PMC5321449.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/2/e1602356/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/94/38/1602356.PMC5321450.pdf
For  This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c4/7b/emss-68497.PMC5321479.pdf
"Clinical Trial  Registration: NCT00951028, https://clinicaltrials.gov/ct2/show/NCT00951028 ), closed to new  participants.",Non-OADS,/arxiv_data1/oa_pdf/05/b5/nihms818514.PMC5321546.pdf
"Clinical Trial  Registration: NCT00951028, https://clinicaltrials.gov/ct2/show/NCT00951028 ).",Non-OADS,/arxiv_data1/oa_pdf/05/b5/nihms818514.PMC5321546.pdf
Available from: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf 30.,Non-OADS,/arxiv_data1/oa_pdf/05/b5/nihms818514.PMC5321546.pdf
"[J Adv Prosthodont 2017;9:1-13] KEYWORDS: Fit; Crown; Digital; Conventional; Impressionhttps://doi.org/10.4047/jap.2017.9.1.1 http://jap.or.kr J Adv Prosthodont 2017;9:1-13 INTRODUCTION In the conventional impression technique, impression mate - rials on a tray are used to take an impression of  intraoral  structures, after which model materials are poured on to obtain a working model.",Non-OADS,/arxiv_data1/oa_pdf/0e/0b/jap-9-1.PMC5321583.pdf
"+82553605130: e-mail, p-venus79@hanmail.net  Received January 5, 2016 / Last Revision November 9, 2016 / Accepted  December 20, 2016  © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0e/0b/jap-9-1.PMC5321583.pdf
oRCiD Mi-Jung Yun  http://orcid.org/0000-0003-3093-8406Jung-Bo Huh  http://orcid.org/0000-0001-7578-1989 RefeRenCes  1.,Non-OADS,/arxiv_data1/oa_pdf/0e/0b/jap-9-1.PMC5321583.pdf
Available from: http://www.ineedce.com.,Non-OADS,/arxiv_data1/oa_pdf/0e/0b/jap-9-1.PMC5321583.pdf
[J Adv Prosthodont 2017;9:14-21] KEYWORDS: Overdenture; Dental mini implants; Magnets; Precision attachmenthttps://doi.org/10.4047/jap.2017.9.1.14 http://jap.or.kr J Adv Prosthodont 2017;9:14-21 INTRODUCTION The retention and stability of  complete denture can influ- ence a patient’s ability to function and are directly related to patient’s confidence and comfort.,Non-OADS,/arxiv_data1/oa_pdf/03/bd/jap-9-14.PMC5321584.pdf
"+82415500251: e-mail, syshin@dankook.ac.krReceived January 26, 2016 / Last Revision October 14, 2016 / Accepted  December 20, 2016  © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/03/bd/jap-9-14.PMC5321584.pdf
ORCID Eunjee Lee  http://orcid.org/0000-0003-2843-3636Soo-Yeon Shin  http://orcid.org/0000-0001-6160-7277 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/03/bd/jap-9-14.PMC5321584.pdf
"[J Adv Prosthodont 2017;9:22-30] KEYWORDS: Complete denture; Glass fiber mesh; Fatigue loading; Fractography; Fracture resistancehttps://doi.org/10.4047/jap.2017.9.1.22 http://jap.or.kr J Adv Prosthodont 2017;9:22-30 INTRODUCTION PMMA (polymethyl methacrylate), a denture base material, is  more aesthetically pleasing and easier to construct and repair compared to metal, as well as forming superior chemical bonds with resin artificial teeth.",Non-OADS,/arxiv_data1/oa_pdf/05/b3/jap-9-22.PMC5321585.pdf
"+82336403153: e-mail, doctorcj@gwnu.ac.kr Received March 14, 2016 / Last Revision November 1, 2016 / Accepted   / November 17, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/05/b3/jap-9-22.PMC5321585.pdf
ORCID So-Min Im  http://orcid.org/0000-0002-3803-3057 Yoon-Hyuk Huh  http://orcid.org/0000-0003-4072-5199 Lee-Ra Cho  http://orcid.org/0000-0003-3989-2870  Chan-Jin Park  http://orcid.org/0000-0003-4734-214X REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/05/b3/jap-9-22.PMC5321585.pdf
"[J Adv Prosthodont 2017;9:31-7] KEYWORDS: Platform switching; Dental implants; Implant abutments; Dental implant-abutment design; Dental implant-abutment interfacehttps://doi.org/10.4047/jap.2017.9.1.31 http://jap.or.kr J Adv Prosthodont 2017;9:31-7 INTRODUCTION Platform switching, also known as diameter shifting, is a tech- nique combining an implant with a reduced diameter abut - ment.1,2 The concept was introduced in the early 1990s after  development of  a wide diameter implant that was connected to the standard abutment.2,3-5 Since it was introduced, the tech- nique has been evaluated by many researchers; it was proposed that connecting the smaller diameter abutment to a larger implant could help prevent crestal bone loss.",Non-OADS,/arxiv_data1/oa_pdf/49/7f/jap-9-31.PMC5321586.pdf
"+82220723816: e-mail, proskwon@snu.ac.kr Received May 13, 2016 / Last Revision October 26, 2016 / Accepted  November 17, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use,  distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/49/7f/jap-9-31.PMC5321586.pdf
ORCID Se-Young Moon  http://orcid.org/0000-0003-1675-0431Young-Jun Lim  http://orcid.org/0000-0003-2504-9671Myung-Joo Kim  http://orcid.org/0000-0003-2020-5284Ho-Beom Kwon  http://orcid.org/0000-0003-4973-7727 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/49/7f/jap-9-31.PMC5321586.pdf
"[J Adv Prosthodont 2017;9:38-44] KEYWORDS: Surface treatment; Indirect resin composite; Microtensile bond strength; Sandblast; Silane; Ultrasonichttps://doi.org/10.4047/jap.2017.9.1.38 http://jap.or.kr J Adv Prosthodont 2017;9:38-44 INTRODUCTION Indirect resin composites (IRCs) are used to fabricate many  kinds of  both intracoronal and extracoronal dental restorations including inlays, onlays, overlays, veneering material for fixed restorations, and removable dentures.",Non-OADS,/arxiv_data1/oa_pdf/46/1e/jap-9-38.PMC5321587.pdf
"+6622007817-9: e-mail, porntida.sup@mahidol.ac.thReceived May 16, 2016 / Last Revision October 21, 2016 / Accepted  November 17, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/46/1e/jap-9-38.PMC5321587.pdf
ORCID Porntida Visuttiwatanakorn  http://orcid.org/0000-0002-8711-6350 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/46/1e/jap-9-38.PMC5321587.pdf
"[J Adv Prosthodont 2017;9:45-51] KEYWORDS: Canine guidance; Dental occlusion; Centric occlusionhttps://doi.org/10.4047/jap.2017.9.1.45 http://jap.or.kr J Adv Prosthodont 2017;9:45-51 INTRODUCTION In many instances, oral implants provide ideal replacement  of  missing teeth.",Non-OADS,/arxiv_data1/oa_pdf/42/ff/jap-9-45.PMC5321588.pdf
"+61390358998: e-mail, jaafar.abduo@unimelb.edu.auReceived May 24, 2016 / Last Revision November 1, 2016 / Accepted  November 30, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/42/ff/jap-9-45.PMC5321588.pdf
ORCID Jaafar Abduo  http://orcid.org/0000-0003-3392-8641 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/42/ff/jap-9-45.PMC5321588.pdf
[J Adv Prosthodont  2017;9:52-6] KEYWORDS: Bond strength; Co-Cr alloy; Selective laser melting; Metal-ceramic restorationshttps://doi.org/10.4047/jap.2017.9.1.52 http://jap.or.kr J Adv Prosthodont 2017;9:52-6 INTRODUCTION The major challenges related to the use of  porcelain-fused- to-metal (PFM) restorations include their durability and fracture resistance.,Non-OADS,/arxiv_data1/oa_pdf/17/b1/jap-9-52.PMC5321589.pdf
"+989123131755: e-mail, drarashazizi@yahoo.comReceived June 3, 2016 / Last Revision September 20, 2016 / Accepted  October 11, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/b1/jap-9-52.PMC5321589.pdf
ORCID Arash Azizi  http://orcid.org/0000-0001-9219-1219 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/17/b1/jap-9-52.PMC5321589.pdf
"[J Adv  Prosthodont 2017;9:57-66] KEYWORDS: Shear strength; Dental bonding; Enamel; Dentin; Resin cementshttps://doi.org/10.4047/jap.2017.9.1.57 http://jap.or.kr J Adv Prosthodont 2017;9:57-66 INTRODUCTION Resin cements are used for cementation of  crowns, porcelain  veneers, inlays, onlays, and inlay-retained fixed partial den-tures.",Non-OADS,/arxiv_data1/oa_pdf/2a/4f/jap-9-57.PMC5321590.pdf
"15-18 Adhesive failure of  porcelain restorations is related  to debonding, fracture, and/or leakage.14,18 In cases of  adhe -Corresponding author:  Ali Can Bulut Department of Prosthodontics, University of Kırıkkale, Faculty of  Dentistry, Yenisehir mahallesi Çelebi Sokak No:1Yahsiyan-Kırıkkale, TurkeyTel: +90 318 2244927-2244913: e-mail, alicanbulut@outlook.comReceived June 7, 2016 / Last Revision September 13, 2016 / Accepted  October 11, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2a/4f/jap-9-57.PMC5321590.pdf
ORCID Ali Can Bulut  http://orcid.org/0000-0002-1586-7403 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/2a/4f/jap-9-57.PMC5321590.pdf
[J Adv Prosthodont 2017;9:67-73] KEYWORDS: Zirconia; Coloring liquids; Color; Fracture load https://doi.org/10.4047/jap.2017.9.1.67 http://jap.or.kr J Adv Prosthodont 2017;9:67-73 INTRODUCTION The importance of esthetics of dental restorations have  surpassed the mechanical advantages of  metal-ceramic res-torations.,Non-OADS,/arxiv_data1/oa_pdf/45/f3/jap-9-67.PMC5321591.pdf
"+905337175954: e-mail, oekren@cu.edu.trReceived June 27, 2016 / Last Revision August 26, 2016 / Accepted  September 28, 2016 © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/f3/jap-9-67.PMC5321591.pdf
ORCID Ekren Orhun  http://orcid.org/0000-0002-3237-8003 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/45/f3/jap-9-67.PMC5321591.pdf
[J Adv Prosthodont 2017;9:74-6] KEYWORDS: Polymer; Polyaryletherketone (PAEK); Implant overdenture; Telescopic abutmenthttps://doi.org/10.4047/jap.2017.9.1.74 http://jap.or.kr J Adv Prosthodont 2017;9:74-6 INTRODUCTION Implant-supported overdenture treatment is very useful for  patients undergoing full mouth rehabilitation.,Non-OADS,/arxiv_data1/oa_pdf/da/71/jap-9-74.PMC5321592.pdf
"+82625305638: e-mail, mcnihil@jnu.ac.krReceived May 25, 2016 / Last Revision November 30, 2016 / Accepted  December 20, 2016  © 2017  The Korean Academy of Prosthodontics This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/da/71/jap-9-74.PMC5321592.pdf
ORCID Chan Park  http://orcid.org/0000-0001-5729-5127Dae-Jeon Jun  http://orcid.org/0000-0001-6991-0262Sang-Won Park  http://orcid.org/0000-0002-9376-9104Hyun-Pil Lim  http://orcid.org/0000-0001-5586-1404 REFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/da/71/jap-9-74.PMC5321592.pdf
"One variant comprised the full extracellular portion of  CD23, including the stalk and head domain; 1 variant was identical with the first, except for an  This is an open access article under the CC BY-NC-ND license ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/11/32/emss-71376.PMC5321597.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/90/86/main.PMC5321611.pdf
http://dx.doi.org/10.1016/j.jcte.2016.09.001Journal of Clinical & Translational Endocrinology 6 (2016) 15–22 Contents lists available at ScienceDirect Journal of Clinical & Translational Endocrinology journal homepage: www.elsevier.com/locate/jcte,Non-OADS,/arxiv_data1/oa_pdf/90/86/main.PMC5321611.pdf
"A complete list of staff and investigators hasbeenprovidedbySorlieP.,etal.inAnnEpidemiol.2010Aug;20: 642–649andisalsoavailableonthestudywebsite http://www.cscc .unc.edu/hchs/ .BryanSayerof Social&ScientiﬁcSystems,Inc.pro- videdstatisticalprogrammingsupportunderContractNo.GS-10F- 0381L.",OADS,/arxiv_data1/oa_pdf/90/86/main.PMC5321611.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ Correspondence to: Qun Zhou, MD, PhD, Associate Professor, Department of Biochemistry and Molecular Biology, University of  Maryland School of Medicine, 108 North Greene Street, Baltimore, MD 21201, United States.",Non-OADS,/arxiv_data1/oa_pdf/d7/d2/nihms-799505.PMC5321620.pdf
"The website of the iPOG network is part of the website of The Hospital for Sick Children (SickKids, Toronto, Canada)and can be found at: http://www.sickkids.ca/Research/iPOG/ .",Non-OADS,/arxiv_data1/oa_pdf/09/2e/520_2016_Article_3501.PMC5321691.pdf
Available from:https://www.stjude.org/about-st-jude.html 3.,Non-OADS,/arxiv_data1/oa_pdf/09/2e/520_2016_Article_3501.PMC5321691.pdf
Available from: http://www.prinsesmaximacentrum.,Non-OADS,/arxiv_data1/oa_pdf/09/2e/520_2016_Article_3501.PMC5321691.pdf
Availablefrom: http://www.mascc.org/ 10.,Non-OADS,/arxiv_data1/oa_pdf/09/2e/520_2016_Article_3501.PMC5321691.pdf
[cited 2015 December22nd] Available from: http://www.sickkids.ca/Research/iPOG/ 34.,Non-OADS,/arxiv_data1/oa_pdf/09/2e/520_2016_Article_3501.PMC5321691.pdf
Available at: http://www.mascc.org1134 Support Care Cancer (2017) 25:1127 –1135,Non-OADS,/arxiv_data1/oa_pdf/fa/63/520_2016_Article_3502.PMC5321708.pdf
"Vosaroxin has shown promising anticancer effects and a phase III clinical trial study for vosaroxin in combination with cytarabine (VALOR) for the treatment of relapsed and refractory acute myeloid leukemia has been completed by Sunesis Pharma- ceuticals, Inc. (http://www.sunesis.com/patients_and_ care- givers/clinical_trials/Vosaroxin.php), as indicated in [86, 87].",Non-OADS,/arxiv_data1/oa_pdf/4f/6b/CG-18-75.PMC5321768.pdf
"http://www.ncbi.nlm.nih .gov/projects/SNP/ (Accessed January 22,   2016 )  [14] The ClinVar database.",OADS,/arxiv_data1/oa_pdf/e2/c9/CG-18-93.PMC5321774.pdf
"http://www.ncbi .nlm.nih.gov/books/NBK1116/  (Accessed January 22, 2016)   [17] The NIH Genetic Testing Registry (GTR).",OADS,/arxiv_data1/oa_pdf/e2/c9/CG-18-93.PMC5321774.pdf
"http://www.uniprot.org/  (Accessed January 22, 2016 )  [19] Exome Sequencing Project (ESP).",OADS,/arxiv_data1/oa_pdf/e2/c9/CG-18-93.PMC5321774.pdf
"http://evs.gs.washington.edu/  EVS/ (Accessed January 22, 2016 )  [20] Ng, P. C.; Henikoff, S. Predicting deleterious amino acid  substitutions.",OADS,/arxiv_data1/oa_pdf/e2/c9/CG-18-93.PMC5321774.pdf
‘‘Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation.’’ <http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2016/07/WC500211315.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/da/45/PSP4-6-71.PMC5321806.pdf
<http://www.ema.europa.eu/ema/index.jsp?curl 5pages/ news_and_events/events/2016/10/event_detail_001331.jsp&mid 5WC0b01ac058004d5c3 >.,Non-OADS,/arxiv_data1/oa_pdf/da/45/PSP4-6-71.PMC5321806.pdf
<https://aidsinfo.nih.gov/contentfiles/lvgui- delines/adultandadolescentgl.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
<http://packageinserts.bms.com/pi/pi_evotaz.pdf >(2009).,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
<http://packageinserts.bms.com/pi/pi_sustiva.pdf >(2009).,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
<http://norvir.com/ >.,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRe- gulatoryInformation/Guidances/ucm072123.pdf >(1999).,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)PK of EFV/ATV/RTV in Aging Dumond et al.,Non-OADS,/arxiv_data1/oa_pdf/5f/e3/PSP4-6-128.PMC5321807.pdf
<http://www.ebi.ac.uk/biomodels- main/agedbrain/ >;<http://www.ebi.ac.uk/biomodels-main/NDModels-map/ >.,Non-OADS,/arxiv_data1/oa_pdf/a1/8f/PSP4-6-73.PMC5321808.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Mathematical Models of Neurodegeneration Lloret-Villas et al .,Non-OADS,/arxiv_data1/oa_pdf/a1/8f/PSP4-6-73.PMC5321808.pdf
<https://aidsinfo.nih.gov/contentfiles/lvgui- delines/adultandadolescentgl.pdf >.,Non-OADS,/arxiv_data1/oa_pdf/63/ef/PSP4-6-120.PMC5321809.pdf
<http://www.gilead.com/medicines >.,Non-OADS,/arxiv_data1/oa_pdf/63/ef/PSP4-6-120.PMC5321809.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)PK of TFV/FTC in Aging Dumond et al.,OADS,/arxiv_data1/oa_pdf/63/ef/PSP4-6-120.PMC5321809.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Multiscale Modeling of Drug Interactions in Humans Thiel et al.,OADS,/arxiv_data1/oa_pdf/00/c4/PSP4-6-136.PMC5321810.pdf
administration and morphine free base dose (mg).18 cUrinary excreted ratio of unchanged morphine was assumed to be 10% from the data of package insert (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202515s000lbl.pdf) and the report by Osborne et al .,OADS,/arxiv_data1/oa_pdf/7f/a2/PSP4-6-110.PMC5321811.pdf
<https://www.pharmgkb.org >.,Non-OADS,/arxiv_data1/oa_pdf/7f/a2/PSP4-6-110.PMC5321811.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Morphine PBPK Model With OCT1 Emoto et al.,OADS,/arxiv_data1/oa_pdf/7f/a2/PSP4-6-110.PMC5321811.pdf
"To show the avail-ability of several software tools developed for NLMEM estima- tion and simulation, the steps of simulating data, estimating parameters, and computing evaluation metrics were per-formed using a variety of software, including R (https://cran.r-project.org/), NONMEM (http://www.iconplc.com/innovation/solutions/nonmem/), MONOLIX (http://lixoft.com/products/ monolix/), and PHOENIX (https://www.certara.com/software/pkpd-modeling-and-simulation/phoenix-nlme/).",OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
"Parameter estimation, computation of evaluation metrics, and software Population parameters were estimated using the default option of the Stochastic Approximation Expectation Maximi- zation algorithm implemented in MONOLIX version 4.3.3(http://lixoft.com/products/monolix/).",OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
"Parameter estimation, computation of evaluation metrics, and software Data simulation was performed using NONMEM version 7.3 (http://www.iconplc.com/innovation/solutions/nonmem/).",OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
<http://www.page-meeting.org/default.,Non-OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
"& Guzy, S. QRPEM—a new standard of accuracy, precision, and efficiency in NLME population PK/PD methods.Pharsight Certara Co .<https://www.certara.com/wp-content/uploads/Resources/ Brochures/BR_Top10ReasonsWhyPhoenixNLME.pdf >(2011).",OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
Supplementary information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://psp-journal.com)Evaluation Graphs for Population PK/PD Models Nguyen et al.,OADS,/arxiv_data1/oa_pdf/07/71/PSP4-6-87.PMC5321813.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b8/be/main.PMC5322169.pdf
The  ascending  aorta  was  exposed http://dx.doi.org/10.1016/j.ijscr.2017.02.002 2210-2612/© 2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/be/main.PMC5322169.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
http://dx.doi.org/10.1016/j.idcr.2017.02.003 2214-2509/©  2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  8  (2017)  6–8 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locat  e/idcr,Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"N  Engl  J Med  2014;371:654 –66,  doi:http://dx.doi.org/10.1056/NEJMra1312353 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Kidney  Int 2001;60:831 –46,  doi:http://dx.doi.org/10.1046/j.1523-1755.2001.060003831.",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Clin Infect  Dis  2012;54:1413 –21,  doi:http://dx.doi.org/10.1093/cid/cis196 .",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Kidney  Int  2006;70:423 –31, doi:http://dx.doi.org/10.1038/sj.ki.5001581 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Kidney  Int 2002;62:1093 –104,  doi:http://dx.doi.org/10.1046/j.1523-1755.2002.00543.x .",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Microbiol  Spectr  2014;2:0024 –2013,  doi:http://dx.doi.org/10.1128/ microbiolspec.EHEC-0024-2013  EHEC-0024-2013 .",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Appl  Microbiol  Biotechnol  2016;100:1597 –610,  doi:http://dx.doi.org/10.1007/ s00253-015-7236-3 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Toxins (Basel)  2011;3:626 –39,  doi:http://dx.doi.org/10.3390/toxins3060626 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"J  Clin  Microbiol  2013;51:481 –6,  doi:http://dx.doi.org/10.1128/ JCM.02219-12 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Emerg  Infect  Dis  2015;21:891 –2,  doi:http://dx.doi.org/ 10.3201/eid2105.140621 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Lancet  (London, England)  1999;353:1498,  doi:http://dx.doi.org/10.1016/S0140-6736(99) 00961-7 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Emerg  Infect  Dis  2016;22:679 –86,  doi:http://dx.doi.org/10.3201/ eid2204.",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Appl  Environ  Microbiol  2013;79:4862 –8,  doi:http://dx.doi.org/10.1128/ AEM.01158-13 .",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"N  Engl  J  Med  2000;342:1930 –6,  doi:http://dx.doi.org/10.1056/ NEJM200006293422601 .",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Trans  R  Soc  Trop Med  Hyg  2012;106:395 –9,  doi:http://dx.doi.org/10.1016/j.trstmh.2012.04.001 .",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Antimicrob  Agents Chemother  2012;56:3277 –82,  doi:http://dx.doi.org/10.1128/AAC.",Non-OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"Emerg  Infect  Dis  2016;22:1604 –12,  doi:http://dx.doi.",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
"PLoS  One  2013;8:e64097,  doi:http://dx.doi.org/10.1371/ journal.pone.0064097 .8  C.  Adams  et  al.",OADS,/arxiv_data1/oa_pdf/e4/54/main.PMC5322170.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Uterine sarcomaLeiomyosarcomaEndometrial stromal sarcomaHistomorphologyImmunohistochemistryMolecular testing 1.,Non-OADS,/arxiv_data1/oa_pdf/62/07/main.PMC5322171.pdf
Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor http://dx.doi.org/10.1016/j.gore.2017.02.006 2352-5789/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/62/07/main.PMC5322171.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/62/07/main.PMC5322171.pdf
This  is  an  open  access  article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3a/47/main.PMC5322173.pdf
http://dx.doi.org/10.1016/j.ijscr.2017.01.054 2210-2612/© 2017  Published  by  Elsevier  Ltd  on  behalf  of  IJS  Publishing  Group  Ltd.,Non-OADS,/arxiv_data1/oa_pdf/3a/47/main.PMC5322173.pdf
"(April)  (2015), http://dx.doi.org/10.1111/ans.13064 .",Non-OADS,/arxiv_data1/oa_pdf/3a/47/main.PMC5322173.pdf
This  is  an  open access article under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/82/3d/main.PMC5322175.pdf
The patient  was  commenced  on  deoxycholic  acid  and  referred  to  our http://dx.doi.org/10.1016/j.ijscr.2017.02.001 2210-2612/© 2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/82/3d/main.PMC5322175.pdf
"Thompson,  R.J.  Ede,  Clearance  of  refractory  bile duct stones  with  extracorporeal  shockwave  lithotripsy,  Gut  47  (2000) 728–731,  http://dx.doi.org/10.1136/gut.47.5.728 .",Non-OADS,/arxiv_data1/oa_pdf/82/3d/main.PMC5322175.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/88/e2/main.PMC5322208.pdf
http://dx.doi.org/10.1016/j.ijscr.2017.02.007 2210-2612/© 2017  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/88/e2/main.PMC5322208.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1d/ff/main.PMC5322209.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.c om/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2017.02.009 2213-0071/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/1d/ff/main.PMC5322209.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Respiratory Medicine Case Reports 20 (2017) 160 e163,Non-OADS,/arxiv_data1/oa_pdf/1d/ff/main.PMC5322209.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Child careChronic disease risk Role modeling Family child care homesObesity 1.,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
http://dx.doi.org/10.1016/j.pmedr.2016.11.010 2211-3355/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
"URL: http://www.cssp.org/publications/neighborhood- investment/strengthening-families/top- ﬁve/almost-like-family-family-child-care- october-2009.pdf Bureau of Labor Statistics, US Department of Labor, Occupational Outlook Handbook, 2016 –17 edition, Childcare Workers.",Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
"2016 –2017; http://www.bls.gov/ooh/ personal-care-and service/childcare-workers.htm (visited May 25, 2016).",Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
"URL: http://usa.childcareaware.org/advocacy-public-policy/ resources/reports-and-research/statefactsheets/ Cohen, S., Kamarck, T., Mermelstein, R., 1983.",Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
URL: https://sleepfoundation.org/media-center/press-release/poll-reveals-sleep- differences-among-ethnic-groups .,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
URL: https://www.choosemyplate.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/2d/21/main.PMC5322210.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: ERDOscillationsMagnetoencephalographyMEGMovement disordersAsymmetry 1.,Non-OADS,/arxiv_data1/oa_pdf/9a/8b/main.PMC5322212.pdf
http://dx.doi.org/10.1016/j.nicl.2017.02.010 2213-1582/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/9a/8b/main.PMC5322212.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9a/8b/main.PMC5322212.pdf
This is an open access article underthe CCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 1.,Non-OADS,/arxiv_data1/oa_pdf/d8/b2/main.PMC5322213.pdf
"However,this is known to be a challenging highly subjective task since the http://dx.doi.org/10.1016/j.nicl.2017.01.033 2213-1582/©2017The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d8/b2/main.PMC5322213.pdf
This is an open access article underthe CC BY-NC-ND license( http://creativecommons.org/licenses/by-nc-nd/4.0/ ),Non-OADS,/arxiv_data1/oa_pdf/d8/b2/main.PMC5322213.pdf
(https://www.nice.org.uk/ guidance/cg185)17National Institute for Health and Care Excellence.,Non-OADS,/arxiv_data1/oa_pdf/4c/62/bjporcpsych003939.PMC5322255.pdf
(https://www.nice.org.uk/guidance/cg178) 18National Institute for Health and Care Excellence.,Non-OADS,/arxiv_data1/oa_pdf/4c/62/bjporcpsych003939.PMC5322255.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ © The Author(s) 2017 Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)Epigenetic activation of AR transcription by PRMT5 X Deng et al 1231 Oncogene (2017) 1223 –1231",Non-OADS,/arxiv_data1/oa_pdf/24/fa/onc2016287a.PMC5322258.pdf
"Permutation methods for peak cluster level errorcorrection (AlphaSim, http://afni.nimh.nih.gov/afni/) were applied for thiswhole-brain analysis by taking into account the signi ﬁcance of the peak voxel ( P-valueo0.005), thereby controlling for multiple comparisons (returning a minimum of 195 voxels).",OADS,/arxiv_data1/oa_pdf/aa/87/mp201655a.PMC5322273.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/ © HT Karim et al (2017) Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Intrinsic functional connectivity in late-life depression HT Karim et al 457 Molecular Psychiatry (2017), 450 –457",Non-OADS,/arxiv_data1/oa_pdf/aa/87/mp201655a.PMC5322273.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ © The Author(s) 2017 Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Hyperactivity caused by chromosome 16p13.11 microduplication M Fujitani et al 374 Molecular Psychiatry (2017), 364 –374",Non-OADS,/arxiv_data1/oa_pdf/9d/50/mp2016106a.PMC5322274.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Multi-omics analysis of a 22q11.2 deletion syndrome mouse model H Wesseling et al 395 Molecular Psychiatry (2017), 384 –395",Non-OADS,/arxiv_data1/oa_pdf/c0/e0/mp201627a.PMC5322275.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)Osmotin ameliorates AD neuropathology SA Shah et al 416 Molecular Psychiatry (2017), 407 –416",Non-OADS,/arxiv_data1/oa_pdf/1f/cc/mp201623a.PMC5322276.pdf
"Find- ing and functional annotation of genes wereperformed using MiGAP (http://www.migap.org), and the result was curated manually.",OADS,/arxiv_data1/oa_pdf/b1/c4/ismej2016143a.PMC5322295.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Genome of a specialized H2-oxidizing symbiont H Kuwahara et al 776 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/b1/c4/ismej2016143a.PMC5322295.pdf
"To view a copyof this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/ Supplementary Information acc ompanies this paper on The ISME Journal web site (http://www.nature.com/ismej)Vitamin B1 precursors sustain key marine picoalgae RW Paerl et al 765 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/a0/22/ismej2016145a.PMC5322297.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/Fe(III) reduction by G. sulfurreducens CE Levar et al 752 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/22/41/ismej2016146a.PMC5322298.pdf
"Annotation, functional and comparative analysis of the symbiont genomes The putative origin of replication was set with GenSkew (http://genskew.csb.univie.ac.at/).",OADS,/arxiv_data1/oa_pdf/d9/d8/ismej2016148a.PMC5322300.pdf
"Phylogenetic trees were visualized with FigTree v1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/) andiTOL (Letunic and Bork, 2011).",OADS,/arxiv_data1/oa_pdf/d9/d8/ismej2016148a.PMC5322300.pdf
"Miller MA, Pfeiffer W, Schwartz T. (2010), Creating the CIPRES Science Gateway for inference of large phylo- genetic trees http://www.phylo.org/ accessed 9 April 2016).",OADS,/arxiv_data1/oa_pdf/d9/d8/ismej2016148a.PMC5322300.pdf
"To view a copyof this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Convergent evolution of mealybug symbioses G Szabó et al 726 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/d9/d8/ismej2016148a.PMC5322300.pdf
"Our QIIME pipeline and NMDS workflow in R are available on github (https://github.com/lmsolden/Qiime-pipeline, h ttps://github.com/lmsol den/NMDS-with-loadings).",OADS,/arxiv_data1/oa_pdf/c5/8f/ismej2016150a.PMC5322302.pdf
"For sequence-based comparison, average amino acid identity (AAI) and average nucleotide identity(ANI) values were calculated using the ANI andAAI calculators from the Kostas lab calculator (http://enve-omics.ce.gatech.edu/).",OADS,/arxiv_data1/oa_pdf/c5/8f/ismej2016150a.PMC5322302.pdf
"Alignments were concatenated to form an 11-gene, 63 taxa alignment and then run through ProtPipeliner, a python scriptdeveloped in-house for generation of phylogenetic trees (https://github.com/lmsolden/protpipeliner).The pipeline runs as follows: alignments are curated with minimal editing by GBLOCKS (Talavara and Castresana, 2007), and model selection conducted via ProtTest 3.4 (Darriba et al., 2011).",OADS,/arxiv_data1/oa_pdf/c5/8f/ismej2016150a.PMC5322302.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www .nature.com/ismej)New roles in hemicellulosic sugar fermentation LM Solden et al 703 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/c5/8f/ismej2016150a.PMC5322302.pdf
"Supplementary information accompanies this paper at http://www.nature.com/srepCompeting financial interests: The authors declare no competing financial interests.How to cite this article: Inagaki, S. et al.",Non-OADS,/arxiv_data1/oa_pdf/ed/3f/srep42398.PMC5322354.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/   © The Author(s) 2017",Non-OADS,/arxiv_data1/oa_pdf/ed/3f/srep42398.PMC5322354.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/87/c0/evv033.PMC5322541.pdf
"Among the samples, the average mapping rate of reads was 93.3%.Potential polymerase chain reaction duplicates were marked using Picard software ( http://picard.sourceforge.net ,l a s t accessed March 5, 2015).",OADS,/arxiv_data1/oa_pdf/87/c0/evv033.PMC5322541.pdf
"1994 ) and only the sites that have the same amino acid residues between human and macaque reference proteins inthe alignment were analyzed through the PolyPhen-2 website(http://genetics.bwh.harvard.edu/pph2/ , last accessed March 5, 2015).",OADS,/arxiv_data1/oa_pdf/87/c0/evv033.PMC5322541.pdf
Supplementary Material Supplementary table S1 andﬁgures S1 andS2a r ea v a i l a b l ea t Genome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/87/c0/evv033.PMC5322541.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-?commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/90/37/evv026.PMC5322549.pdf
"We started by aligning species-speciﬁc assemblies to the probe sequences using the programLASTZ (available from http://www.bx.psu.edu/miller_lab/ last accessed February 20, 2015).",OADS,/arxiv_data1/oa_pdf/90/37/evv026.PMC5322549.pdf
Available from: http://dx.doi.org/10.6084/m9.ﬁgshare.658946 .,OADS,/arxiv_data1/oa_pdf/90/37/evv026.PMC5322549.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/da/2e/evv036.PMC5322551.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/e6/evv024.PMC5322552.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/51/95/evv037.PMC5322555.pdf
"De novo assembly was performed using CLCbio wb6.0 ( http://www.clcbio.com/ , last accessed March 10, 2015).",OADS,/arxiv_data1/oa_pdf/51/95/evv037.PMC5322555.pdf
"2000)(http://www.ncbi.nlm.nih.gov/COG/ , last accessed March 10, 2015) with an Evalue cutoff of 1e /C05.F o re a c hC O Gm a p - ping, functional assignment was provided based on COG gen-eral category letter associati ons.",OADS,/arxiv_data1/oa_pdf/51/95/evv037.PMC5322555.pdf
"2014 )(http://www.cazy.org/ , last accessed March 10, 2015) on dbCAN web server ( Yin et al.",OADS,/arxiv_data1/oa_pdf/51/95/evv037.PMC5322555.pdf
"Transposable Elements an d Repeat-Induced Point Mutation Analysis The transposable elements (TEs) were classiﬁed by subjecting genome sequences of Bb, Ht3 ,Ht6,andOsto BLASTn against the Repbase ( http://girinst.org , last accessed March 10, 2015) libraries of RepeatMasker ( http://www.repeatmasker.org ,l a s t accessed March 10, 2015).",OADS,/arxiv_data1/oa_pdf/51/95/evv037.PMC5322555.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/55/a3/evv027.PMC5322560.pdf
Organelle intronswere identiﬁed with RNAweasel ( http://megasun.bch.umon- treal.ca/RNAweasel/ ) and through alignments with other chla- mydomonadalean organelle DNAs.,Non-OADS,/arxiv_data1/oa_pdf/55/a3/evv027.PMC5322560.pdf
Available from: http://www.who.int/ceh/risks/cehair/en/.,OADS,/arxiv_data1/oa_pdf/3a/e6/JRMS-21-108.PMC5322685.pdf
Available from: http://www.euro.who.int/__data/assets/ pdf_file/0004/97042/4.4.‑Exposure‑of‑children‑to‑chemical‑ hazards‑in‑food‑EDITED_layouted.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3a/e6/JRMS-21-108.PMC5322685.pdf
Available from: http://www.lea‑test.fi/.,Non-OADS,/arxiv_data1/oa_pdf/87/6f/IJO-64-888.PMC5322702.pdf
Available from: http://www.epidata.dk.,Non-OADS,/arxiv_data1/oa_pdf/87/6f/IJO-64-888.PMC5322702.pdf
"lumc.nl/LOVD2/Usher_montpellier/home.php?select_ db=CHM, http://www.retina‑international.org/sci‑news/ databases/mutation‑database/chm‑mutation/).",OADS,/arxiv_data1/oa_pdf/d9/12/IJO-64-924.PMC5322709.pdf
"The PARP family: ADP-ribose writers The PARP family consists of 17 members that have distinct structural domains, activities, subcellular [Keywords : poly(ADP-ribose) (PAR); mono(ADP-ribose) (MAR); poly (ADP-ribose) polymerase (PARP); gene regulation; DNA repair; RNAbiology]Corresponding author: lee.kraus@utsouthwestern.eduArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.291518.116.© 2017 Gupte et al.",Non-OADS,/arxiv_data1/oa_pdf/5a/0f/101.PMC5322727.pdf
"This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License(Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/5a/0f/101.PMC5322727.pdf
2016) created a da-tabase (http://ADPriboDB.leunglab.org) that provides acomprehensive list of ADP-ribosylated proteins derivedfrom >400 publications.,OADS,/arxiv_data1/oa_pdf/5a/0f/101.PMC5322727.pdf
"In particular,seminal work from Wasserman (1926) and others illustrat-ed that adipocytes first emerge in conjunction with dense [Keywords : adipocyte precursor; adipogenesis; beige adipocytes; brown adipocytes; white adipocytes]Corresponding author: rana.gupta@utsouthwestern.eduArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.293704.116.© 2017 Hepler et al.",Non-OADS,/arxiv_data1/oa_pdf/06/b4/127.PMC5322728.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/06/b4/127.PMC5322728.pdf
"Aftersix months, it is available under a Creative Commons License (Attribu-tion-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/06/b4/127.PMC5322728.pdf
Graphic illustrations in this review weredesigned by Visually Medical (http://www.visuallymedical.com).,Non-OADS,/arxiv_data1/oa_pdf/06/b4/127.PMC5322728.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.293910.116.© 2017 Zhu et al.,OADS,/arxiv_data1/oa_pdf/33/75/141.PMC5322729.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/33/75/141.PMC5322729.pdf
"Aftersix months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creati-vecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/33/75/141.PMC5322729.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.285684.116.© 2017 Lo et al.,Non-OADS,/arxiv_data1/oa_pdf/c5/9b/154.PMC5322730.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/c5/9b/154.PMC5322730.pdf
"Aftersix months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creati-vecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/c5/9b/154.PMC5322730.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.290635.116.,Non-OADS,/arxiv_data1/oa_pdf/f9/75/172.PMC5322731.pdf
"This article, published in Genes &Development , is available under a Creative Commons License (Attribution-NonCom-mercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/f9/75/172.PMC5322731.pdf
Article and publication date areonline at http://www.genesdev.org/cgi/doi/10.1101/gad.291948.116.© 2017 Liao et al.,Non-OADS,/arxiv_data1/oa_pdf/92/87/184.PMC5322732.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/92/87/184.PMC5322732.pdf
"Aftersix months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creati-vecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/92/87/184.PMC5322732.pdf
Analysis of the somatic mutation data set and focal deletion data set The data sets of somatic mutations and focal deletions of lung ad- enocarcinoma patients were from TCGA (http://cancergenome.nih.gov).,OADS,/arxiv_data1/oa_pdf/92/87/184.PMC5322732.pdf
2010)was used to identify DEGs and generate the CPM expression val- ues used for GSEA (http://www.broadinstitute.org/gsea) (Subra- manian et al.,OADS,/arxiv_data1/oa_pdf/92/87/184.PMC5322732.pdf
"After modeling the myeloid progenitor ’s chromosomal contact data in the confines of a toroidalnucleus, the investigators found similar results and [Keywords : genome topology; Lamin B receptor; neutrophils; nucleoli; rDNA]Corresponding author: katia.georgopoulos@cbrc2.mgh.harvard.eduArticle is online at http://www.genesdev.org/cgi/doi/10.1101/gad.296228.117.© 2017 Georgopoulos This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).After six months, it is available under a Creative Commons License (At-tribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/ce/de/85.PMC5322735.pdf
"*Correspondence to: Roberto Maggi; Email: roberto.maggi@unimi.it Submitted: 02/10/2014; Revised: 06/10/2014; Accepted: 07/15/2014; Published Online: 07/28/2014 http://dx.doi.org/10.4161/neur.29950Citation: Cariboni A, Conti L, Andrè V, Aprile D, Zasso J, Maggi R. Establishment of a radial glia-like mouse fetal hypothalamic neural stem cell line (AC1) able to differentiate into neuroendocrine cells.",Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
"Neurogenesis 2014; 1:e29950; http://dx.doi.org/10.4161/neur.29950Establishment of a radial glia-like mouse fetal  hypothalamic neural stem cell line (AC1) able   to differentiate into neuroendocrine cells Anna Cariboni1,2,†, Luciano Conti3,†, Valentina Andrè1, Davide Aprile1, Jacopo Zasso3, and r oberto Maggi1,2,* 1Dipartimento di Scienze f armacologiche e b iomolecolari; Sez.",Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Brain Res Brain Res Rev 1997; 24:255-91;  PMID:9385456 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Development 2007; 134:3771-80; PMID:17898002 ;  http://dx.doi.org/10.1242/dev.006379 3.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Mol Cell Endocrinol 2010; 323:115- 23; PMID:20385202 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Nat Neurosci 2012; 15:700-2; PMID:22446882 ; http://dx.doi.org/10.1038/ nn.3079 5.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
J Neurosci 2004; 24:2886- 97; PMID:15044527 ; http://dx.doi.org/10.1523/ JNEUROSCI.4161-03.2004 6.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Development 2005; 132:5185-97; PMID:16284116 ; http://dx.doi.org/10.1242/ dev.02094 7.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Proc Natl Acad Sci U S A 2008; 105:11796-801; PMID:18697938 ; http://dx.doi.org/10.1073/ pnas.0803078105 8.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
PLoS One 2009; 4:e4392; PMID:19197372 ;  http://dx.doi.org/10.1371/journal.pone.0004392 9.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
PLoS Biol  2005; 3:e283;  PMID:16086633 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Neurobiol Dis 2009; 34:320-31; PMID:19236914 ;  http://dx.doi.org/10.1016/j.nbd.2009.02.00711.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Brain Res  Dev Brain Res 1988; 44:95-108; PMID:3069243 ;  http://dx.doi.org/10.1016/0165-3806(88)90121-6 12.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Cell  Mol Life Sci 2011; 68:1769-83; PMID :20981563 ;  http://dx.doi.org/10.1007/s00018-010-0548-7 13.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Cell Death Differ 2008; 15:1847- 56; PMID:19011641 ; http://dx.doi.org/10.1038/ cdd.2008.118 14.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Prog Neurobiol 2007; 83:53-67; PMID:17449166 ;  http://dx.doi.org/10.1016/j.pneurobio.2007.02.008 15.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Expert Opin Drug Discov 2013; 8:1083-94;  PMID:23725548 ; http://dx.doi.org/10.1517/174604 41.2013.805199 17.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
J  Toxicol Environ Health B Crit Rev 2011; 14:292-9;  PMID:21790313 ; http://dx.doi.org/10.1080/109374 04.2011.578553 18.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Nat Rev Neurosci  2010; 11:176-87;  PMID:20107441 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Dev Dyn 2008;  237:2295-303;  PMID:18729222 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Am J Physiol Endocrinol Metab 2009; 297:E563- 7; PMID:19383874 ; http://dx.doi.org/10.1152/ ajpendo.00064.200921.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
J Histochem Cytochem 2003;  51:41-54;  PMID:12502753 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Genes Dev 1995; 9:3122-35; PMID :8543156 ;  http://dx.doi.org/10.1101/gad.9.24.3122 23.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Genes Dev  1998; 12:3264-75;  PMID:9784500 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Genes Cells  2001; 6:361-74;  PMID:11318878 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Mol  Endocrinol 2006; 20:1623-32; PMID:16469766 ;  http://dx.doi.org/10.1210/me.2005-0518 26.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Genes Dev 1999; 13:2787-800;  PMID:10557207 ; http://dx.doi.org/10.1101/ gad.13.21.2787 27.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Annu Rev Neurosci 2001; 24:677-736;  PMID:11520916 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
Brain Res 2007; 1174:28-38; PMID:17854778 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6a/9e/kngs-01-01-10929950.PMC5322806.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/ by-nc-nd/3.0/  © The Author(s) 2017OPEN Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/c7/6a/srep41664.PMC5322809.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3c/68/tcrm-13-207.PMC5322810.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2017:13 207–213Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  207ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S12248 9 evaluation of external pressure to the sacral  region in the lithotomy position using the  noninvasive pressure distribution measurement  system Ju Mizuno1 T oru Takahashi2 1Department of anesthesiology and  Pain Medicine, Juntendo University,   Faculty of Medicine, Bunkyo-ku,   T okyo, 2Faculty of health and Welfare  science, Okayama Prefectural  University, soja-shi, Okayama, JapanBackground:  Pressure ulcers (PUs) in the sacral region can be a complication of surgical  procedures performed in the lithotomy position.",Non-OADS,/arxiv_data1/oa_pdf/3c/68/tcrm-13-207.PMC5322810.pdf
"The development of PUs has been Correspondence: Ju Mizuno Department of anesthesiology and Pain  Medicine, Juntendo University, Faculty  of Medicine, 3-1-3 hongo, Bunkyo-ku,  Tokyo 113-8431, Japan Tel +81 3 3813 3111 Fax +81 3 5689 3820 email jmizuno@juntendo.ac.j p Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Mizuno and Takahashi Running head recto: External pressure to the sacral region DOI: http://dx.doi.org/10.2147/TCRM.S122489",Non-OADS,/arxiv_data1/oa_pdf/3c/68/tcrm-13-207.PMC5322810.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/3c/68/tcrm-13-207.PMC5322810.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/68/tcrm-13-207.PMC5322810.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Vascular Health and Risk Management  2017:13 43–54Vascular Health and Risk Management Dovepress submit your manuscript | www.dovepress.com Dovepress  43 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/VHRM.S105721An evidence-based practice-oriented review  focusing on canagliflozin in the management of  type 2 diabetes Joseph A Messana1  Stanley S Schwartz2,3  Raymond R T ownsend1 1Nephrology Division, Perelman  School of Medicine, University of  Pennsylvania, 2Main Line Health,   3Department of Medicine, University  of Pennsylvania, Philadelphia, PA, USAAbstract:  Caring for patients with type 2 diabetes mellitus (T2DM) has entered an era with  many recent additions to the regimens used to clinically control their hyperglycemia.",Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"Moreover, the prevalence of T2DM among adolescents is increasing, 6 and this is expected to increase by an  additional 50% by 2050.7 Tragically, earlier onset and a longer duration of diabetes  enhance the likelihood of microvascular and macrovascular disease manifestations, including coronary artery disease, stroke, peripheral artery disease, and kidney failure, Correspondence: Raymond R Townsend   Renal, Electrolyte and Hypertension  Division, Perelman School of Medicine, University of Pennsylvania, 122 Founders Building, 3400 Spruce Street, Philadelphia, PA 19104, USA Tel +1 215 614 0423   Fax +1 215 662 3459   Email townsend@upenn.eduJournal name: Vascular Health and Risk Management  Article Designation: REVIEWY ear: 2017V olume: 13Running head verso: Messana et alRunning head recto: Canagliflozin in the management of T2DMDOI: http://dx.doi.org/10.2147/VHRM.S105721",Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"The FDA issued a safety announcement regarding the issue, encouraging additional vigilance among providers (http://www.medscape.com/viewarticle/862009?src=medscapeapp-ipad&ref=email; accessed on August 29, 2016; MedScape account [free] needed).",Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"To date, a combined analysis of nine studies of canagliflozin conducted prior to FDA approval observed a lower occur - rence of major adverse CV events, including fatal/nonfatal heart attack, fatal/nonfatal stroke, death from CV causes, or hospitalization due to unstable angina, with canagliflozin ver - sus other antihyperglycemic medication (18.9 vs 20.5 events per 1000 patient-years) as shown at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000SumR.pdf (accessed on  September 1, 2016).",Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
Available from: http://www.cdc.gov/diabetes/pdfs/data/2014-report-national-diabetes-statistics-report-data-sources.pdf.,OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
Available from: https://clini-caltrials.gov/ct2/show/NCT02065791.,Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"Vascular Health and Risk Management  2017:13submit your manuscript | www.dovepress.com Dovepress Dovepress Vascular Health and Risk Management  Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.",Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.Dovepress 54 Messana et al,Non-OADS,/arxiv_data1/oa_pdf/a5/8a/vhrm-13-043.PMC5322811.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2017:11 277–281Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  277PersPectivesopen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/PPA.S12307 3 Forming a support group for people affected by  inflammatory bowel disease Nidhi swarup1 saumya Nayak2 Jessie Lee2 srinivas Pai raikar2 David Hou2 senthil sockalingam2 Ken J Lee2 1crohn’s and colitis society of  singapore (ccss), the Arcadia,   2Quintiles iMs, science Park One,   singaporeAbstract:  Inflammatory bowel disease (IBD) – primarily Crohn’s disease and ulcerative  colitis – is a debilitating lifelong condition with significant health and economic costs.",Non-OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"Patient advocacy  and/or support groups such as CCSS facilitate such conversations between individuals  with similar conditions and can be of great benefit in raising disease awareness and  providing appropriate guidance on the disease management.correspondence: Nidhi swarup crohn’s and colitis society of singapore  (ccss), 237 Arcadia road #04-06, the  Arcadia, singapore 289844, singapore tel +65 9756 4066 email info@ibd.org.s g Journal name: Patient Preference and Adherence Article Designation: Perspectives Y ear: 2017 Volume: 11 Running head verso: Swarup et al Running head recto: Forming a support group for people affected by IBD DOI: http://dx.doi.org/10.2147/PPA.S123073",Non-OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"Based on close contact with Crohn’s and Colitis UK  (http://www.crohnsandcolitis.org.u k), Nidhi worked with 10  Singapore-based members of Rotary to set up a Management  Committee for the new CCSS which was registered in 2012.3  Ultimately, seed money came from Rotary.",Non-OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"Available from: https://clinicaltrials.gov/ct2/results/map?term=   crohns+diseas e. Accessed July 19, 2016.",OADS,/arxiv_data1/oa_pdf/bc/22/ppa-11-277.PMC5322812.pdf
"Jenkins-CI (https://jenkins.io/) is a leading, open-source  continuous integration server.",OADS,/arxiv_data1/oa_pdf/d8/43/10.1177_1087057116679993.PMC5322829.pdf
CellProfiler version 2.1.2 for Linux was downloaded from http://cellprofiler.org.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/10.1177_1087057116679993.PMC5322829.pdf
Availability of Supporting Data Scripts and associated Jenkins-CI project configuration files will be made available through the Novartis public git repository at https://github.com/orgs/Novartis.,OADS,/arxiv_data1/oa_pdf/d8/43/10.1177_1087057116679993.PMC5322829.pdf
2013. http://gitgear.com/why_jenkins/CI_Ranking_2013Q3_F1.pdf  13.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/10.1177_1087057116679993.PMC5322829.pdf
http://biouno.org/  14.,Non-OADS,/arxiv_data1/oa_pdf/d8/43/10.1177_1087057116679993.PMC5322829.pdf
Supplementary material for this article is available on the Journal of  Biomolecular Screening Web site at http://jbx.sagepub.com/supplemental.,Non-OADS,/arxiv_data1/oa_pdf/2a/82/10.1177_1087057116677821.PMC5322830.pdf
"All image processing was performed with the Harmony  software (PerkinElmer); data analysis and curve fitting were done in MATLAB and R (2016, https://www.R-project.org).",OADS,/arxiv_data1/oa_pdf/2a/82/10.1177_1087057116677821.PMC5322830.pdf
The R script used for the estimation of cell cycle distribu-tions from DAPI intensity distributions is available at https://github.com/hoerldavid/CellCycleFit.,OADS,/arxiv_data1/oa_pdf/2a/82/10.1177_1087057116677821.PMC5322830.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e3/ab/dddt-11-441.PMC5322835.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 441–449Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  441Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12491 2 reversal of multidrug resistance in  human lung cancer cells by delivery of  3-octadecylcarbamoylacrylic acid–cisplatin-based  liposomes Juan song Weifang ren Tingting Xu Yi Zhang hongyu guo shanshan Zhu li Yang Department of Pharmaceutics,   college of Pharmacy, shenyang  Pharmaceutical University, shenyang,   liaoning, People’s republic of chinaAbstract:  Liposome-based drug delivery system would be an innovative and promising  candidate to circumvent multidrug resistance (MDR) of cisplatin (CDDP).",Non-OADS,/arxiv_data1/oa_pdf/e3/ab/dddt-11-441.PMC5322835.pdf
"MDR of CDDP can result from  numerous mechanisms, which may be divided into the following categories: decreased  cellular uptake of CDDP, increased cellular efflux of CDDP, increased DNA repair,  and altered drug inactivation.4 Liposome can effectively bypass drug efflux through nonspeci fic or speci fic  endocytosis, which suggests the potential for MDR reversal.5,6 Interestingly, only  a few studies have reported about the use of liposomal CDDP to circumvent tumor  resistance, and the corresponding mechanisms still remain elusive.7,8 More importantly, correspondence: li Yang Department of Pharmaceutics,  college of Pharmacy, shenyang  Pharmaceutical University,  103 Wenhua road, shenyang, liaoning  110016, People’s republic of china Tel/fax +86 24 2398 6349 email pharm305@126.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Song et al Running head recto: OMI–CDDP–N-loaded liposomes for cancer therapy DOI: http://dx.doi.org/10.2147/DDDT.S124912",Non-OADS,/arxiv_data1/oa_pdf/e3/ab/dddt-11-441.PMC5322835.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/e3/ab/dddt-11-441.PMC5322835.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e3/ab/dddt-11-441.PMC5322835.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/07/7c/copd-12-651.PMC5322836.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 651–653International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  651Letteropen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/COPD.S12746 6 Is exposure to biomass smoke really associated  with COPD?",Non-OADS,/arxiv_data1/oa_pdf/07/7c/copd-12-651.PMC5322836.pdf
"Also in Table 5 the authors have reported that 115 participants (95 without Correspondence: rahul Kodgule Chest research Foundation,  Marigold Complex, Kalyani Nagar,  Pune 411 014, Maharashtra, India tel +91 99 2141 2644 Fax +91 20 2703 5371 email drrahul@crfindia.co m Journal name: International Journal of COPD Article Designation: Letter Y ear: 2017 Volume: 12 Running head verso: Das et al Running head recto: Association between exposure to biomass smoke and COPD DOI: http://dx.doi.org/10.2147/COPD.S127466",Non-OADS,/arxiv_data1/oa_pdf/07/7c/copd-12-651.PMC5322836.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/07/7c/copd-12-651.PMC5322836.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/07/7c/copd-12-651.PMC5322836.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d1/82/opth-11-369.PMC5322837.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2017:11 369–375Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  369Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S12341 9 Five-year outcomes of pars plana vitrectomy  for macular edema associated with branch retinal  vein occlusion akihiro nishida1,2 hiroshi Kojima1,2 Takanori Kameda1,2 Michiko Mandai1,3 Yasuo Kurimoto1,2 1Department of Ophthalmology, Kobe  City Medical Center general hospital,   2Department of Ophthalmology,   institute of Biomedical research and  innovation, 3laboratory for retinal  regeneration, riKen Center for  Developmental Biology, Chuo-ku,   Kobe, hyogo, JapanPurpose:  Long-term outcomes of pars plana vitrectomy (PPV) for macular edema (ME)  associated with branch retinal vein occlusion (BRVO) have been previously reported, but the  studies did not report the number of additional treatments after surgery.",Non-OADS,/arxiv_data1/oa_pdf/d1/82/opth-11-369.PMC5322837.pdf
"Many treatments for this disorder have been reported,  such as photocoagulation,1,2 intravitreal or sub-Tenon injection of triamcinolone  acetonide (STTA),3–9 intravitreal tissue plasminogen activator injection,10,11 and dexam - ethasone intravitreal implantation.12 It has also been reported that pars plana vitrectomy  (PPV) is effective for reducing ME and improving visual acuity (VA) in patients with  BRVO.2,13–18 Although the precise mechanism by which PPV reduces ME is unknown,  it has been suggested that PPV may have beneficial effects on retinal ischemia by  allowing oxygenated fluid to circulate in the vitreous cavity,19 releasing vitreomacu - lar attachment in persistent ME,17,20 improving perifoveal microcirculation,21 and/or  increasing the clearance of VEGF in the vitreous cavity.22 Recently, intravitreal injection Correspondence: akihiro nishida Department of Ophthalmology, Kobe  City Medical Center general hospital,  2-1-1 Minatojimaminamimachi, Chuo-ku,  Kobe, hyogo 650-0047, Japan Tel +81 78 302 4321 Fax +81 78 302 7537 email aki_n@kcho.j p Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Nishida et al Running head recto: Five-year outcomes of vitrectomy for BRVO DOI: http://dx.doi.org/10.2147/OPTH.S123419",Non-OADS,/arxiv_data1/oa_pdf/d1/82/opth-11-369.PMC5322837.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d1/82/opth-11-369.PMC5322837.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/82/opth-11-369.PMC5322837.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/b7/5d/ott-10-965.PMC5322838.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 965–971OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  965Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12044 0 BRAFV600 mutations in solid tumors, other than  metastatic melanoma and papillary thyroid cancer,  or multiple myeloma: a screening study allen l cohn1 Bann-Mo Day2 sarang abhyankar3 edward McKenna2 T odd riehl4 igor Puzanov5 1Medical research, rocky Mountain  cancer centers, Denver, cO, 2Us  Medical affairs, 3global safety  and risk Management, 4Product  Development Oncology, genentech,   inc., south san Francisco, ca,   5Melanoma section, Division of  hematology-Oncology, Department  of Medicine, Vanderbilt University  Medical center, nashville, Tn , UsaBackground:  Mutations in the BRAF gene have been implicated in several human cancers.",Non-OADS,/arxiv_data1/oa_pdf/b7/5d/ott-10-965.PMC5322838.pdf
"Keywords:  genetic testing, proto-oncogene proteins B-raf, PLX4032 Introduction Mutations of the BRAF  gene were first identified and implicated in human cancers  by Davies et al in 2002.1 BRAF , which has been implicated in human cancer, is one  of three highly conserved serine–threonine protein kinase genes ( ARAF , BRAF , and  CRAF ) in the RAS–RAF–MEK–ERK cascade.2 Mutations in the BRAF  gene have  been reported in 7%–15% of all human cancers, with melanoma having one of the  highest incidences (40%–70%).1,2 The most common locus of mutation is at position  V600, causing constitutive hyperactivation, proliferation, survival, and oncogenic  transformation.2 Other tumor types with a marked prevalence of BRAFV600 mutations include hairy  cell leukemia (79%–100%),3,4 histiocytic conditions, including Erdheim–Chester  disease and Langerhans cell histiocytosis (55%),5 papillary thyroid carcinoma (45%),6  serous ovarian cancer (35%),7 colorectal cancer (12%),1 non-small cell lung cancer  (NSCLC; up to 5%),8 and multiple myeloma (4%).9 Oncogenic BRAFV600 mutations  are often associated with an aggressive phenotype and shorter disease-free and overall  survival than the wild type.4,6,8,10correspondence: allen l cohn rocky Mountain cancer centers, 1800  Williams street, Denver, cO 80218, Usa Tel +1 303 388 4876  Fax +1 303 377 8375 email allen.cohn@usoncology.co mJournal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Cohn et al Running head recto: BRAFV600 mutations in solid tumors or multiple myeloma DOI: http://dx.doi.org/10.2147/OTT.S120440",Non-OADS,/arxiv_data1/oa_pdf/b7/5d/ott-10-965.PMC5322838.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b7/5d/ott-10-965.PMC5322838.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b7/5d/ott-10-965.PMC5322838.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/80/26/opth-11-357.PMC5322839.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2017:11 357–367Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  357Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S10422 0 Ahmed glaucoma valve implant: surgical technique  and complications ivano Riva1 Gloria Roberti1 Francesco Oddone1 Anastasios GP Konstas2 Luciano Quaranta3 1iRCCS “Fondazione GB Bietti  per l’Oftalmologia”, Rome, italy;   21st University Department of  Ophthalmology, Glaucoma Unit,   AHePA Hospital, Thessaloniki, Greece;   3Department of Medical and Surgical  Specialties, Section of Ophthalmology,   University of Brescia, Brescia, italyAbstract:  Implantation of Ahmed glaucoma valve is an effective surgical technique to reduce  intraocular pressure in patients affected with glaucoma.",Non-OADS,/arxiv_data1/oa_pdf/80/26/opth-11-357.PMC5322839.pdf
"Correspondence: Luciano Quaranta Divisione di Oculistica, Azienda  Ospedaliera Spedali Civili di  Brescia, Piazzale Spedali Civili, 1,  25123 Brescia, italy Tel +39 030 399 5847 Fax +39 030 396 622 email luciano.quaranta@unibs.i t Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2017 Volume: 11 Running head verso: Riva et al Running head recto: Ahmed glaucoma valve for refractory glaucoma DOI: http://dx.doi.org/10.2147/OPTH.S104220",Non-OADS,/arxiv_data1/oa_pdf/80/26/opth-11-357.PMC5322839.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/80/26/opth-11-357.PMC5322839.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/80/26/opth-11-357.PMC5322839.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2017:10 435–438Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  435 CASE REPORT open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S126923A case report of complex auricular neuralgia  treated with the great auricular nerve and  facet blocks Marzieh Eghtesadi1 Elizabeth Leroux2 Grisell Vargas-Schaffer3 1Department of Pain Clinic, Headache  Management, Centre Hospitalier de  l’Université de Montréal (CHUM), Centre de Recherche de l’Université de Montréal (CRCHUM),  2Department of General  Neurology, Headache Management, Centre Hospitalier de l’Université de Montréal (CHUM), Centre de Recherche de l’Université de Montréal (CRCHUM),  3Department of Anesthesiology, Pain  Clinic, Centre Hospitalier de l’Université de Montréal (CHUM), Centre de Recherche de l’Université de Montréal (CRCHUM), Montreal, QC, CanadaBackground: The great auricular nerve is a cutaneous branch of the cervical plexus originating  from the C2 and C3 spinal nerves.",Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
"Correspondence: Marzieh Eghtesadi Department of Pain Clinic, Headache Management, Centre Hospitalier de l’Université de Montréal (CHUM), 3840 rue Saint Urbain, Hôpital Hôtel-Dieu du CHUM, Clinique antidouleur 2 étage, Pavillon Jean Mance, Montreal, QC H2W 1T8, CanadaTel +1 514 890 8000Fax +1 514 412 7132Email marzieh.eghtesadi@mail.mcgill.caJournal name: Journal of Pain Research  Article Designation: CASE REPORTY ear: 2017V olume: 10Running head verso: Eghtesadi et alRunning head recto: Complex auricular neuralgia treated with GAN and facet blocksDOI: http://dx.doi.org/10.2147/JPR.S126923 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
Or use: http://youtu.be/bccCtE3DBxE,Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
"Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 438 Eghtesadi et al to identify a cause or trigger to this dysfunction.,Non-OADS,/arxiv_data1/oa_pdf/24/62/jpr-10-435.PMC5322840.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a7/77/dddt-11-451.PMC5322841.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 451–461Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  451Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12999 1 insight into resistance mechanisms of aZD4547  and e3810 to FgFr1 gatekeeper mutation via  theoretical study Donglou liang1,* Qiaowan chen2,* Yujin guo1 Ting Zhang3 Wentao guo4 1Pharmacy Department, Jining First  People’s hospital, 2Department of  Obstetrics, affiliated hospital of Jining  Medical University, Jining, shandong,   3Department of rheumatology,   The First affiliated hospital of  Wenzhou Medical University,   4school of Pharmacy, Wenzhou  Medical University, Wenzhou,   Zhejiang, People’s republic of china *These authors contributed equally  to this workAbstract:  Inhibitors targeting the amplification of the fibroblast growth factor receptor 1   (FGFR1) have found success in the treatment of FGFR1-positive squamous cell lung and  breast cancers.",Non-OADS,/arxiv_data1/oa_pdf/a7/77/dddt-11-451.PMC5322841.pdf
"FGFRs, a subfamily of the receptor tyrosine  kinase superfamily with four distinct isoforms (FGFR1–4), are composed of extracel - lular ligand-binding domain, a transmembrane helix and an intracellular tyrosine kinase  domain (KD).1 The binding of fibroblast growth factor (FGF) and FGFR triggers the  dimerization of the extracellular receptor domains, transphosphorylation of the intracel - lular KD, and the subsequent activation of downstream signaling pathways, including  the mitogen-activated protein kinase and phosphoinositide-3-kinase (PI3K)/Akt.2,3 In FGFR1, mutation or amplification can lead to aberrant FGFR1 activity, impli - cating this kinase in cancers, for example, non-small-cell lung cancer, breast cancer, correspondence: Ting Zhang Department of rheumatology, The First  Affiliated Hospital of Wenzhou Medical  University, shangcai, nanbaixiang,  Ouhai, Wenzhou 325000, People’s  republic of china Tel/fax +86 577 5557 9263 email ting_zhang06@sina.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Liang et al Running head recto: Resistance mechanisms of AZD4547 and E3810 to FGFR1 DOI: http://dx.doi.org/10.2147/DDDT.S129991",Non-OADS,/arxiv_data1/oa_pdf/a7/77/dddt-11-451.PMC5322841.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/a7/77/dddt-11-451.PMC5322841.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/77/dddt-11-451.PMC5322841.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2017:10 29–41Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 29 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S124098 Metered Cryospray™: a novel uniform, controlled,  and consistent in vivo application of liquid  nitrogen cryogenic spray Thomas I Mulcahey1 James E Coad2 Wei Li Fan1 Daniel J Grasso1 Brian M Hanley1 Heather V Hawkes1 Sean A McDermott1 John P O’Connor1 Ellen E Sheets1 Charles J Vadala1 1CSA Medical Inc., Lexington,   MA, 2Pathology Laboratory for  Translational Medicine, West Virginia  University, Morgantown, WV, USAAbstract: In this article, a novel cryotherapy approach using a uniform, controlled, and  consistent in vivo application of liquid nitrogen (LN2) spray as a Metered Cryospray™ (MCS)  process is described.",Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
"Unlike other cryogen devices that hold the cryogen within a contained probe or a  needle, CSA Medical Inc. has pioneered the use of an LN 2 spray within the body to Correspondence: John P O’Connor CSA Medical Inc., 91 Hartwell Avenue, Lexington, MA 02421, USATel +1 781 538 4755Fax +1 781 538 4730Email joconnor@csamedical.comJournal name: Medical Devices: Evidence and Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Mulcahey et alRunning head recto: LN 2 Metered Cryospray™ DOI: http://dx.doi.org/10.2147/MDER.S124098 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
Or use: http://youtu.be/mgp5_k-VHyM,Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
"Medical Devices: Evidence and Research 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
Available from: https://www.corning.com/media/worldwide/cls/documents/t_cryoanimalcc.pdf.,Non-OADS,/arxiv_data1/oa_pdf/dd/2d/mder-10-029.PMC5322842.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/10/a9/main.PMC5322843.pdf
Oral rinse and gargle sample collection was initiated in 2007 for allContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/pvrPapillomavirus Research http://dx.doi.org/10.1016/j.pvr.2016.07.003 2405-8521/ &2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/10/a9/main.PMC5322843.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/10/a9/main.PMC5322843.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.pvr.2016.07.003 .,OADS,/arxiv_data1/oa_pdf/10/a9/main.PMC5322843.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Hepatocellular Carcinoma 2017:4 29–39Journal of Hepatocellular Carcinoma Dovepress submit your manuscript | www.dovepress.com Dovepress 29 EXPERT OPINION open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JHC.S125396 Liver Imaging Reporting and Data System: an  expert consensus statement Khaled M Elsayes1 Ania Z Kielar2 Michelle M Agrons3 Janio Szklaruk1 An Tang4 Mustafa R Bashir5 Donald G Mitchell6 Richard K Do7 Kathryn J Fowler8 Victoria Chernyak9 Claude B Sirlin10 1Department of Diagnostic Radiology,  The University of T exas MD Anderson  Cancer Center, Houston, TX, USA;  2Department of Diagnostic Radiology,  University of Ottawa, Ottawa, ON, Canada;  3Department of Diagnostic  Radiology, Baylor College of Medicine, Houston, TX, USA;  4Department of  Radiology, Radio-Oncology and Nuclear Medicine, Université de Montréal, Montreal, QC, Canada;  5Department of  Diagnostic Radiology, Duke University School of Medicine, Durham, NC,  6Department of Diagnostic Radiology,  Thomas Jefferson University, Philadelphia, PA,  7Department of Radiology, Memorial  Sloan Kettering Cancer Center, New Y ork, NY,  8Mallinckrodt Institute of  Radiology, Washington University in Saint Louis, Saint Louis, MO,  9Department  of Radiology Albert Einstein College of Medicine, Bronx, New Y ork, NY,  10Department of Diagnostic Radiology,  University of California, San Diego, CA, USAAbstract:  The increasing incidence and high morbidity and mortality of hepatocellular carci- noma (HCC) have inspired the creation of the Liver Imaging Reporting and Data System (LI- RADS).",Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"11,12 Contrast-enhanced magnetic  resonance imaging (MRI) and computed tomography (CT) are the two most widely used Correspondence: Khaled M Elsayes Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USATel +1 713 745 3025Fax +1 713 794 4379Email kmelsayes@mdanderson.orgJournal name: Journal of Hepatocellular Carcinoma Article Designation: EXPERT OPINIONY ear: 2017V olume: 4Running head verso: Elsayes et alRunning head recto: Liver Imaging Reporting and Data SystemDOI: http://dx.doi.org/10.2147/JHC.S125396",Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"Available from: https://nrdr.acr.org/lirads/.17 Abbreviations:  LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; OPTN, Organ Procurement and Transplantation Network; AASLD,  American Association for the Study of Liver Diseases.",Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
Available from: http://optn.transplant.hrsa.,Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"Available from: http://optn.transplant.hrsa.gov37 and Wald et al.23 Abbreviations:  LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; CT, computed tomography; MR, magnetic resonance; OPTN, Organ  Procurement and Transplantation Network.",OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
Available from: http://www.acr.org/Quality-Safety/Resources/LIRADS.,Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
Available from: https://nrdr.acr.org/lirads/.,OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
Available from: http://optn.transplant.hrsa.gov.,Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"Journal of Hepatocellular Carcinoma 2017:4submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Hepatocellular Carcinoma Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journalThe Journal of Hepatocellular Carcinoma is an international, peer- reviewed, open access journal that offers a platform for the dissemina-tion and study of clinical, translational and basic research findings in this rapidly developing field.",Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 39 Liver Imaging Reporting and Data System  27.,Non-OADS,/arxiv_data1/oa_pdf/c0/ac/jhc-4-029.PMC5322844.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/29/ee/ott-10-993.PMC5322845.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 993–1000OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  993Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12858 8 Prognostic role of long noncoding rna nea T1  in various carcinomas: a meta-analysis Tao chen1,* hui Wang1,* Peng Yang1 Zhen-Yu he2 1Department of general surgery,   The second clinical Medical college  of nanjing Medical University,   2Department of general surgery,   second affiliated hospital of nanjing  Medical University, nanjing, Jiangsu,   People’s republic of china *These authors contributed equally  to this workAbstract:  A number of studies have revealed that nuclear paraspeckle assembly transcript 1  (NEAT1), a long noncoding RNA (lncRNA), was aberrantly regulated in various cancers.",Non-OADS,/arxiv_data1/oa_pdf/29/ee/ott-10-993.PMC5322845.pdf
"Keywords:  NEAT1, lncRNA, prognosis, lymph node metastasis, meta-analysis Introduction Long noncoding RNAs (lncRNAs) are a class of RNAs larger than 200 nucleotides  and lack protein coding capability.1 Recently, large-scale studies have shown that  these kinds of nonprotein-coding transcripts play critical roles in cellular regulatory  processes, such as transcriptional regulation, epigenetic modification, and human  disease.2 Moreover, with the advances in next-generation sequencing, accumulating  evidence has shown the dysregulated expression of numerous lncRNAs in human  cancers.3 Meanwhile, emerging reports have demonstrated that lncRNAs may act as  oncogenes and tumor suppressor genes through affecting cell proliferation, apoptosis,  migration, and genomic stability.4,5 The aberrant expression profiles of lncRNAs in  different cancer types indicated that this class of molecules could be applied to tumor  diagnosis, prognosis, and therapies.6–8 Nuclear paraspeckle assembly transcript 1 (NEAT1) gene is located on chromo - some 11q13.1 and has six transcripts.9 The transcript NEAT1-001, also named lncRNA  NEAT1, owns two isoforms: 3.7-kb-long NEAT1_1 and 23-kb-long NEAT1_2.10  Previous studies revealed that lncRNA NEAT1 functions as an essential structural  component of a nuclear domain called paraspeckles.11,12 Cumulatively, further studies  identified that NEAT1 was aberrantly expressed in a number of solid tumors, including  colorectal cancer, gastric cancer, and other human malignancies.13–22 Moreover, correspondence: Zhen-Yu he Department of general surgery,  Second Affiliated Hospital of Nanjing  Medical University, 121 Jiangjiayuan  road, nanjing 210011, Jiangsu,  People’s republic of china Tel +86 25 5850 9900 Fax +86 25 5850 9900 email hezhenyu1968@126.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Chen et al Running head recto: Prognostic role of lncRNA NEAT1 in various carcinomas DOI: http://dx.doi.org/10.2147/OTT.S128588",Non-OADS,/arxiv_data1/oa_pdf/29/ee/ott-10-993.PMC5322845.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/29/ee/ott-10-993.PMC5322845.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/29/ee/ott-10-993.PMC5322845.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical Epidemiology 2017:9 105–111Clinical Epidemiology Dovepress submit your manuscript | www.dovepress.com Dovepress 105 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CLEP .S124454 Validity of data in the Danish Colorectal Cancer  Screening Database Mette Kielsholm Thomsen1  Sisse Helle Njor1  Morten Rasmussen2  Dorte Linnemann3  Berit Andersen4  Gunnar Baatrup5,6  Lennart Jan Friis-Hansen7  Jens Christian Riis  Jørgensen8  Ellen Margrethe Mikkelsen1 1Department of Clinical Epidemiology,   Aarhus University Hospital, Aarhus,   2Department of Digestive Diseases  K, Bispebjerg Hospital, Copenhagen,   3Department of Pathology, Herlev  and Gentofte Hospital, Herlev,   4Department of Public Health  Programs, Randers Regional  Hospital, Randers, 5Department of  Surgery, Odense University Hospital,   6Department of Clinical Science,   University of Southern Denmark,  Odense,  7Center for Genomic  Medicine, Rigshospitalet, University of Copenhagen, Copenhagen,   8Department of Colorectal Cancer  Surgery, Vejle Hospital, Vejle, DenmarkBackground: In Denmark, a nationwide screening program for colorectal cancer was imple- mented in March 2014.",Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
"1 The screening procedure is based  on a single-sample immunochemical fecal occult blood test (iFOBT), which has been documented to detect invisible amounts of blood in stool samples, associated with bleeding lesions related to precancerous adenomas or bowel cancer, at early Correspondence: Mette Kielsholm  Thomsen; Ellen Margrethe Mikkelsen   Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200 Aarhus N, Aarhus, Denmark Tel +45 8716 7212; +45 8716 8207 Email mko@clin.au.dk; em@clin.au.dkJournal name: Clinical Epidemiology Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Thomsen et alRunning head recto: Validity of data in the Danish Colorectal Cancer Screening DatabaseDOI: http://dx.doi.org/10.2147/CLEP .S124454",Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
"Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical Epidemiology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journalClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica-tion of risk factors and screening procedures to develop optimal pre-ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
Available from: https://sundhedsstyrelsen.dk/da/sygdom-og-behan-dling/screening/tarmkraeftscreening#.,Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
Available from: http://dccg.dk/retningslinjer/august2014/2014_screen-ing.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
Available from: https://www.regionh.dk/kliniskedatabaser/rkkp-databaser/Docu-ments/_Pilot_datavalidering_DTS_20150528_endelig_inklbilag.pdf.,OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
Available from: http://www.regionshospitalet-randers.dk/siteassets/afdelinger/afdeling-for-folkeundersogelser/pdf-episerver/retningslinjer/2014_09_25-manual-for-implementeirng-og-drift-af-tvarregional-tarmkraftscreening---version-1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
Available from: http://www.danskpatologi.dk/doc/pdf/CRC-screeningsprogram%20retningslinjer%20v12.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/4d/clep-9-105.PMC5322846.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 57–64Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress 57 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DMSO.S123935 Association between obesity and heart rate  variability indices: an intuition toward cardiac  autonomic alteration – a risk of CVD Ram Lochan Yadav1 Prakash Kumar Yadav1 Laxmi Kumari Yadav2 Kopila Agrawal3 Santosh Kumar Sah4 Md Nazrul Islam1 1Department of Physiology,   2Department of Microbiology,   Chitwan Medical College, Bharatpur,   3Department of Physiology, BP Koirala  Institute of Health Sciences, Dharan,   4Department of Biochemistry, Janaki  Medical College, Janakpur, NepalBackground: Obese people have a higher prevalence of cardiovascular disease, which is sup- posed to be due to autonomic dysfunction and/or metabolic disorder.",Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
"Keywords: obesity, heart rate variability, HRV , body mass index, BMI, waist–hip ratio, WHR,  cardiac autonomic regulation Introduction Obesity is one of the leading disorders that increases the all-cause mortality in patients  with increased body mass index (BMI), especially causing death from cardiovascular Correspondence: Ram Lochan Yadav Department of Physiology, Chitwan Medical College, Bharatpur-13, 44200, NepalTel +977 98 4809 6590Email dr.ramlochan04@gmail.comJournal name: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Y adav et alRunning head recto: Association between obesity and HRV indicesDOI: http://dx.doi.org/10.2147/DMSO.S123935 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
Or use: http://youtu.be/6Cvs4h2aUoA,Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.,Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is  an international, peer-reviewed open-access journal committed to   the rapid publication of the latest laboratory and clinical findings   in the fields of diabetes, metabolic syndrome and obesity research.",Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 64 Yadav et al 11.,Non-OADS,/arxiv_data1/oa_pdf/fb/99/dmso-10-057.PMC5322847.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 985–992OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  985Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12534 4 Breast and cervical cancer-screening uptake  among females in ardabil, northwest iran: a   community-based study esmaeil Farzaneh1 heshmatolah heydari2 ali akbar shekarchi3 aziz Kamran4 1Department of Forensic Medicine  and Toxicology, ardabil University  of Medical sciences, ardabil, iran;   2Department of nursing, lorestan  University of Medical sciences,   Khorramabad, iran; 3Department of  Pathology, 4Department of Public  health, ardabil University of Medical  sciences, ardabil, iranPurpose:  Breast and cervical cancers are the most commonly diagnosed type of cancer and  cause of cancer-related deaths in Iranian females.",Non-OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
"According to applied  research of the Iranian Ministry of Health and Medical Education, during 2006–2010 correspondence: aziz Kamran Department of Public health, Khalkhal  Faculty of Medical sciences, ardabil  University of Medical sciences, ardabil  5614995935, iran email a.kamran@arums.ac.i r Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Farzaneh et al Running head recto: Breast and cervical cancer-screening uptake in Iran DOI: http://dx.doi.org/10.2147/OTT.S125344",Non-OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
Available  from: http://apps.who.int/iris/bitstream/10665/94830/5/97892415486 94_per.pd f. Persian.,OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f3/38/ott-10-985.PMC5322848.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/06/d0/ndt-13-515.PMC5322850.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 515–526Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  515OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S12019 0 Efficacy and tolerability of escitalopram in  treatment of major depressive disorder with  anxiety symptoms: a 24-week, open-label,  prospective study in chinese population Kaida Jiang1 lingjiang li2 Xueyi Wang3 Maosheng Fang4 Jianfei shi5 Qiuyun cao6 Jincai he7 Jinan Wang8 Weihao Tan8 cuili hu8 1Psychiatry Department, shanghai  Mental health center, shanghai,   2Psychiatry Department,The second  Xiangya hospital, central south  University, changsha, 3Psychiatry  Department, First affiliated hospital  of Hebei Medical University,   shijiazhuang, 4Psychiatry Department,   Wuhan Mental health center,   Wuhan, 5Psychiatry Department,   hangzhou the 7th hospital, hangzhou,   6Psychology Department, Nanjing  Drum T ower hospital, Nanjing,   7Neurology Department, First  affiliated hospital of Wenzhou  Medical University, Wenzhou, 8Medical  affairs Department, Xi’an Janssen  Pharmaceutical ltd., Beijing, People’s  Republic of ChinaBackground:  Significant anxiety symptoms are associated with poor clinical course and  outcome in major depressive disorder (MDD).",Non-OADS,/arxiv_data1/oa_pdf/06/d0/ndt-13-515.PMC5322850.pdf
"Keywords:  anxiety, Chinese, escitalopram, long term, major depressive disorder Introduction Anxiety symptoms are particularly common in patients with depressive disorders.1–3  Anxiety symptoms increase the disease severity and lead to chronic course with marked  functional impairment and a higher risk of suicide in patients with depression.1,4–6  Although the Diagnostic and Statistical Manual of Mental Disorders  (DSM)-V criteria  define the anxiety distress specifier of major depressive disorder (MDD), there is no  consensus on the diagnosis of anxious depression.7 A syndromal approach (MDD  co-occurring with a syndromally defined anxiety disorder) has been proposed that  includes patients with comorbid anxiety and depressive disorders based on either correspondence: cuili hu Xi’an Janssen Pharmaceutical ltd,  19F, Tower 3, china central Place,  No 77 Jian guo road, chao Yang,  Beijing 100025, People’s Republic  of china Tel +86 10 5821 8709 Fax +86 10 5821 8703 email chu9@its.jnj.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Jiang et al Running head recto: Escitalopram in major depressive disorder with anxiety symptoms DOI: http://dx.doi.org/10.2147/NDT.S120190",Non-OADS,/arxiv_data1/oa_pdf/06/d0/ndt-13-515.PMC5322850.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/06/d0/ndt-13-515.PMC5322850.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/06/d0/ndt-13-515.PMC5322850.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3c/78/opth-11-377.PMC5322851.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2017:11 377–385Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  377Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S12016 2 rituximab as a monotherapy or in combination  therapy for the treatment of non-paraneoplastic  autoimmune retinopathy arash Maleki1,2 neerav lamba1,2 lina Ma1,2 stacey lee1,2 alexander schmidt1,2 C stephen Foster1–3 1Massachusetts eye research  and surgery institution, 2Ocular  immunology and Uveitis Foundation,   Waltham, 3harvard Medical school,   Boston, M a, UsaPurpose:  To examine the efficacy of rituximab as a monotherapy or in combination therapy  for the treatment of patients with non-paraneoplastic autoimmune retinopathy.",Non-OADS,/arxiv_data1/oa_pdf/3c/78/opth-11-377.PMC5322851.pdf
"Correspondence: C stephen Foster Massachusetts eye research and surgery  institution, 440 Main street, suite 201,  Waltham, Ma 02451, Usa Tel +1 781 891 6377 Fax +1 781 647 1430 email sfoster@mersi.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Maleki et al Running head recto: Rituximab in autoimmune retinopathy DOI: http://dx.doi.org/10.2147/OPTH.S120162",Non-OADS,/arxiv_data1/oa_pdf/3c/78/opth-11-377.PMC5322851.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/3c/78/opth-11-377.PMC5322851.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3c/78/opth-11-377.PMC5322851.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/52/ab/ijwh-9-081.PMC5322852.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2017:9 81–88International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  81RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S9887 6 Postcesarean wound infection: prevalence, impact,  prevention, and management challenges Sivan Zuarez-easton1 Noah Zafran1,2 Gali Garmi1,2 Raed Salim1,2 1Department of Obstetrics and  Gynecology, emek Medical Center,   Afula, 2Rappaport Faculty of  Medicine, Technion-Israel Institute  of T echnology, Haifa, IsraelAbstract:  Surgical site infection (SSI) is one of the most common complications following  cesarean section, and has an incidence of 3%–15%.",Non-OADS,/arxiv_data1/oa_pdf/52/ab/ijwh-9-081.PMC5322852.pdf
"The following Correspondence: Raed Salim Department of Obstetrics and  Gynecology, emek Medical Center, Yitzhak  Rabin Boulevard 21, Afula 18101, Israel Tel +972 4 649 4031 Fax +972 4 814 1533 email salim_ra@clalit.org.i l Journal name: International Journal of Women’s Health Article Designation: Review Y ear: 2017 Volume: 9 Running head verso: Zuarez-Easton et al Running head recto: Postcesarean wound infection DOI: http://dx.doi.org/10.2147/IJWH.S98876",Non-OADS,/arxiv_data1/oa_pdf/52/ab/ijwh-9-081.PMC5322852.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/52/ab/ijwh-9-081.PMC5322852.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/52/ab/ijwh-9-081.PMC5322852.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 973–984OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  973Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11987 9 antiangiogenic drugs used with chemotherapy  for patients with recurrent ovarian cancer:  a meta-analysis suYi Yi longJia Zeng Yan Kuang ZhiJuan cao chengJun Zheng Yue Zhang Meng liao lu Yang Department of gynaecology and  Obstetrics, The First affiliated  hospital of guangxi Medical  University, nanning, guangxi,   People’s  republic of chinaObjective:  The value of antiangiogenic inhibitors for patients with recurrent ovarian cancer  has not been completely affirmed.",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"The addition of antiangiogenic drugs in the treatment of relapsed  ovarian cancer has not yet been fully defined.3correspondence: Yan Kuang Department of gynaecology and  Obstetrics, The First Affiliated Hospital  of guangxi Medical University,  6 shuangyong road, nanning, guangxi  530021, People’s republic of china Tel +86 138 7716 6099 email 461161401@qq.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Yi et al Running head recto: Antiangiogenic drugs for patients with recurrent ovarian cancer DOI: http://dx.doi.org/10.2147/OTT.S119879",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"Available  from: http://www.cancer.org/research/cancerfactsstatistics/cancerfacts - figures2008/inde x. Accessed December 31, 2008.",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"Available  from: http://www.nccn.or g. Accessed 2, 2015.",Non-OADS,/arxiv_data1/oa_pdf/ff/1f/ott-10-973.PMC5322854.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/c5/24/cia-12-399.PMC5322937.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 399–404Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  399OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S12559 2 high coronary calcium score and post-procedural  CK-MB are noninvasive predictors of coronary  stent restenosis Jae-Beom lee1 Yun-seok Choi2 Woo-Baek Chung2 Ami Kwon2 Chul-soo Park2 Man-Y oung lee2 1Anyang sam hospital, 2Division of  Cardiology, Department of Internal  Medicine, Y ouido st Mary’s hospital,   College of Medicine, The Catholic  University of Korea, seoul, KoreaPurpose:  High coronary calcium score (CCS) and post-procedural cardiac enzyme may be  related with poor outcomes in patients with coronary stent implantation.",Non-OADS,/arxiv_data1/oa_pdf/c5/24/cia-12-399.PMC5322937.pdf
"It must be elucidated what, other than the severity of coronary  calcification, predicts stent restenosis.Correspondence: Yun-seok Choi Division of Cardiology, Department of  Internal Medicine, College of Medicine,  The Catholic University of Korea,  Yeouido st Mary’s hospital, yuksam-ro  10, seoul 150-713, Korea Tel +82 2 3779 1325 Fax +82 2 3779 1374 email cys71@catholic.ac.k r Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Lee et al Running head recto: Coronary calcium score and stent restenosis DOI: http://dx.doi.org/10.2147/CIA.S125592",Non-OADS,/arxiv_data1/oa_pdf/c5/24/cia-12-399.PMC5322937.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/c5/24/cia-12-399.PMC5322937.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/c5/24/cia-12-399.PMC5322937.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Biologics: Targets and Therapy 2017:11 5–11Biologics: Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress  5 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BTT .S124476Biosimilars and the extrapolation of indications  for inflammatory conditions John RP T esser1 Daniel E Furst2 Ira Jacobs3 1Arizona Arthritis & Rheumatology  Associates, Phoenix, AZ, 2UCLA  Health, Los Angeles, CA, 3Pfizer Inc,   New Y ork, NY, USAAbstract: Extrapolation is the approval of a biosimilar for use in an indication held by the origi- nator biologic not directly studied in a comparative clinical trial with the biosimilar.",Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"One key component of the EMA, FDA, and WHO regulatory guidelines for  biosimilars is the provision for regulatory approval of the biosimilar for one or more Correspondence: John RP Tesser Arizona Arthritis & Rheumatology Associates, 4550 E. Bell Road, Suite 272, Phoenix, AZ 85032, USATel +1 480 443 8400Email jtesser1@cox.netJournal name: Biologics: Targets and Therapy Article Designation: REVIEWY ear: 2017V olume: 11Running head verso: Tesser et alRunning head recto: Biosimilar extrapolation of indicationsDOI: http://dx.doi.org/10.2147/BTT.S124476",Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEU-TICS_FOR_WEB_22APRIL2010.pdf.,OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAn - nouncements/ucm494227.htm.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://media.biogen.com/press-release/biosimilars/flixabi-biogens-infliximab-biosimilar-referencing-remicade-approved-europe.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://media.biogen.com/press-release/biosimilars/benepali-first-etanercept-biosimilar-referencing-enbrel-approved-european-.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"Bethesda, MD: Office of New Drugs (OND) Therapeutic Biologics and Biosimilars Team, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA); [updated Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrug-sareDevelopedandApproved/ApprovalApplications/TherapeuticBio-logicApplications/Biosimilars/UCM428732.pdf.",Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_remsima_160195-eng.php#sbd.,OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php.,OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-monoclonal-antibody-approved-in-Korea.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-infliximab-launched-in-Japan.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.pfizer.ca/node/7526.,OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"Biologics: Targets and Therapy 2017:11submit your manuscript | www.dovepress.com Dovepress Dovepress Biologics: Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/biologics-targets-and-therapy-journalBiologics: Targets and Therapy is an international, peer-reviewed journal  focusing on the patho-physiological rationale for and clinical applica-tion of Biologic agents in the management of autoimmune diseases, cancers or other pathologies where a molecular target can be identified.",Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 11 Biosimilar extrapolation of indications 34.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrug-sareDevelopedandApproved/ApprovalApplications/NewDrugAppli-cationNDA/default.htm.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.gabionline.net/Biosimilars/Gen-eral/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
Available from: http://www.genengnews.com/keywordsandtools/print/3/34899/.,Non-OADS,/arxiv_data1/oa_pdf/c7/ae/btt-11-005.PMC5322938.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 381–397Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  381RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S11763 7 effectiveness of person-centered care on people  with dementia: a systematic review and  meta-analysis Sun Kyung Kim Myonghwa Park education and Research Center for  evidence Based Nursing Knowledge,   College of Nursing, Chungnam  National University, Daejeon,   Republic of KoreaBackground:  Person-centered care is a holistic and integrative approach designed to maintain  well-being and quality of life for people with dementia, and it includes the elements of care,  the individual, the carers, and the family.",Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
"Keywords:  dementia, meta-analysis, patient-centered care, person-centered care, neuropsy - chiatric symptoms, systematic reviewCorrespondence: Myonghwa Park education and Research Center for  evidence Based Nursing Knowledge,  College of Nursing, Chungnam National  University, 266 Munhwa-ro, Jung-gu,  Daejeon 35015, Republic of Korea Tel +82 42 580 8328 email mhpark@cnu.ac.k r Journal name: Clinical Interventions in Aging Article Designation: Review Y ear: 2017 Volume: 12 Running head verso: Kim and Park Running head recto: Systematic review of person-centered care for dementia DOI: http://dx.doi.org/10.2147/CIA.S117637",Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode”http://creativecommons.,Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/bc/d6/cia-12-381.PMC5322939.pdf
"1, 16 –25 http://dx.doi.org/10.1080/15384047.2016.1252880",Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
World J Gastrointest Oncol 2016; 8:99-104;PMID:26798440; http://dx.doi.org/10.4251/wjgo.v8.i1.99 3.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
World J Gastrointest Oncol 2016; 8:297-304; PMID:26989465; http://dx.doi.org/10.4251/wjgo.v8.i3.297 4.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
MolCell Biol 2005; 25:1146-61; PMID:15657440; http://dx.doi.org/ 10.1128/MCB.25.3.1146-1161.2005 6.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Exp Opin Therap Targets 2013; 1:77-87; PMID:23062118; http://dx.doi.org/10.1517/14728222.2013.731047 7.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Melanoma Res 2001; 11:379-83; PMID:11479426; http://dx.doi.org/10.1097/00008390-200108000-00008 8.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Cancer Biol Ther 2009; 8:1831-7; PMID:19729995; http://dx.doi.org/10.4161/cbt.8.19.9592 10.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Clin Cancer Res 2011;17:4474-83; PMID:21555373; http://dx.doi.org/10.1158/1078-0432.CCR-10-2370 11.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Pharm Res 2008; 25:2117-24; PMID:18427961; http://dx.doi.org/10.1007/s11095- 008-9581-8 12.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Mol Cancer Ther 2008; 7:2884-93; PMID:18790769; http://dx.doi.org/10.1158/1535-7163.MCT-08-0438 13.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Neurosci Res 2000; 61:134-9; PMID:10878585; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Biol Chem 2003; 278:19995-20005; PMID:12644474; http://dx.doi.org/10.1074/jbc.M205865200 16.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Cancer Biol Ther 2002; 1:152-60; PMID:12170775; http://dx.doi.org/10.4161/cbt.61 17.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Oncogene 1999; 18:623-31; PMID:9989812; http://dx.doi.org/ 10.1038/sj.onc.1202344 18.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Cell Bio-chem 2010; 109:885-95; PMID:20127709; http://dx.doi.org/10.1002/ jcb.22504 20.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
FEBS open bio 2014; 4:763-76; PMID:25349781; http://dx.doi.org/10.1016/j.fob.2014.08.005 21.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Gastroenterology 2000;118:1012-7; PMID:10833474; http://dx.doi.org/10.1016/S0016-5085(00)70352-0 22.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
"Das TP, Suman S, Alatassi H, Ankem MK, Damodaran C. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.Cell Death Dis 2016; 7:e2111; PMID:26913603; http://dx.doi.org/ 10.1038/cddis.2015.403 24.",Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Nat Immunol 2013; 14:172-8; PMID:23222971; http://dx.doi.org/10.1038/ni.2492 26.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
PloS one 2014; 9:e103609; PMID:25084355; http://dx.doi.org/10.1371/journal.pone.0103609 27.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Immunol 2008; 181:1780-6; PMID:18641315; http://dx.doi.org/10.4049/jimmunol.181.3.1780 28.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Biochem Biophys Res Commun 2012; 417:582-7; PMID:22178074; http://dx.doi.org/10.1016/j.bbrc.2011.12.010 29.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Biol Chem 2015; 290:28428-37; PMID:26442586; http://dx.doi.org/10.1074/jbc.M115.670901 30.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Immunol 2006; 176:6277-85; PMID:16670339; http://dx.doi.org/10.4049/jimmunol.176.10.6277 31.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Tumour Biol 2015; 36:8761-72; PMID:26055142; http://dx.doi.org/10.1007/s13277-015-3572-2 32.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Intern Med 2015; 278:323-32; PMID:25880119; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Autoimmun 2012; 39:77-82; PMID:22402340; http://dx.doi.org/10.1016/j.jaut.2012.01.014 34.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
"Chaudhry P, Singh M, Parent S, Asselin E. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation.Mol Cell Biol 2012; 32:826-39; PMID:22184067; http://dx.doi.org/ 10.1128/MCB.06321-11 35.",Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Toxicol Lett 2013; 224:7-15; PMID:24144893; http://dx.doi.org/10.1016/j.toxlet.2013.10.008 36.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Oncogene 1999; 18:1205-8; PMID:10022126; http://dx.doi.org/10.1038/sj.onc.1202416 37.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
EMBO J2008; 27:2181-93; PMID:18650932; http://dx.doi.org/10.1038/ emboj.2008.149 38.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Cancer Res 2007; 67:1927-34; PMID:17332319; http://dx.doi.org/10.1158/0008-5472.CAN-06-2687 39.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
J Cell Biochem 2008; 103:358-68; PMID:18041764; http://dx.doi.org/10.1002/jcb.21642 40.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Oncotarget 2016; 7:36971-87;PMID:27175591; http://dx.doi.org/10.18632/oncotarget.9235 41.,OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Mol Cell Biol 2003; 23:5516-25; PMID:12897127; http://dx.doi.org/10.1128/ MCB.23.16.5516-5525.2003 42.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Cancer Chemother Pharmacol 2016; 77:1103-24;PMID:26886018; http://dx.doi.org/10.1007/s00280-016-2976-z 43.,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
Nat Methods 2012; 9:671-5;PMID:22930834; http://dx.doi.org/10.1038/nmeth.2089CANCER BIOLOGY & THERAPY 25,Non-OADS,/arxiv_data1/oa_pdf/22/5f/kcbt-18-01-1252880.PMC5323013.pdf
"Published with license by Taylor & Francis Group, LLC © Fei Feng, Bin Wang, Xiuxuan Sun, Yumeng Zhu, Hao Tang, Gang Nan, Lijuan Wang, Bo Wu, Muren Huhe, Sh uangshuang Liu, Tengyue Diao, Rong Hou, Yang Zhang, and Zheng ZhangThis is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
"1, 51 –62 http://dx.doi.org/10.1080/15384047.2016.1276126",Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
CA: A Can- cer J Clinicians 2013; 63(1):11-30; PMID:23335087; http://dx.doi.org/ 10.3322/caac.21166 2.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Lancet 2011; 378 (9804):1727-1740; http://dx.doi.org/10.1016/s0140-6736(10)62101-0 3.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Biomarkers2016; 21(5):474-8:1-4; PMID:27098116; http://dx.doi.org/10.3109/1354750X.2016.1172111 4.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
OncoTargets therapy 2016; 9:1471-1476;PMID:27042115; http://dx.doi.org/10.2147/OTT.S96160 6.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Indian J Radiol Imaging 2016; 26(1):81-91;PMID:27081229; http://dx.doi.org/10.4103/0971-3026.178347 7.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Radiat Oncol 2016; 11(1):61; PMID:27117590; http://dx.doi.org/10.1186/s13014-016-0636-4 8.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
BMC Cancer 2016; 16(1):266; PMID:27067521; http://dx.doi.org/10.1186/s12885-016-2234-0 9.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Lung Cancer 2016; 96:56-62; PMID:27133751; http://dx.doi.org/10.1016/j.lungcan.2016.03.016 10.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Oncotarget 2016; 7(18):26916-24; PMID:27029035; http://dx.doi.org/10.18632/ oncotarget.8309 11.,OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
BMC Res Notes 2016; 9(1):134; PMID:26928578;http://dx.doi.org/10.1186/s13104-016-1919-4 12.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
JExp Clin Cancer Res 2016; 35(1):70; PMID:27102688; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Oncology letters 2016; 11 (2):1413-1417; PMID:26893752; http://dx.doi.org/10.3892/ol.2015.4066 14.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Eur J Cancer 2009; 45(14):2473-2487; PMID:19596191; http://dx.doi.org/10.1016/j.ejca.2009.06.005 15.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Histopathology 2009; 54 (6):677-687; PMID:19438743; http://dx.doi.org/10.1111/j.1365-2559.2009.03280.x 16.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Mol Cell Bio-chem 2013; 383(1 –2):1-11; PMID:24013786; http://dx.doi.org/ 10.1007/s11010-013-1722-7 17.,OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
"Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Bas- baum C. EMMPRIN regulates the canonical Wnt/beta-catenin signal- ing pathway, a potential role in accelerating lung tumorigenesis.Oncogene 2010; 29(29):4145-4156; PMID:20514014; http://dx.doi.org/10.1038/onc.2010.166 19.",Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Annals Surg Oncol 2013; 20(3):1044-1052; PMID:22592183; http://dx.doi.org/10.1245/s10434-012-2377-4 20.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Annals Surg Oncol 2014; 21(13):4359- 4368; PMID:25084765; http://dx.doi.org/10.1245/s10434-014-3816-1 21.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Neoplasma 2011; 58(5):449-454; PMID:21745000; http://dx.doi.org/10.4149/neo_2011_05_449 22.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Mol Cancer Therapeutics 2015; 14(1):162-173; PMID:25376611; http://dx.doi.org/10.1158/1535-7163.MCT-14-0104 23.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Annals Oncol 2006; 17(Suppl 5):v7-12; PMID:16807468; http://dx.doi.org/10.1093/annonc/mdj941 24.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Cancer Chemotherapy Pharmacol 2006; 58(2):266-271; PMID:16308698; http://dx.doi.org/10.1007/s00280-005-0143-z 26.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
"He Q, Gao J, Ge S, Wang T, Li Y, Peng Z, Li Y, Shen L. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitu- mor activity against human gastric cancer cells in vitro and in vivo .J Cancer Res Clin Oncol 2014; 140(9):1575-1583; PMID:24804814;http://dx.doi.org/10.1007/s00432-014-1693-4 27.",Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Pancreas 2016; 45(2):269-280;PMID:26495790; http://dx.doi.org/10.1097/mpa.0000000000000452 28.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Mol Clin Oncol 2013; 1 (5):918-924; PMID:24649271; http://dx.doi.org/10.3892/mco.2013.159 30.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
J Biol Chem 1998; 273(13):7770-7775; PMID:9516487; http://dx.doi.org/10.1074/jbc.273.13.7770 31.,OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Modern Pathol 2004; 17(7):861-867; PMID:15098015; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Drug Metab Rev 2009; 41(2):77-88; PMID:19514966; http://dx.doi.org/10.1080/03602530902741828 33.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Clin Cancer Res 2014; 20(21):5435-5445;PMID:25224279; http://dx.doi.org/10.1158/1078-0432.CCR-14-054235.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
BMC PHARMACOL 2004; 4:8; PMID:15157282; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Radiotherapy Oncol 2002; 63(3):329-338;PMID:12142097; http://dx.doi.org/10.1016/S0167-8140(02)00106-8 37.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Exp Hematol Oncol 2014; 3:31; PMID:25937997; http://dx.doi.org/10.1186/2162-3619-3-31 38.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Toxicol Pathol 2013; 41(7):951-969; PMID:23475561; http://dx.doi.org/10.1177/0192623312474727 39.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
Oncol Letters 2016; 11(5):3179-3184; PMID:27123085; http://dx.doi.org/10.3892/ol.2016.4340 40.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
PloS One 2014; 9(2):e88856; PMID:24551180; http://dx.doi.org/ 10.1371/journal.pone.0088856 42.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
J Exp Clin Cancer Res 2011; 30:20; PMID:21329503; http://dx.doi.org/10.1186/1756-9966-30-20 43.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
J Exp Clin Cancer Res 2016; 35(1):71; PMID:27102814; http://dx.doi.org/10.1186/s13046-016- 0349-4 44.,Non-OADS,/arxiv_data1/oa_pdf/82/48/kcbt-18-01-1276126.PMC5323017.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"3, 280 –285 http://dx.doi.org/10.1080/15384101.2016.1252883",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"ORCID Maria Grazia Cipolleschi http://orcid.org/0000-0003-4454-3771 Elisabetta Rovida http://orcid.org/0000-0002-5949-3239 Persio Dello Sbarba http://orcid.org/0000-0001-6411-569X References [1] Marzi I, Cipolleschi MG, D ’Amico M, Stivarou T, Rovida E, Vinci MC, Pandol ﬁS, Dello Sbarba P, Stecca B, Olivotto M. The involve- ment of a Nanog, Klf 4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming.Cell Cycle 2013; 12:353-64; PMID:23287475; http://dx.doi.org/10.4161/cc.23200 [2] Cipolleschi MG, Marzi I, Santini R, Fredducci D, Vinci MC, D ’Amico M, Rovida E, Stivarou T, Torre E, Dello Sbarba P, Stecca B, Olivotto M.Hypoxia-resistant pro ﬁle implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets.",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Cell Cycle 2014; 13:268-78; PMID:24200964; http://dx.doi.org/10.4161/cc.27031 [3] Bertino JR, G €oker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Stem Cells 1996; 14:5-9; PMID:8820944; http://dx.doi.org/10.1002/stem.140005 [4] Olivotto M, Caldini R, Chevanne M, Cipolleschi MG.",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
J Cell Physiol 1983; 116:149-58; PMID:6863398; http://dx.doi.org/10.1002/jcp.1041160205 [5] Yoshida T. Experimental production of tumours by subcutaneous injection of an olive oil solution of o-aminoazotoluene.,OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Arch Biochem Biophys 1983; 223:433-40;PMID:6859869; http://dx.doi.org/10.1016/0003-9861(83)90607-0 [7] Stivarou T, Cipolleschi MG, D ’Amico M, Mannini A, Mini E, Rovida E, Dello Sbarba P, Olivotto M, Marzi I.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Biochem J 2000; 350:609-29; PMID:10970772; http://dx.doi.org/10.1042/ bj3500609 [9] Sur P, Doig MT, Priest DG.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Biochem J 1982; 216:295-8; http://dx.doi.org/10.1042/bj2160295 [10] Gonen N, Assaraf YG.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Drug resistance update 2012;15:183-210; http://dx.doi.org/10.1016/j.drup.2012.07.002 [11] Hillcoat BL, Marshall L, Patterson J. Dihydrofolate reductase induced by folic acid in cultured human cells.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Cell Death Dis2013; 4:e877; PMID:24157871; http://dx.doi.org/10.1038/ cddis.2013.393 [15] Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrel DK, Lindor JZ, Dzeja PP, Ikeda Y, Perez-Terzic C, Terzic A. Somatic oxidative bio-energetics transitions into pluripotency-dependent glycolysis to facil- itate nuclear reprogramming.",OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10.1016/j.cmet.2011.06.011 [16] Rovida E, Peppicelli S, Bono S, Bianchini F, Tusa I, Cheloni G, Marzi I, Cipolleschi MG, Calorini L, Dello Sbarba P. The metabolically- modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
"Nutr Clin Pract 2005; 20:411-22; PMID:16207681; http://dx.doi.org/10.1177/0115426505020004411 [18] Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB.",Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
Urology 2013; 82:1197-2; PMID:23992971; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
Cancer Epidemiol Biomarkers Prev 2010; 19:2023-34; PMID:20696661; http://dx.doi.org/10.1158/1055-9965.EPI-09- 1097 [21] Blagosklonny MV.,Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
Cell Death Differ 2005; 12:592-602; PMID:15818400; http://dx.doi.org/10.1038/sj.cdd.4401610 [22] Blagosklonny MV.,Non-OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
2004; 6:425;http://dx.doi.org/10.1016/S1535-6108(03)00336-2CELL CYCLE 285,OADS,/arxiv_data1/oa_pdf/47/71/kccy-16-03-1252883.PMC5323031.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 167–168Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 167 LETTER open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S131030 How should pediatric communication skills be  taught?",Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
"Correspondence:  Alysha Bhatti Faculty of Medicine, Imperial College London, Prince Consort Road, Kensington, London, SW7 2BB, UKEmail ab6412@imperial.ac.uk Journal name: Advances in Medical Education and Practice Article Designation: LETTERY ear: 2017V olume: 8Running head verso: Bhatti and AhmedRunning head recto: How should pediatric communication skills be taught?DOI: http://dx.doi.org/10.2147/AMEP .S131030",Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 168 Bhatti and Ahmed A further avenue to explore is that of simulation train- ing, as we feel that this educational strategy is currently  underused in undergraduate pediatric teaching.",Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
Available from: http://www.gmc-uk.org/static/documents/content/0_18_years.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
Available from: http://www.gmcuk.org/RCGP_Curricu-lum_3.04_Children_and_Y oung_People.pdf_49502510.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f9/c7/amep-8-167.PMC5323061.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical and Experimental Gastroenterology 2017:10 47–56Clinical and Experimental Gastroenterology Dovepress submit your manuscript | www.dovepress.com Dovepress  47 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S121129Bioavailability of a dexlansoprazole  delayed‑release orally disintegrating tablet:  effects of food and mode of administration Michael Kukulka Sai Nudurupati Maria Claudia Perez Takeda Development Center  Americas, Inc., Deerfield, IL, USABackground: Dexlansoprazole is a proton pump inhibitor (PPI) approved for use in dual  delayed-release capsule and orally disintegrating tablet (ODT) formulations.",Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
"1Correspondence: Michael Kukulka Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL 60015, USATel +1 224 554 2205Fax +1 224 554 7933Email michael.kukulka@takeda.comJournal name: Clinical and Experimental Gastroenterology Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Kukulka et alRunning head recto: Effects of food and mode of administration of dexlansoprazoleDOI: http://dx.doi.org/10.2147/CEG.S121129",Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
2006. http://www.nature.com/gimo/contents/ pt1/full/gimo34.html.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
2006. http://www.nature.com/gimo/contents/pt1/full/gimo35.html.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
Available from: https://clinicaltrials.gov/ct2/manage-recs/fdaaa.,Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
"Clinical and Experimental Gastroenterology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical‑and‑experimental‑gastroenterology‑journalClinical and Experimental Gastroenterology is an international, peer- reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of   gastroenterology in the clinic and laboratory.",Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 56 Kukulka et al Supplementary materials Table S1  Study 1 treatment sequences Sequence Participants (n) Treatment regimen Planned Enrolled Period 1 Period 2 Period 3 1 24 24 Test 1A Test 1B Reference 2 24 24 Test 1B Reference Test 1A 3 24 24 Reference Test 1A Test 1B Notes: Test 1A: a single dose of dexlansoprazole 30‑mg ODT administered on the tongue without water, 30 minutes after a high‑fat meal.",Non-OADS,/arxiv_data1/oa_pdf/4c/e3/ceg-10-047.PMC5323062.pdf
1/8 http://ejgo.orgABSTRACT Objective:  Tamoxifen has been used to prevent the recurrence of breast cancer.,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
"2017 Mar;28(2):e10 https://doi.org/10.3802/jgo.2017.28.e10 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Jul 25, 2016 Revised:  Sep 19, 2016 Accepted:  Sep 28, 2016 Correspondence to Seung-Yup Ku Department of Obstetrics and Gynecology,  Seoul National University College of Medicine,  Seoul National University Hospital, 103  Daehak-ro, Jongno-gu, Seoul 03080, Korea.",Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
"ORCID Hoon Kim http://orcid.org/0000-0002-5623-6368 Wonshik Han http://orcid.org/0000-0001-7310-0764 Seung-Yup Ku http://orcid.org/0000-0002-6423-854X Chang Suk Suh http://orcid.org/0000-0003-1835-7350 Seok Hyun Kim http://orcid.org/0000-0003-0649-3224Hoon Kim,1 Wonshik Han,2 Seung-Yup Ku,1 Chang Suk Suh,1 Seok Hyun Kim,1   Young Min Choi1 1 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul National  University Hospital, Seoul, Korea 2 Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital,  Seoul, KoreaFeature of amenorrhea in  postoperative tamoxifen users with  breast cancer",Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
Serum estradiol was measured using a radioimmunoassay kit  2/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
3/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
4/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users Table 1.,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
5/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users Table 2.,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
"Indeed, a previous study showed an increase  6/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users",Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
PUBMED  | CROSSREF 7/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
PUBMED  | CROSSREF 8/8 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e10Amenorrhea in tamoxifen users,Non-OADS,/arxiv_data1/oa_pdf/05/8b/jgo-28-e10.PMC5323281.pdf
1/11 http://ejgo.orgABSTRACT Objective:  The aim of this study was to build a model to predict the risk of lymphovascular  space invasion (LVSI) in women with endometrial cancer (EC).,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
"2017 Mar;28(2):e11 https://doi.org/10.3802/jgo.2017.28.e11 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Sep 26, 2016 Accepted:  Oct 3, 2016 Correspondence to Xipeng Wang Department of Gynecology, Shanghai  First Maternity and Infant Hospital, Tongji  University, 2699 Gaoke West Rd, Pudong New  Area, Shanghai 200040, China.",Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
"ORCID Xingchen Zhou http://orcid.org/0000-0003-4245-4249 Husheng Wang http://orcid.org/0000-0002-4203-2188 Xipeng Wang http://orcid.org/0000-0001-9029-0803 Funding This study was supported by grants from the  National Natural Science Foundation of China  (81372787), the Shanghai Municipal Bureau of  Health (20134033), the Shanghai Health System  joint research project (2013ZYJB0201) and the  Top 100 Medical Elite in Shanghai (XBR 2011065).Xingchen Zhou,* Husheng Wang,* Xipeng Wang Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, Shanghai, ChinaPreoperative CA125 and fibrinogen  in patients with endometrial  cancer: a risk model for predicting  lymphovascular space invasion",Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
They were  2/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
The ROC curves of the LVSI positive and negative groups were drawn  3/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
4/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion Table 1.,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
5/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion Table 3.,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
6/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion A /one.LP-Speciﬁcity0.6 0.4 0.2 0 0.2 0.4 0.6 0.8 1.0Sensitivity0.81.0 /one.LP-Speciﬁcity0.2 0.4 0.6 0.8 1.0 0B 0.6 0.4 0.2Sensitivity0.81.0 CA/one.LP/two.LP/five.LP LVSICA/one.LP/nine.LP/hyphen.cap/nine.LP C /one.LP-Speciﬁcity0.6 0.4 0.2 0 0.2 0.4 0.6 0.8 1.0Sensitivity0.81.0 /one.LP-Speciﬁcity0.2 0.4 0.6 0.8 1.0 0D 0.6 0.4 0.2Sensitivity0.81.0 LVSIFnLVSICEA LVSIWBC Fig.,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
There were 59 patients  7/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion Table 4.,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
8/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
PUBMED  | CROSSREF 9/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
PUBMED  | CROSSREF 10/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
PUBMED  | CROSSREF 11/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e11A risk model for predicting lymphovascular space invasion,Non-OADS,/arxiv_data1/oa_pdf/26/9e/jgo-28-e11.PMC5323282.pdf
1/11 http://ejgo.orgABSTRACT Objective:  Our objective was to determine the feasibility and detection rates and clarify the  most effective combination of injected tracer types for sentinel lymph node (SLN) mapping in  uterine cervical cancer in patients who have undergone laparoscopic surgery or neoadjuvant  chemotherapy (NAC).,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"2017 Mar;28(2):e13 https://doi.org/10.3802/jgo.2017.28.e13 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Apr 6, 2016 Revised:  Sep 28, 2016 Accepted:  Oct 21, 2016 Correspondence to Yoshito Terai Department of Obstetrics and Gynecology,  Osaka Medical College, 2-7 Daigaku-machi,  Takatsuki, Osaka 569-8686, Japan.",Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"ORCID Yoshito Terai http://orcid.org/0000-0001-8662-7426 Keisuke Ashihara http://orcid.org/0000-0002-1885-4093 Satoshi Tsunetoh http://orcid.org/0000-0002-1931-9498 Hiroyuki Akagi http://orcid.org/0000-0002-8174-6191 Takashi Yamada http://orcid.org/0000-0003-1797-3880 Conflict of Interest No potential conflict of interest relevant to this  article was reported.Tomohito Tanaka,1 Yoshito Terai,1 Keisuke Ashihara,1 Satoshi Tsunetoh,1   Hiroyuki Akagi,2 Takashi Yamada,3 Masahide Ohmichi1 1Department of Obstetrics and Gynecology, Osaka Medical College, Osaka, Japan 2Department of Radiology, Osaka Medical College, Osaka, Japan 3Department of Pathology, Osaka Medical College, Osaka, JapanThe detection of sentinel lymph  nodes in laparoscopic surgery  for uterine cervical cancer using  99m-technetium-tin colloid,  indocyanine green, and blue dye",Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
Lymphoscintigraphy was performed  2/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"3/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer Total number of patients, /one.LP/one.LP/nine.LP patients Systematic PLND, /one.LP/one.LP/six.LP patients  No systematic PLND, /three.LP patients Number of sides with detected SLNs, /one.LP/eight.LP/nine.LP sides Number of sides with no detected SLNs, /four.LP/three.LP sides Metastasis in SLNs, /two.LP/two.LP sides Metastasis in ipsilateral nodes, /nine.LP sides No metastasis in ipsilateral nodes, /one.LP/five.LP/eight.LP sides No metastasis in SLNs, /one.LP/six.LP/seven.LP sides Negative predictive value, /one.LP/five.LP/eight.LP/slash.cap/one.LP/six.LP/seven.LPFalse negative rate, /nine.LP/slash.cap/one.LP/six.LP/seven.LP Sensitivity, /two.LP/two.LP/slash.cap/three.LP/one.LP Fig.",Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"The mean age of the patients was 46.0 years, and the mean body mass index  4/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer Table 1.",Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"The total detection rate, sensitivity, and FN  5/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer Table 2.",Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
6/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
7/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer Table 3.,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
8/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
PUBMED 9/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
PUBMED 10/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
PUBMED  | CROSSREF 11/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e13Sentinel lymph node biopsy in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/03/07/jgo-28-e13.PMC5323283.pdf
"1/11 http://ejgo.orgABSTRACT Objective:  Cancer stem cells (CSCs) represent a subpopulation of undifferentiated  tumorigenic cells thought to be responsible for tumor initiation, maintenance, drug  resistance, and metastasis.",Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
"2017 Mar;28(2):e14 https://doi.org/10.3802/jgo.2017.28.e14  pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  May 12, 2016 Revised:  Oct 15, 2016 Accepted:  Oct 27, 2016 Correspondence to Chi-Heum Cho Department of Obstetrics and Gynecology,  Keimyung University, School of Medicine,   56 Dalseong-ro, Jung-gu, Daegu 41931, Korea.",Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
ORCID Hye-Won Chung http://orcid.org/0000-0001-5142-4346 Sang-Hoon Kwon http://orcid.org/0000-0002-9121-3954 Jin-Eui Lee http://orcid.org/0000-0003-2072-2775 Chi-Heum Cho http://orcid.org/0000-0002-0437-4099 Funding This research was supported by the Keimyung  University Research Grant of 2012.,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
"Primary culture conditions of OCCs Ascites was collected from patients diagnosed with advanced stage high-grade serous ovarian  carcinoma, after obtaining written informed consent under protocols approved by the  2/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer",Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
After reaction with horseradish  3/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
"In comparison with the control, PTX reduced the viability of OCCs in a  4/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer",Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
5/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer * * *** **** 80100140 120 60 40 20 Paclitaxel concentration (nM) Salinomycin concentration (µM)OCCs OCSCs OCCs OCSCs OCCs OCSCsA 0 20 50 100 10 0 0.5 1 50Cell survival rate (% of control) 80100140 120 60 40 20CCell survival rate (% of control)80100140 120 60 40 20BCell survival rate (% of control) Control PTX /two.LP/zero.LP nM Sal /zero.LP./five.LP  µM PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM00 Fig.,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
6/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer A B C D SOX/two.LP OCT/three.LP/slash.cap/four.LP GAPDH SOX/two.LP OCT/three.LP/slash.cap/four.LP GAPDH Scrambled siRNAsiRNA SOX/two.LP SOX/two.LP OCT/three.LP/slash.cap/four.LP β-actin Paclitaxel concentration (nM)0 10 50 100 2000Cell survival rate (% of control)80100120 60 40 20*NT OCSCs Scrambled siRNA siRNA SOX/two.LP *ControlPTX /two.LP/zero.LP nMSal /zero.LP./five.LP µMPTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µMControlPTX /two.LP/zero.LP nMSal /zero.LP./five.LP µMPTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM Fig.,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
7/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer AControl PTX /two.LP/zero.LP nM Sal /zero.LP./five.LP  µM PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM B Control PTX /two.LP/zero.LP nM Sal /zero.LP./five.LP  µM PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM0Sphere number (/greater.cap/five.LP/zero.LP  µm)1520 10 5 *** Fig.,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
"CSCs are characterized by self- renewal capability, differentiation potential, chemoresistance, and the ability to promote  8/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer B Control PTX /two.LP/zero.LP nM Sal /zero.LP./five.LP  µM PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µMControl PTX /two.LP/zero.LP nM Sal /zero.LP./five.LP  µM PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM0Caspase-/three.LP activity (fold-increase)1.53.0 2.5 2.0 1.0 0.51.53.0 2.5 2.01.0 0.5* **C 0Cytoplasmic histone-associated DNA fragments(A /four.LP/zero.LP/five.LPnm) * * *Annexin V intensityAPI intensityControl Q/three.LP/hyphen.cap/one.LP /four.LP./five.LP/seven.LP%Q/three.LP/hyphen.cap/two.LP /one.LP./eight.LP/two.LP% Q/three.LP/hyphen.cap/three.LP /nine.LP/two.LP./eight.LP/two.LP%Q/three.LP/hyphen.cap/four.LP /zero.LP./eight.LP/zero.LP% 102.5104105106.5101.5105.5104103PTX /two.LP/zero.LP nM Q/three.LP/hyphen.cap/one.LP /nine.LP./four.LP/nine.LP%Q/three.LP/hyphen.cap/two.LP /three.LP./nine.LP/six.LP% Q/three.LP/hyphen.cap/three.LP /eight.LP/five.LP./two.LP/three.LP%Q/three.LP/hyphen.cap/four.LP /one.LP./three.LP/two.LP% 102.5104105106.5101.5105.5104103Sal /zero.LP./five.LP  µM Q/three.LP/hyphen.cap/one.LP /eight.LP./one.LP/eight.LP%Q/three.LP/hyphen.cap/two.LP /one.LP/four.LP./four.LP/five.LP% Q/three.LP/hyphen.cap/three.LP /seven.LP/four.LP./one.LP/eight.LP%Q/three.LP/hyphen.cap/four.LP /three.LP./one.LP/nine.LP% 102.5104105106.5101.5105.5104103PTX /two.LP/zero.LP nM + Sal /zero.LP./five.LP  µM Q/three.LP/hyphen.cap/three.LP /five.LP/five.LP./one.LP/four.LP%Q/three.LP/hyphen.cap/four.LP /four.LP./two.LP/five.LP%Q/three.LP/hyphen.cap/one.LP /one.LP/two.LP./seven.LP/zero.LP%Q/three.LP/hyphen.cap/two.LP /two.LP/seven.LP./nine.LP/one.LP% 102.5104105106.5101.5105.5104103 Fig.",Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
9/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
PUBMED  | CROSSREF 10/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
CROSSREF 11/11 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e14Salinomycin induces apoptosis in ovarian cancer,Non-OADS,/arxiv_data1/oa_pdf/96/b0/jgo-28-e14.PMC5323284.pdf
"1/10 http://ejgo.orgABSTRACT Objective:  To develop an algorithmic quantitative skin and subcutaneous tissue volume  measurement protocol for lower extremity lymphedema (LEL) patients using computed  tomography (CT), to verify the usefulness of the measurement techniques in LEL patients,  and to observe the structural characteristics of subcutaneous tissue according to the  progression of LEL in gynecologic cancer.",Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
"2017 Mar;28(2):e18 https://doi.org/10.3802/jgo.2017.28.e18 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Aug 22, 2016 Revised:  Nov 3, 2016 Accepted:  Nov 16, 2016 Correspondence to Yun-Hee Kim Department of Physical and Rehabilitation  Medicine, Center for Prevention and  Rehabilitation, Heart Vascular Stroke Institute,  Samsung Medical Center, Sungkyunkwan  University School of Medicine, 81 Irwon-ro,  Gangnam-gu, Seoul 06351, Korea.",Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
"ORCID Ji Sung Yoo http://orcid.org/0000-0003-3559-8412 Myong Cheol Lim http://orcid.org/0000-0001-8964-7158 Yun-Hee Kim http://orcid.org/0000-0001-6101-8851Ji Sung Yoo,1 Seung Hyun Chung,1 Myong Cheol Lim,2 Young Jae Kim,3   Kwang Gi Kim,3 Ji Hye Hwang,4 Yun-Hee Kim5 1Rehabilitation Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Korea 2 Gynecologic Cancer Branch, Center for Uterine Cancer, and Center for Clinical Trials, Research Institute  and Hospitaland Cancer Control and Policy, Graduate School of Cancer Science and Policy, National  Cancer Center, Goyang, Korea 3 Biomedical Engineering Branch, Division of Precision Medicine and Cancer Informatics, Research Institute,  National Cancer Center, Goyang, Korea 4 Department of Physical and Rehabilitation Medicine, Center for Supportive Care, Samsung Medical Center,  Sungkyunkwan University School of Medicine, Seoul, Korea 5 Department of Physical and Rehabilitation Medicine, Center for Prevention and Rehabilitation, Heart Vascular  Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaComputed tomography-based  quantitative assessment of lower  extremity lymphedema following  treatment for gynecologic cancer",Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
The  2/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
"The CT images were segmented according to the respective layers of the leg regions, and the  3/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema A B Fig.",Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
4/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema A B Fig.,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
The mean interval between  5/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema Fig.,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
The chronic lymphedema group had a significantly larger  6/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema Table 2.,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
"Theoretically, lower leg edema could easily develop in patients with DVT from extensive disease  7/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema Table 3.",Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
8/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
PUBMED  | CROSSREF 9/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
CROSSREF 10/10 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e18CT-based quantitative assessment of lymphedema,Non-OADS,/arxiv_data1/oa_pdf/78/4e/jgo-28-e18.PMC5323285.pdf
1/14 http://ejgo.orgABSTRACT Objective:  To compare the survival outcomes of patients with cervical squamous cell  carcinoma (SCC) and adenocarcinoma/adenosquamous carcinoma (AC/ASC) among patients  with locally advanced cervical cancer that were treated with definitive radiotherapy.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
"2017 Mar;28(2):e19 https://doi.org/10.3802/jgo.2017.28.e19 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Aug 17, 2016 Revised:  Nov 21, 2016 Accepted:  Nov 28, 2016 Correspondence to Seiji Mabuchi Department of Obstetrics and Gynecology,  Osaka University, Graduate School of  Medicine, 2-2 Yamadaoka, Suita,   Osaka 565-0871, Japan.",Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
"ORCID Eriko Yokoi http://orcid.org/0000-0001-9514-1356 Seiji Mabuchi http://orcid.org/0000-0003-1803-1166 Ryoko Takahashi http://orcid.org/0000-0003-0397-4575 Yuri Matsumoto http://orcid.org/0000-0003-4300-5517 Katsumi Kozasa http://orcid.org/0000-0002-9572-4989 Conflict of Interest No potential conflicts of interest relevant to  this article was reported.Eriko Yokoi, Seiji Mabuchi, Ryoko Takahashi, Yuri Matsumoto, Hiromasa Kuroda,  Katsumi Kozasa, Tadashi Kimura Department of Obstetrics and Gynecology, Osaka University, Graduate School of Medicine, Osaka, JapanImpact of histological subtype on  survival in patients with locally  advanced cervical cancer that were  treated with definitive radiotherapy:  adenocarcinoma/adenosquamous  carcinoma versus squamous cell  carcinoma",Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
"At our institution, the histological classification of cancer is  performed by two independent gynecological pathologists based on the World Health  2/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer",Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
3/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
4/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer Table 1.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
The estimated 5-year OS rates  5/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer Table 2.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
6/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer A SCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/two.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/four.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 B SCC AC/ASC p/equal.cap/zero.LP./zero.LP/one.LP/zero.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/three.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 C SCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/four.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/five.LP/three.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 D SCC AC/ASC p/equal.cap/zero.LP./zero.LP/two.LP/nine.LP Time (mo)0.6 0.40.2 0 24 36 46 60Pelvic failure-free survival0.81.0 12 Distant metastasis-free survivalSCC AC/ASC p/equal.cap/zero.LP./seven.LP/eight.LP/nine.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12Fig.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
As shown in  7/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancerA SCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/two.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/four.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 B SCC AC/ASC p/equal.cap/zero.LP./zero.LP/one.LP/zero.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/three.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 C SCC AC/ASC p/equal.cap/zero.LP./zero.LP/zero.LP/four.LP Time (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 Overall survivalSCC AC/ASC p/equal.cap/zero.LP./zero.LP/five.LP/three.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 D SCC AC/ASC p/equal.cap/zero.LP./zero.LP/two.LP/nine.LP Time (mo)0.6 0.40.2 0 24 36 46 60Pelvic failure-free survival0.81.0 12 Distant metastasis-free survivalSCC AC/ASC p/equal.cap/zero.LP./seven.LP/eight.LP/nine.LP Time (mo)0.6 0.4 0.2 0 24 36 46 600.81.0 12 Fig.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
8/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer Table 4.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
The patients who received CCRT combined with NAC and adjuvant  9/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer A p/less.cap/zero.LP./zero.LP/zero.LP/one.LP Risk factor /two.LP Risk factor /three.LPRisk factor /zero.LP Risk factor /one.LP Risk factor /two.LP Risk factor /three.LPRisk factor /zero.LP Risk factor /one.LP Risk factor /two.LPRisk factor /three.LPRisk factor /zero.LP Risk factor /one.LPTime (mo)0.6 0.40.2 0 24 36 46 60Progression-free survival0.81.0 12 B p/equal.cap/zero.LP./zero.LP/zero.LP/three.LP Time (mo)0.60.40.2 0 24 36 46 600.81.0 12p/equal.cap/zero.LP./two.LP/nine.LP/one.LP Time (mo)0.60.40.2 0 24 36 46 600.81.0 12Pelvic failure-free survival Distant metastasis-free survival Fig.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
10/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
"Click here to view Supplementary Table 1 Univariate/multivariate analysis of prognostic factors for PFS (patients treated with  definitive RT) AC, adenocarcinoma; ASC, adenosquamous carcinoma; CI, confidence interval; CR,  complete response; FIGO, International Federation of Gynecology and Obstetrics; HR,  11/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer",Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
PUBMED  | CROSSREF 12/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
PUBMED  | CROSSREF 13/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
Available from: http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
PUBMED  | CROSSREF 14/14 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e19Adeno/adenosquamous carcinoma in cervical cancer,Non-OADS,/arxiv_data1/oa_pdf/e3/87/jgo-28-e19.PMC5323286.pdf
"1/19 http://ejgo.orgABSTRACT In recent years, progress in our understanding of immune-modulatory signaling pathways in  immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer  immunotherapy.",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"2017 Mar;28(2):e20 https://doi.org/10.3802/jgo.2017.28.e20 pISSN 2005-0380·eISSN 2005-0399 Review Article Received:  Aug 11, 2016 Revised:  Nov 4, 2016 Accepted:  Nov 28, 2016 Correspondence to David Shao Peng Tan Department of Hematology-Oncology,  National University Hospital, 5 Lower Kent  Ridge Road, Singapore 119074, Singapore.",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
ORCID Valerie Heong http://orcid.org/0000-0001-8894-1355 Natalie Ngoi http://orcid.org/0000-0003-2071-0715 David Shao Peng Tan http://orcid.org/0000-0001-9087-5262 Conflict of Interest Corresponding author Dr. David Tan consults  on the advisory board for Astra Zeneca.,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"Deficiency in MMR increases mutation rates up to 1,000-fold and  is causally associated with the development of endometrial cancer (approximately 24% of  2/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"When comparing the pathologic features of sporadic MSI-high  endometrial carcinoma, sporadic endometrial cancer in women less than 50 years who were  Lynch syndrome-negative, and Lynch syndrome-associated MSI-high, endometrial carcinoma,  the sporadic group consisting of women less than 50 years with endometrial carcinoma and the  sporadic MLH1  methylation group were almost entirely composed of tumors with endometrioid  3/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"Rationale for immune checkpoint inhibitors in advanced EOC In a previous study examining the prognostic relevance of the host immune response  in ovarian cancer, intratumoral CD3+ T-cell infiltration was found to be an independent  4/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
5/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
In order to generate clinically effective  6/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers Table 1.,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"Indeed, 9 patients with advanced EOC or breast cancer were treated  7/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers Table 2.",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
8/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers Table 3.,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"In advanced non-small-cell lung cancer (NSCLC), PD-L1 expression of  9/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
Combination with targeted treatment There is growing evidence that oncogenic pathways in tumors can promote resistance to  checkpoint blockade with activation of the PI3K-AKT pathway and/or phosphatase and tensin  homolog (PTEN) loss in patients with melanoma [ 84] while preclinical studies observed  oncogenic epidermal growth factor receptor (EGFR) signaling was able to remodel the TME  10/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
11/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"However, despite encouraging clinical  12/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers",Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 13/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 14/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 15/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 16/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 17/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 18/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
PUBMED  | CROSSREF 19/19 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e20Immune checkpoint inhibitors in gynecological cancers,Non-OADS,/arxiv_data1/oa_pdf/ac/68/jgo-28-e20.PMC5323287.pdf
"1/13 https://ejgo.orgABSTRACT Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among  the gynecologic malignant tumors in Japan.",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"2017 Mar;28(2):e32 https://doi.org/10.3802/jgo.2017.28.e32 pISSN 2005-0380·eISSN 2005-0399 Review Article Received:  Jan 10, 2017 Revised:  Jan 26, 2017 Accepted:  Jan 29, 2017 Correspondence to Wataru Yamagami Department of Obstetrics and Gynecology,  Keio University School of Medicine, 35  Shinanomachi, Shinjuku-ku, Tokyo 160-8582,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"ORCID Wataru Yamagami http://orcid.org/0000-0003-3925-6057 Fumiaki Takahashi http://orcid.org/0000-0001-9201-1089 Kazuhiko Ino http://orcid.org/0000-0002-6198-0730 Toru Hachisuga http://orcid.org/0000-0003-2888-2538 Daisuke Aoki http://orcid.org/0000-0002-9596-8326 Hidetaka Katabuchi http://orcid.org/0000-0002-2403-6134Wataru Yamagami,1,7 Satoru Nagase,2,7 Fumiaki Takahashi,3 Kazuhiko Ino,4,7   Toru Hachisuga,5,7 Daisuke Aoki,1,7 Hidetaka Katabuchi6,7 1Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan 2Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan 3 Department of Clinical Research Network, Clinical Research, Innovation and Education Center, Tohoku  University Hospital, Sendai, Japan 4Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan 5 Department of Obstetrics and Gynecology, University of Occupational and Environmental Health Japan,  Kitakyushu, Japan 6Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan 7Gynecologic Tumor Committee, Japan Society of Obstetrics and Gynecology, Tokyo, JapanClinical statistics of gynecologic  cancers in Japan",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"Clinicopathologic factors for cervical cancer (without CIN3), endometrial  cancer, and ovarian cancer, including age, clinical stage, postsurgical stage, histological type,  and therapeutic strategy were retrieved from the gynecologic cancer registry and used for  2/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan",OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"In 2014, 12.8% of the  cervical cancer patients were classified as stage IA1, 2.1% as stage IA2, 29.8% as stage IB1,  3/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"In young patients aged 39 years or  less, 73%– 79% of the patients were classified as stage I and 11%–14% were classified as stage  4/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan Endometrial cancer Ovarian cancerCervical cancerEndometrial cancer Ovarian cancerCervical cancer 1977 0Number Year2,0004,0006,0008,00010,00012,00014,00016,000 1975 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011A 1977 0.0per /one.LP/zero.LP/zero.LP,/zero.LP/zero.LP/zero.LP Year0.51.01.52.02.53.03.54.0 1975 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011B Fig.",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
5/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan A I II III IV Unknown2014 2010 2005/four.LP/eight.LP./nine.LP% /five.LP/four.LP./zero.LP% /five.LP/four.LP./three.LP% /two.LP/two.LP./five.LP% /one.LP/zero.LP./one.LP% /one.LP/one.LP./two.LP% /one.LP./nine.LP%/two.LP/one.LP./two.LP% /one.LP/two.LP./three.LP% /eight.LP./four.LP% /four.LP./one.LP%/two.LP/three.LP./six.LP% /one.LP/four.LP./eight.LP% /eight.LP./one.LP% /four.LP./six.LP% /four.LP/one.LP./eight.LP% /seven.LP/six.LP./three.LP% /four.LP/six.LP./five.LP% /seven.LP/eight.LP./eight.LP% /four.LP/seven.LP./five.LP% /two.LP/five.LP./six.LP% /one.LP/two.LP./two.LP% /one.LP/three.LP./three.LP% /one.LP./five.LP%/one.LP/three.LP./two.LP% /two.LP./six.LP% /three.LP./nine.LP%/one.LP./four.LP%/two.LP/four.LP./six.LP% /one.LP/five.LP./one.LP% /one.LP/zero.LP./three.LP% /three.LP./five.LP%/one.LP/one.LP./zero.LP% /four.LP./zero.LP% /five.LP./nine.LP% /two.LP./seven.LP%/two.LP/six.LP./four.LP% /one.LP/seven.LP./six.LP% /one.LP/zero.LP./zero.LP% /four.LP./two.LP%/seven.LP/three.LP./three.LP% /one.LP/three.LP./nine.LP% /five.LP./two.LP% /six.LP./zero.LP% /one.LP./five.LP% /seven.LP/five.LP./five.LP /one.LP/six.LP./nine.LP/one.LP/eight.LP./two.LP/two.LP/zero.LP./one.LP /four.LP./one.LP /one.LP./zero.LP /one.LP./one.LP/one.LP./six.LP /zero.LP./five.LP/two.LP./one.LP/one.LP./three.LP/one.LP./zero.LP /zero.LP./three.LP/zero.LP./six.LP/three.LP./seven.LP/three.LP./eight.LP/seven.LP/five.LP./three.LP /seven.LP/two.LP./eight.LPB ≤39 ≥402014 2010 2005 ≤39≥40 ≤39 ≥40 C 80% 0%20%40%60% Squamous cell carcinoma Adenocarcinoma Adenosquamous  carcinoma Neuroendocrine tumor Undiﬀerentiated carcinoma Others/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LP D 40% 0%10% 5%15%25%35% 20%30% Surgery Surgery-radiation Surgery- chemotherapySurgery-CCRT Radiation Chemoradiation Chemotherapy Others/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
6/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
7/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan A I II III IV Unknown2014 2010 2005/six.LP/four.LP./eight.LP% /six.LP/three.LP./two.LP% /seven.LP/one.LP./nine.LP% /eight.LP/four.LP./eight.LP/eight.LP/two.LP./six.LP /eight.LP/one.LP./seven.LP /three.LP./eight.LP /two.LP./four.LP/two.LP./four.LP/two.LP./two.LP /zero.LP./four.LP /zero.LP./six.LP /zero.LP./five.LP /zero.LP./three.LP/zero.LP./two.LP/zero.LP./two.LP /one.LP./five.LP/two.LP./four.LP/two.LP./three.LP/five.LP./zero.LP /five.LP./two.LP/four.LP./nine.LP /one.LP./seven.LP/two.LP./zero.LP/two.LP./eight.LP/four.LP./six.LP/five.LP./five.LP/six.LP./zero.LP% /one.LP/three.LP./three.LP% /seven.LP./five.LP% /one.LP./four.LP%/eight.LP./one.LP% /one.LP/nine.LP./four.LP% /seven.LP./three.LP% /two.LP./zero.LP%/eight.LP./five.LP% /one.LP/eight.LP./nine.LP% /six.LP./five.LP% /one.LP./two.LP%/seven.LP/zero.LP./eight.LP% /six.LP/four.LP./three.LP% /six.LP/eight.LP./five.LP% /six.LP/two.LP./nine.LP% /seven.LP/six.LP./four.LP% /seven.LP/one.LP./seven.LP% /five.LP./nine.LP% /one.LP/three.LP./five.LP% /seven.LP./six.LP% /one.LP./three.LP%/seven.LP./two.LP% /nine.LP./zero.LP% /five.LP./zero.LP% /two.LP./four.LP%/eight.LP./zero.LP% /one.LP/nine.LP./seven.LP% /seven.LP./four.LP% /two.LP./zero.LP%/nine.LP./two.LP% /one.LP/five.LP./one.LP% /five.LP./six.LP% /one.LP./five.LP%/eight.LP./five.LP% /one.LP/nine.LP./three.LP% /six.LP./seven.LP% /one.LP./two.LP%/nine.LP./one.LP% /one.LP/four.LP./one.LP% /five.LP./zero.LP% /one.LP./zero.LP%B ≤39 ≥402014 2010 2005 ≤39≥40 ≤39 ≥40 C 100% 0%20%40%80% 60% Endometrioid adenocarcinomaSerous adenocarcinomaClear cell adenocarcinomaMucinous adenocarcinomaSquamous cell carcinomaMixed carcinomaCarcinosarcoma Others/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LP D 70% 0%10%20%40%60% 30%50% Surgery Surgery-radiation Surgery- chemotherapySurgery-CCRT Radiation CCRT (or radiation- chemotherapy)Chemotherapy or hormonal therapyOthers/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
8/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
9/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan A I II III IV NAC Unknown2014 2010 2005/four.LP/one.LP./one.LP% /eight.LP./eight.LP% /three.LP/four.LP./two.LP% /seven.LP./seven.LP% /seven.LP./nine.LP% /four.LP/three.LP./two.LP% /nine.LP./three.LP% /three.LP/zero.LP./three.LP% /eight.LP./four.LP% /eight.LP./six.LP% /four.LP/three.LP./three.LP% /nine.LP./one.LP% /two.LP/seven.LP./six.LP% /seven.LP./two.LP% /one.LP/two.LP./six.LP%/zero.LP./three.LP%/six.LP/six.LP./six.LP% /seven.LP./zero.LP% /two.LP/zero.LP./five.LP% /four.LP./three.LP% /zero.LP./zero.LP% /six.LP/two.LP./one.LP% /six.LP./eight.LP% /two.LP/two.LP./six.LP% /four.LP./three.LP% /zero.LP./four.LP% /zero.LP./three.LP% /zero.LP./one.LP% C 40% 0%10% 5%15%30%35% 20%25% Endometrioid adenocarcinomaSerous adenocarcinomaClear cell adenocarcinomaMucinous adenocarcinomaOther epithelial tumorGerm cell tumorSex-cord tumorUndiﬀerentiated carcinomaMixed carcinomaOthers/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LP D 70%80%90%100% 0%10%20%40%60% 30%50% Surgery Surgery-chemotherapy Surgery-others Chemotherapy Chemotherapy-others Others/two.LP/zero.LP/zero.LP/five.LP /two.LP/zero.LP/one.LP/zero.LP /two.LP/zero.LP/one.LP/four.LPB ≤39 ≥402014 2010 2005 ≤39≥40 ≤39 ≥40/one.LP./seven.LP% /three.LP./eight.LP% /six.LP/three.LP./six.LP% /seven.LP./three.LP% /two.LP/zero.LP./seven.LP% /four.LP./eight.LP% /zero.LP./zero.LP% /three.LP./six.LP%/three.LP/seven.LP./nine.LP% /nine.LP./zero.LP% /three.LP/six.LP./zero.LP% /eight.LP./two.LP% /eight.LP./six.LP% /zero.LP./three.LP% /four.LP/zero.LP./nine.LP% /nine.LP./six.LP% /three.LP/one.LP./two.LP% /eight.LP./nine.LP% /nine.LP./two.LP% /zero.LP./two.LP% /four.LP/one.LP./five.LP% /nine.LP./three.LP% /two.LP/eight.LP./two.LP% /seven.LP./five.LP% /one.LP/three.LP./four.LP% /zero.LP./one.LP% /three.LP/six.LP./two.LP /three.LP/three.LP./zero.LP/three.LP/five.LP./seven.LP /one.LP/two.LP./eight.LP /one.LP/one.LP./zero.LP /nine.LP./six.LP /two.LP./four.LP/one.LP./nine.LP/one.LP./three.LP/three.LP./four.LP/five.LP./one.LP/three.LP./nine.LP/two.LP./six.LP/two.LP./eight.LP/two.LP./six.LP/two.LP/one.LP./seven.LP/two.LP/four.LP./five.LP /two.LP/four.LP./eight.LP /one.LP/five.LP./eight.LP/one.LP/six.LP./nine.LP/one.LP/seven.LP./five.LP /three.LP./eight.LP/three.LP./three.LP/three.LP./zero.LP /zero.LP./nine.LP /one.LP./two.LP/one.LP./three.LP/zero.LP./five.LP /zero.LP./three.LP/zero.LP./three.LP Fig.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
10/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan Table 1.,OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
"In Japan,  11/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan",Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available from: http://ganjoho.jp/reg_stat/statistics/dl/index.html.,OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available from:  http://fa.kyorin.co.jp/jsog/readPDF.php?file=to63/59/3/KJ00005049882.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
12/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available from:  http://fa.kyorin.co.jp/jsog/readPDF.php?file=64/3/064031029.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available from:  http://fa.kyorin.co.jp/jsog/readPDF.php?file=66/3/066030995.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available  from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=64/3/064031078.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available  from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=66/3/066031039.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
Available from: http://fa.kyorin.co.jp/jsog/readPDF.php?file=68/3/068031161.pdf.,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
PUBMED  | CROSSREF 13/13 https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e32Clinical statistics of gynecologic cancer in Japan,Non-OADS,/arxiv_data1/oa_pdf/70/35/jgo-28-e32.PMC5323288.pdf
1/7 http://ejgo.orgABSTRACT Objective:  The aim of this study was to compare responses to single-agent chemotherapies and  evaluate the predictive factors of resistance in low risk (LR) gestational trophoblastic disease  (GTD).,Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
"2017 Mar;28(2):e8 https://doi.org/10.3802/jgo.2017.28.e8 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  May 21, 2016 Revised:  Sep 19, 2016 Accepted:  Sep 28, 2016 Correspondence to Jeong-Yeol Park Department of Obstetrics and Gynecology,  University of Ulsan College of Medicine, Asan  Medical Center, 88 Olympic-ro 43-gil, Songpa- gu, Seoul 05505, Korea.",Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
"ORCID Young-Jae Lee http://orcid.org/0000-0001-6557-2454 Jeong-Yeol Park http://orcid.org/0000-0003-2475-7123 Yong-Man Kim http://orcid.org/0000-0003-3225-5748 Joo-Hyun Nam http://orcid.org/0000-0002-8440-3370 Conflict of Interest No potential conflict of interest relevant to this  article was reported.Young-Jae Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim,  Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center,  Seoul, KoreaComparing and evaluating the efficacy  of methotrexate and actinomycin D as  first-line single chemotherapy agents  in low risk gestational trophoblastic  disease",Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
"The ACT-D group  regimen consisted of either a bi-weekly pulsed intravenous (IV) regimen (ACT-D, 1.25 mg/m2)  2/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D",Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
CR was achieved in 48 of 71 patients  3/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D Table 1.,Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
4/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D Table 2.,Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
"Compared  with MTX, ACT-D may be the better option as a first-line single chemotherapy agent for  5/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D",Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
PUBMED  | CROSSREF 6/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D,Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
PUBMED  | CROSSREF 7/7 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e8Comparing methotrexate and actinomycin D,Non-OADS,/arxiv_data1/oa_pdf/26/dd/jgo-28-e8.PMC5323289.pdf
1/9 http://ejgo.orgABSTRACT Objective:  The Gynecologic Cancer Lymphedema Questionnaire (GCLQ) was designed to  identify gynecologic cancer patients with lower limb lymphedema (LLL).,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"2017 Mar;28(2):e9 https://doi.org/10.3802/jgo.2017.28.e9 pISSN 2005-0380·eISSN 2005-0399 Original Article Received:  Aug 20, 2016 Revised:  Sep 19, 2016 Accepted:  Sep 28, 2016 Correspondence to Myong Cheol Lim Center for Uterine Cancer and Gynecologic  Cancer Branch, Research Institute and  Hospital, National Cancer Center, 323 Ilsan-ro,  Ilsandong-gu, Goyang 10408, Korea.",Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"ORCID Se Ik Kim http://orcid.org/0000-0002-9790-6735 Jungnam Joo http://orcid.org/0000-0001-6961-8122 Sang-Yoon Park http://orcid.org/0000-0001-8325-6009 Myong Cheol Lim http://orcid.org/0000-0001-8964-7158Se Ik Kim,1,* Namjoo Kim,2,3,* Seonjoo Lee,2,4,* Sujung Lee,2 Jungnam Joo,5   Sang-Soo Seo,2 Seung Hyun Chung,6 Sang-Yoon Park,2,7 Myong Cheol Lim2,7 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea 2Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea 3Department of Statistics, Dongguk University School of Medicine, Seoul, Korea 4Bio Medical Laboratory Science, Yonsei University Wonju College of Medicine, Wonju, Korea 5Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea 6Rehabilitation Clinic, Research Institute and Hospital, National Cancer Center, Goyang, Korea 7Gynecologic Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, KoreaDevelopment of the short version of  the Gynecologic Cancer Lymphedema  Questionnaire: GCLQ-7",Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"Meanwhile, the patients with the following conditions were excluded:  1) edema with unclear cause, 2) active thrombosis, 3) tumors or local infection in the  lower extremity, 4) uncontrolled diabetes mellitus, 5) severe cardiac dysfunction, 6) renal  2/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ",Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"Statistical analysis was performed by using the R statistical software version 2.12.1 (R Foundation  for Statistical Computing, Vienna, Austria; ISBN 3-900051-07-0; http://R-project.org ).",OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
3/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
4/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ Table 1.,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
5/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ Heaviness 0 /one.LP-Speciﬁcity0.2 0.4 0.6 0.8 1.00.6 0.4 0.2Sensitivity0.81.0 Area under ROC curve = /zero.LP./eight.LP/zero.LP/five.LP/seven.LP Swelling-limb 0 /one.LP-Speciﬁcity0.2 0.4 0.6 0.8 1.00.6 0.4 0.2Sensitivity0.81.0 Hip swelling ROC area: /zero.LP./five.LP/nine.LP/zero.LP/nine.LP Groin swelling ROC area: /zero.LP./seven.LP/four.LP/three.LP/three.LP Reference Numbness 0 /one.LP-Speciﬁcity0.6 0.4 0.2 0.2 0.4 0.6 0.8 1.0Sensitivity0.81.0 Firmness tightness ROC area: /zero.LP./six.LP/five.LP/three.LP/three.LP Tenderness ROC area: /zero.LP./five.LP/seven.LP/seven.LP/one.LP Tingling ROC area: /zero.LP./five.LP/nine.LP/six.LP/seven.LPStiﬀness ROC area: /zero.LP./six.LP/two.LP/three.LP/four.LP Reference Infection related /one.LP-Speciﬁcity0 0.2 0.4 0.6 0.8 1.00.6 0.4 0.2Sensitivity0.81.0 Redness ROC area: /zero.LP./five.LP/nine.LP/one.LP/eight.LP Blisters ROC area: /zero.LP./five.LP/three.LP/zero.LP/three.LPIncreased temperature ROC area: /zero.LP./five.LP/seven.LP/seven.LP/one.LP Reference/one.LP-Speciﬁcity0.6 0.4 0.2 0 0.2 0.4 0.6 0.8 1.0Sensitivity0.81.0 Hip ROC area: /zero.LP./five.LP/zero.LP/zero.LP/nine.LP Knee ROC area: /zero.LP./five.LP/one.LP/six.LP/five.LPAnkle ROC area: /zero.LP./four.LP/seven.LP/one.LP/nine.LP Foot ROC area: /zero.LP./five.LP/one.LP/six.LP/five.LP Toes ROC area: /zero.LP./five.LP/one.LP/six.LPLeg or foot ROC area: /zero.LP./five.LP/nine.LP/four.LP/five.LP Reference Swelling-general /one.LP-Speciﬁcity0 0.2 0.4 0.6 0.8 1.00.6 0.4 0.2Sensitivity0.81.0 Swelling ROC area: /zero.LP./nine.LP/seven.LP/zero.LP/one.LP Pitting ROC area: /zero.LP./six.LP/six.LP/seven.LP/one.LPPockets of ﬂuid ROC area: /zero.LP./five.LP/four.LP/five.LP/five.LP Reference Physical functioning /one.LP-Speciﬁcity0.6 0.4 0.20.0 0.0 0.2 0.4 0.6 0.8 1.0Sensitivity0.81.0 Area under ROC curve = /zero.LP./six.LP/five.LP/five.LP/five.LP Aching Fig.,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
By  6/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ Table 2.,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"At the same time, the  7/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ",Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
PUBMED  | CROSSREF 8/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
PUBMED  | CROSSREF 9/9 http://ejgo.org https://doi.org/10.3802/jgo.2017.28.e9Development of the short version of the GCLQ,Non-OADS,/arxiv_data1/oa_pdf/7c/27/jgo-28-e9.PMC5323290.pdf
"The number of citable and noncitable articles per year,  and the countries of origin of authors and editorial board members were obtained from the homepage of the journal (available from: http://www.irjournal.org/).",OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.1Intest Res 2017;15(1):1-4PERSPECTIVE The great rise of Intestinal Research  as an international  journal 3 years after its language change to English as evidenced by journal metrics Geum Hee Jeong1, Sun Huh2 1Division of Nursing and 2Department of Parasitology and Institute of Medical Education, Hallym University College of Medicine, Chuncheon, Korea Received December 16, 2016.",Non-OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
"Title Year Volume PageTimes  citedPublication  type 1 Intestinal permeability regulation by tight junction: implication on  inflammatory bowel diseases2015 13 11 26 Review 2 Clinical application of genetics in management of colorectal cancer 2014 12 184 22 Review 3 Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence  and mortality: an evidence-based review of published prospective and  retrospective studies2014 12 268 16 Review 4 The safety and efficacy of azathioprine and 6-mercaptopurine in the  treatment of Korean patients with Crohn's disease2009 7 22 11 Original article 5 Inflammatory bowel disease-related colorectal cancer in the Asia-Pacific  region: past, present, and future2014 12 194 11 Review 6 Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection:  importance of controlling mucosal inflammation to prevent cytomegalovirus  reactivation2014 12  5 9 Review 7 Lipopolysaccharide: basic biochemistry, intracellular signaling, and  physiological impacts in the gut2014 12 90 9 Review 8 Clinical manifestations and course of intestinal Behçet's disease: an analysis in  relation to disease subtypes2005 3 48 8 Original article 9 Clinicopathological characteristics of colon cancer diagnosed at primary  health care institutions2014 12 131 8 Original article aAvailable from: http://apps.webofknowledge.com [cited 2016 Dec 15].",Non-OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
Available from: http://www.irjournal.org  [cited 2016 Dec 15].200 180 160 140 120 100 80 60 40 20No.,OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
https://doi.org/10.5217/ir.2017.15.1.1 • Intest Res 2017;15(1):1-4 3 www.irjournal.org period of 3 years after changing the language to English only  (Fig.,Non-OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
I also suggest uploading the full text JATS XML files to ScienceCentral (http://e-sciencecentral.org/) to enable automatic translation into 80 character languages and rapid search via Google Scholar.,Non-OADS,/arxiv_data1/oa_pdf/79/a7/ir-15-1.PMC5323298.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.103Intest Res 2017;15(1):103-108ORIGINAL ARTICLE Status of serum vitamin B12 and folate in patients with  inflammatory bowel disease in China Shaozhong Huang, Jiayi Ma, Mingming Zhu, Zhihua Ran Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Background/Aims: Inflammatory bowel disease (IBD) primarily involves the intestinal tract and can affect vitamin absorp-tion.",Non-OADS,/arxiv_data1/oa_pdf/9a/ab/ir-15-103.PMC5323299.pdf
https://doi.org/10.5217/ir.2017.15.1.103 • Intest Res 2017;15(1):103-108 105 www.irjournal.org METHODS  1.,OADS,/arxiv_data1/oa_pdf/9a/ab/ir-15-103.PMC5323299.pdf
"https://doi.org/10.5217/ir.2017.15.1.103 • Intest Res 2017;15(1):103-108 107 www.irjournal.org others have found contradicting results.3,5,10-15 In our study,  the patients with CD had significantly lower levels of serum  vitamin B12 than the UC patients and controls, while the  prevalence of vitamin B12 deficiency was similar in the UC  patients and controls.",Non-OADS,/arxiv_data1/oa_pdf/9a/ab/ir-15-103.PMC5323299.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.109Intest Res 2017;15(1):109-117ORIGINAL ARTICLE Determining the optimal surveillance interval after a colonoscopic polypectomy for the Korean population?",Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
"https://doi.org/10.5217/ir.2017.15.1.109 • Intest Res 2017;15(1):109-117 111 www.irjournal.org coagulation mode of the available electrocautery equipment  (Erbe USA Inc., Marietta, GA, USA).",OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
https://doi.org/10.5217/ir.2017.15.1.109 • Intest Res 2017;15(1):109-117 113 www.irjournal.org 2.,Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
"https://doi.org/10.5217/ir.2017.15.1.109 • Intest Res 2017;15(1):109-117 115 www.irjournal.org DISCUSSION In view of optimal resource distribution, the optimal inter - val for surveillance colonoscopy is important because the  need for surveillance colonoscopy has been dramatically increased as a result of increased use of CRC screening in Korea.",Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
http://www.nhis.or.kr/bbs7/boards/B0075/5959.,Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
http://www.nhic.or.kr.,Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
https://doi.org/10.5217/ir.2017.15.1.109 • Intest Res 2017;15(1):109-117 117 www.irjournal.org 20.,Non-OADS,/arxiv_data1/oa_pdf/cf/17/ir-15-109.PMC5323300.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.118Intest Res 2017;15(1):118-123ORIGINAL ARTICLE Intestinal barrier integrity and function in infants with cholestasis Nagla H. Abu Faddan1, Tahra M. K. Sherif2, Omnia A. Mohammed2, Khalid A. Nasif3,   Ebtesam M. El Gezawy2 Departments of 1Pediatrics and 2Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, 3Department of Biochemistry, Faculty of  Medicine, Minya University, Minya, Egypt Background/Aims: The safety of the human body is maintained by effective monitoring of the mucosal surface integrity and protection against potentially harmful compounds.",Non-OADS,/arxiv_data1/oa_pdf/d9/da/ir-15-118.PMC5323301.pdf
"https://doi.org/10.5217/ir.2017.15.1.118 • Intest Res 2017;15(1):118-123 119 www.irjournal.org bacterial endocytosis by enterocytes and prevent bacterial  translocation.6 In addition, bile has trophic effects on the  intestinal mucosa, as it increases villous density and induces hypertrophy of the intestinal wall components.",Non-OADS,/arxiv_data1/oa_pdf/d9/da/ir-15-118.PMC5323301.pdf
https://doi.org/10.5217/ir.2017.15.1.118 • Intest Res 2017;15(1):118-123 121 www.irjournal.org 2.,Non-OADS,/arxiv_data1/oa_pdf/d9/da/ir-15-118.PMC5323301.pdf
https://doi.org/10.5217/ir.2017.15.1.118 • Intest Res 2017;15(1):118-123 123 www.irjournal.org Gezawy were in charge of the laboratory part of this study.,Non-OADS,/arxiv_data1/oa_pdf/d9/da/ir-15-118.PMC5323301.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.124Intest Res 2017;15(1):124-129CASE REPORT Metronidazole-induced encephalopathy in a patient with Crohn’s disease Jihye Kim1, Jaeyoung Chun1, Jae Yong Park1, Seung Wook Hong1, Joo Young Lee1, Jin Woo Kang1,   Seongjun Hwang2, Sang-Bae Ko3, Jong Pil Im1, Joo Sung Kim1 1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul,   Departments of 2Internal Medicine and 3Neurology, Seoul National University College of Medicine, Seoul, Korea Metronidazole is a widely used antibiotic for the treatment of anaerobic bacterial infections.",Non-OADS,/arxiv_data1/oa_pdf/28/b9/ir-15-124.PMC5323302.pdf
"https://doi.org/10.5217/ir.2017.15.1.124 • Intest Res 2017;15(1):124-129 125 www.irjournal.org his first surgical treatment for active CD, he underwent right  hemicolectomy and small bowel segmental resection to treat an intra-abdominal abscess communicating with multiple fis - tulas.",Non-OADS,/arxiv_data1/oa_pdf/28/b9/ir-15-124.PMC5323302.pdf
https://doi.org/10.5217/ir.2017.15.1.124 • Intest Res 2017;15(1):124-129 127 www.irjournal.org became comatose (Glasgow coma scale score of 8) 2 hours  after receiving a single 500 mg IV dose of metronidazole.,Non-OADS,/arxiv_data1/oa_pdf/28/b9/ir-15-124.PMC5323302.pdf
https://doi.org/10.5217/ir.2017.15.1.124 • Intest Res 2017;15(1):124-129 129 www.irjournal.org 9.,Non-OADS,/arxiv_data1/oa_pdf/28/b9/ir-15-124.PMC5323302.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.130Intest Res 2017;15(1):130-132CASE REPORT Capsule retention caused by duodenal metastases from primary appendiceal adenocarcinoma Jen-Wei Chou1,2,3,4, Ken-Sheng Cheng1,2 1School of Medicine, China Medical University, Taichung, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine,  China Medical University Hospital, Taichung, Taiwan, R.O.C; 3Taiwan Society of Inflammatory Bowel Disease; 4Taiwan Association for the  Study of Small Intestinal Diseases Metastatic small bowel cancers are extremely rare in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/36/fd/ir-15-130.PMC5323303.pdf
https://doi.org/10.5217/ir.2017.15.1.130 • Intest Res 2017;15(1):130-132 131 www.irjournal.org tion showed a man with thin stature.,Non-OADS,/arxiv_data1/oa_pdf/36/fd/ir-15-130.PMC5323303.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.133Intest Res 2017;15(1):133-137CASE REPORT Crohn’s disease with ankylosing spondylitis in an adolescent patient who had undergone long ileo-colonic anastomosis for Hirschsprung’s disease as an infant Ha Yeon Kim1*, Tae Wook Kim2* 1Department of Internal Medicine, Dong-A University College of Medicine, Busan, 2Department of Internal Medicine,   Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea Crohn’s disease (CD) is a chronic, idiopathic, inflammatory disorder of the gastrointestinal tract.",Non-OADS,/arxiv_data1/oa_pdf/46/16/ir-15-133.PMC5323304.pdf
https://doi.org/10.5217/ir.2017.15.1.133 • Intest Res 2017;15(1):133-137 135 www.irjournal.org was discharged on admission day 12.,Non-OADS,/arxiv_data1/oa_pdf/46/16/ir-15-133.PMC5323304.pdf
https://doi.org/10.5217/ir.2017.15.1.133 • Intest Res 2017;15(1):133-137 137 www.irjournal.org 11.,OADS,/arxiv_data1/oa_pdf/46/16/ir-15-133.PMC5323304.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.138Intest Res 2017;15(1):138-141BRIEF COMMUNICATION Pivot to Asia: inflammatory bowel disease burden Prashant Singh1, Ashwin Ananthakrishnan2, Vineet Ahuja3 1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, 2Division of Gastroenterology, Massachusetts General  Hospital, Boston, MA, USA, 3Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India Received October 21, 2016.",Non-OADS,/arxiv_data1/oa_pdf/33/51/ir-15-138.PMC5323305.pdf
https://doi.org/10.5217/ir.2017.15.1.138 • Intest Res 2017;15(1):138-141 139 www.irjournal.org United States was about 0.8 million.,OADS,/arxiv_data1/oa_pdf/33/51/ir-15-138.PMC5323305.pdf
https://doi.org/10.5217/ir.2017.15.1.138 • Intest Res 2017;15(1):138-141 141 www.irjournal.org 16.,Non-OADS,/arxiv_data1/oa_pdf/33/51/ir-15-138.PMC5323305.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.142Intest Res 2017;15(1):142-143IMAGES OF THE ISSUE Polypoid lesions at the anal canal: what do they hint?",Non-OADS,/arxiv_data1/oa_pdf/cd/34/ir-15-142.PMC5323306.pdf
"https://doi.org/10.5217/ir.2017.15.1.142 • Intest Res 2017;15(1):142-143 143 www.irjournal.org Answer to the Images: Anal Condyloma Acuminatum Since anal condyloma was highly suspected, he was re- ferred to the colorectal surgeon for further management.",Non-OADS,/arxiv_data1/oa_pdf/cd/34/ir-15-142.PMC5323306.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.38Intest Res 2017;15(1):38-67REVIEW Second Korean guidelines for the management of Crohn’s disease Jae Jun Park1, Suk-K yun Yang2, Byong Duk Ye2, Jong Wook Kim3, Dong Il Park4,   Hyuk Yoon5, Jong Pil Im6, Kang Moon Lee7, Sang Nam Yoon8, Heeyoung Lee9;   IBD Study Group of the Korean Association for the Study of Intestinal Diseases 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 2Department of Internal Medicine, University of Ulsan College  of Medicine, Seoul, 3Department of Internal Medicine, Inje University College of Medicine Ilsan Paik Hospital, Goyang, 4Department of Internal  Medicine, Sungkyunkwan University School of Medicine, Seoul, 5Department of Internal Medicine, Seoul National University Bundang  Hospital, Seongnam, 6Department of Internal Medicine, Seoul National University Hospital, Seoul, 7Department of Internal Medicine, The  Catholic University of Korea College of Medicine, Suwon, 8Department of Surgery, Hallym University College of Medicine, Chuncheon, 9Center  for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Korea Crohn’s disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopatho-genesis.",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 39 www.irjournal.org a common disease in developed Western countries but is a  very rare disease in Asia including Korea.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
Part 2:  management13Australia/English Journal of  Gastroenterology  and Hepatology2016 31/56-68 aGuidelines are freely available on the web (https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068978/).,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 41 www.irjournal.org criteria (Supplementary Table 2, Supplementary Fig.",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"The final draft is being co-published by the  Korean Journal of Gastroenterology  and the Intestinal Re- search  for facilitated distribution, and will be distributed by  the Korean Medical Guideline Information Center (http://www.guideline.or.kr).",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 43 www.irjournal.org ≥100.38 In some studies, a reduction of ≥70 is defined as a  response.40,41 Meanwhile, for HBI, response is defined as a  reduction of ≥3.42 Relapse is defined as the recurrence of a symptom in a  patient with clinical remission, and is generally defined as  CDAI >150.38 In some clinical studies, relapse was defined as  CDAI >150 plus an increase of 70 or 100, which somewhat differed among those studies.",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 45 www.irjournal.org According to the Cochrane reviews of RCTs that tested the  efficacy of systemic corticosteroid therapy in active CD, sys - temic corticosteroids showed a significantly higher efficacy  of remission induction than did placebo (RR, 1.99; 95% CI, 1.51–2.64).",OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 47 www.irjournal.org of >2 years, small-bowel involvement, smoking, and normal  CRP .",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 49 www.irjournal.org the anti-infliximab antibody formation rate,99,100 admission  rate, and surgery rate related to CD were lower than in the  episodic therapy group.99 In addition, the rate of complete  mucosal healing was higher in the scheduled infliximab therapy group than in the episodic therapy group scheduled after response to infliximab induction therapy (54% vs. 7%;  P=0.007), which proved the superiority of scheduled admin- istration of infliximab.101 Overall, episodic administration of  anti-TNF drugs increases the risk of relapse, especially in pa-tients who had failed treatment with immunomodulators.",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 51 www.irjournal.org group (53.1% in 8 weeks group and 48.8% in 12 weeks  group) than in the placebo group (35.9%) (according to the interval  P=0.005 and P=0.04, respectively).89 These results  suggest that vedolizumab and ustekinumab can be effective alternative agents in patients with loss of response to anti-TNF .",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 53 www.irjournal.org Meanwhile, the Perianal Disease Activity Index (PDAI)  was proposed for the exclusive assessment of perianal fis - tulas.",Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 55 www.irjournal.org No placebo-controlled randomized studies have evaluated  the efficacy of adalimumab as a primary outcome variable  in patients with fistulizing CD.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 57 www.irjournal.org 50.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 59 www.irjournal.org 1.,OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068978/.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 61 www.irjournal.org 30.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 63 www.irjournal.org 85.,OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 65 www.irjournal.org 135.,OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
https://doi.org/10.5217/ir.2017.15.1.38 • Intest Res 2017;15(1):38-67 67 www.irjournal.org 189.,Non-OADS,/arxiv_data1/oa_pdf/53/63/ir-15-38.PMC5323307.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.5Intest Res 2017;15(1):5-6EDITORIAL Received December 13, 2016.",Non-OADS,/arxiv_data1/oa_pdf/68/48/ir-15-5.PMC5323308.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.68Intest Res 2017;15(1):68-74ORIGINAL ARTICLE Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients Shinta Mizuno1, Kosaku Nanki1, Katsuyoshi Matsuoka1, Keiichiro Saigusa1, Keiko Ono1, Mari Arai1,   Shinya Sugimoto1, Hiroki Kiyohara1, Moeko Nakashima1, Kozue Takeshita1,2, Makoto Naganuma1,   Wataru Suda2,3, Masahira Hattori3,4, Takanori Kanai1 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, and 2Department of Immunology, Keio University School  of Medicine, Tokyo, 3Laboratory of Metagenomics, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, 4Graduate School of  Advanced Science and Engineering, Waseda University, Tokyo, Japan Background/Aims: Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease.",Non-OADS,/arxiv_data1/oa_pdf/c6/87/ir-15-68.PMC5323309.pdf
https://doi.org/10.5217/ir.2017.15.1.68 • Intest Res 2017;15(1):68-74 69 www.irjournal.org sociated with intestinal inflammation.5 Previous reports  of murine models suggested that different populations of  intestinal microbiota influence one another by proliferat - ing in an identical environment and that the microbiota are remarkably stable.,Non-OADS,/arxiv_data1/oa_pdf/c6/87/ir-15-68.PMC5323309.pdf
https://doi.org/10.5217/ir.2017.15.1.68 • Intest Res 2017;15(1):68-74 71 www.irjournal.org analyzed in this study were deposited into the DNA Data- Bank of Japan (DDBJ)/GenBank/ European Molecular Biol - ogy Laboratory (EMBL) database under accession number DRA004886.,OADS,/arxiv_data1/oa_pdf/c6/87/ir-15-68.PMC5323309.pdf
https://doi.org/10.5217/ir.2017.15.1.68 • Intest Res 2017;15(1):68-74 73 www.irjournal.org nomic profiles of the patient samples showed no significant  change pre-FMT versus post-FMT (Fig.,OADS,/arxiv_data1/oa_pdf/c6/87/ir-15-68.PMC5323309.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.7Intest Res 2017;15(1):7-37REVIEW Second Korean guidelines for the management of ulcerative colitis Chang Hwan Choi1*, Won Moon2*, You Sun Kim3, Eun Soo Kim4, Bo-In Lee5,   Yunho Jung6, Yong Sik Yoon7, Heeyoung Lee8, Dong Il Park9, Dong Soo Han10;   IBD Study Group of the Korean Association for the Study of Intestinal Diseases 1Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 2Department of Internal Medicine, Kosin University  College of Medicine, Busan, 3Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, 4Division of  Gastroenterology and Hepatology, Department of Internal Medicine, K yungpook National University School of Medicine, Daegu, 5Division  of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,  6Division of Gastroenterology, Department of Medicine, Soonchunhyang University College of Medicine, Cheonan, 7Division of Colon and Rectal  Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 8Center for Preventive Medicine and Public  Health, Seoul National University Bundang Hospital, Seongnam, 9Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan  University School of Medicine, Seoul, 10Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 9 www.irjournal.org of the evidence, values and preference, and lastly, resource  allocation, and classified as strong or weak.24,25 The definition  of quality of evidence and classification of the recommenda-tions are shown in Table 2.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
The final draft was co-published by the  Korean Journal of Gastroenterology  and Intestinal Research   for facilitated distribution and will be distributed by the Ko-rean Medical Guideline Information Center (http://www.guideline.or.kr).,Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 11 www.irjournal.org causes nausea, vomiting, indigestion, headache, pancreatitis,  hepatitis, drug-induced connective tissue disorders, marrow suppression, interstitial nephritis, hemolytic anemia, mega-loblastic anemia, and reversible male infertility.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 13 www.irjournal.org Oral 5-ASA are recommended for remission induction in  patients with mild to moderate left-sided and extensive coli- tis.32,57 A meta-analysis about the effect of oral 5-ASA in mild  to moderate UC showed that the remission failure rate in the oral 5-ASA group (0.86; 95% CI, 0.81−0.91) was lower than that in the placebo group (0.79; 95% CI, 0.73−0.85), indicat - ing the therapeutic effects of oral 5-ASA treatment in mild to moderate UC.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 15 www.irjournal.org 8 weeks was higher in the 160/80 mg adalimumab group  (16.5%) than in the placebo group (9.3%) ( P=0.019)and that  at the 52 weeks of treatment was also significantly higher in the adalimumab group (17.3%) than in the placebo group (8.5%) ( P=0.004).93 In a subanalysis of patients with moder - ate to severe UC who previously used infliximab and were currently using corticosteroids or immunomodulators, the remission rate at the 52 weeks without corticosteroid use was significantly higher in the adalimumab group (10.2%) than in the placebo group (3.0%).",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 17 www.irjournal.org corticosteroid, infliximab was administered on the 4th day.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 19 www.irjournal.org receiving anti-TNF agents.,Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 21 www.irjournal.org (log-rank, P=0.080) than those who changed to a different  anti-TNF agent.161 As vedolizumab works in a different mechanism with  anti-TNF medication, it can be effective for patients with  either primary or secondary anti-TNF therapy failure.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 23 www.irjournal.org three studies used ≥3.0 g/day of oral 5-ASA as maximum  dose.,Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 25 www.irjournal.org Patients who require corticosteroid therapy have higher  risks of relapse and colectomy than patients who do not need  it.183,218,219 Considering the adverse events associated with cor - ticosteroid use, the ultimate goal of UC treatment is to main-tain the remission state without corticosteroid use.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 27 www.irjournal.org when vedolizumab was maintained for up to 78 weeks, 60%  of the patients maintained remission and no specific adverse effect was observed during the long-term period.",Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
http://www.ncbi.nlm.nih.gov/books/NBK247597/.,Non-OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 29 www.irjournal.org 21.,OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 31 www.irjournal.org 73.,OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 33 www.irjournal.org 126.,OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 35 www.irjournal.org 174.,OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
https://doi.org/10.5217/ir.2017.15.1.7 • Intest Res 2017;15(1):7-37 37 www.irjournal.org 225.,OADS,/arxiv_data1/oa_pdf/6b/b6/ir-15-7.PMC5323310.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.75Intest Res 2017;15(1):75-82ORIGINAL ARTICLE 15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue Dong-Hoon Yang1, Yeon-Mi Ryu2, Sun-Mi Lee2, Jin- Yong Jeong2, Soon Man Yoon3, Byong Duk Ye1,   Jeong-Sik Byeon1, Suk-K yun Yang1, Seung-Jae Myung1 1Department of Gastroenterology and 2Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul,  3Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea Background/Aims: Cyclooxygenase-2 (COX-2), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and microsomal prostaglandin E synthase-1 (mPGEs-1) regulate prostaglandin E 2 (PGE2) expression and are involved in colon carcinogenesis.",Non-OADS,/arxiv_data1/oa_pdf/d6/f5/ir-15-75.PMC5323311.pdf
"https://doi.org/10.5217/ir.2017.15.1.75 • Intest Res 2017;15(1):75-82 77 www.irjournal.org necrosis factor for 72 hours, and the expression of COX-2 in  the normal tissues from an adenoma patient were used to determine the relative expression level of each gene.",OADS,/arxiv_data1/oa_pdf/d6/f5/ir-15-75.PMC5323311.pdf
"https://doi.org/10.5217/ir.2017.15.1.75 • Intest Res 2017;15(1):75-82 79 www.irjournal.org mPGEs-1, and PGE2 in the adjacent normal tissue increased  in 30.8% (4/15), 18.8% (3/16), and 55% (11/20) of samples  and the expression of 15-PGDH in the adjacent normal tissue decreased in 40% (8/20) of samples.",OADS,/arxiv_data1/oa_pdf/d6/f5/ir-15-75.PMC5323311.pdf
https://doi.org/10.5217/ir.2017.15.1.75 • Intest Res 2017;15(1):75-82 81 www.irjournal.org samples and 16 of 20 (80%) adenoma samples scored 0 in  immunohistochemical staining.,OADS,/arxiv_data1/oa_pdf/d6/f5/ir-15-75.PMC5323311.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.83Intest Res 2017;15(1):83-89ORIGINAL ARTICLE Analysis of the clinical indications for opiate use in inflammatory bowel disease Youran Gao1, Sundas Khan2, Meredith Akerman3, Keith Sultan1 1Department of Gastroenterology and Hepatology, Hofstra Northwell School of Medicine, Manhasset, NY, 2Department of Internal Medicine,  Northwell Health Systems, Hofstra Northwell School of Medicine, Manhasset, NY, 3Feinstein Institute for Medical Research Biostatistics Unit,  Manhasset, NY, USA Background/Aims: Opiate use for inflammatory bowel disease (IBD), particularly high-dose (HD) use, is associated with increased mortality.",Non-OADS,/arxiv_data1/oa_pdf/58/58/ir-15-83.PMC5323312.pdf
https://doi.org/10.5217/ir.2017.15.1.83 • Intest Res 2017;15(1):83-89 85 www.irjournal.org first visit were used for the main analysis.,OADS,/arxiv_data1/oa_pdf/58/58/ir-15-83.PMC5323312.pdf
"https://doi.org/10.5217/ir.2017.15.1.83 • Intest Res 2017;15(1):83-89 87 www.irjournal.org related surgeries were more likely to take a high dose of  opioids (12.70% vs. 1.41%, P=0.0128).",Non-OADS,/arxiv_data1/oa_pdf/58/58/ir-15-83.PMC5323312.pdf
https://doi.org/10.5217/ir.2017.15.1.83 • Intest Res 2017;15(1):83-89 89 www.irjournal.org REFERENCES 1.,OADS,/arxiv_data1/oa_pdf/58/58/ir-15-83.PMC5323312.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.90Intest Res 2017;15(1):90-96ORIGINAL ARTICLE Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases Naoki Minami1, Minoru Matsuura1, Yorimitsu Koshikawa1, Satoshi Yamada1, Yusuke Honzawa1, Shuji  Yamamoto1, Hiroshi Nakase2  1Department of Gastroenterology and Hepatology, Graduate School of Medicine K yoto University, K yoto, 2Department of Gastroenterology and  Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan Background/Aims: Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant.",Non-OADS,/arxiv_data1/oa_pdf/45/0d/ir-15-90.PMC5323313.pdf
"https://doi.org/10.5217/ir.2017.15.1.90 • Intest Res 2017;15(1):90-96 91 www.irjournal.org Many drugs, including 5-aminosalicylate (5-ASA), cortico- steroids, immunomodulators, and biologics, are being used  to treat IBD.3 According to the guidelines of the European  Crohn’s and Colitis Organization (ECCO),4 these drugs can  be used safely during pregnancy.",Non-OADS,/arxiv_data1/oa_pdf/45/0d/ir-15-90.PMC5323313.pdf
https://doi.org/10.5217/ir.2017.15.1.90 • Intest Res 2017;15(1):90-96 93 www.irjournal.org with thiopurine or calcineurin inhibitors ( Table 3).,Non-OADS,/arxiv_data1/oa_pdf/45/0d/ir-15-90.PMC5323313.pdf
"https://doi.org/10.5217/ir.2017.15.1.90 • Intest Res 2017;15(1):90-96 95 www.irjournal.org can affect the fetus and newborn.4,9 The use of IFX beyond  the second trimester raises concerns about the infant’s im- mune function, as the drug has been detected in infants up to 6 months after birth.",Non-OADS,/arxiv_data1/oa_pdf/45/0d/ir-15-90.PMC5323313.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1598-9100  • eISSN 2288-1956 https://doi.org/10.5217/ir.2017.15.1.97Intest Res 2017;15(1):97-102ORIGINAL ARTICLE Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India Parnita Harsh1, Vipin Gupta2, Saurabh Kedia2, Sawan Bopanna2, Sucharita Pilli2, Surendernath2,   Govind Kumar Makharia2, Vineet Ahuja2 1Department of Molecular and Cell Biology, University of Illinois at Urbana-Champaign, Champaign, IL, USA, 2Department of  Gastroenterology, All India Institute of Medical Sciences, New Delhi, India Background/Aims: Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and blood transfusions and therefore are at a high risk of contracting infections due to hepatitis B (HBV) and hepatitis C (HCV) and hu-man immunodeficiency virus (HIV).",Non-OADS,/arxiv_data1/oa_pdf/6a/32/ir-15-97.PMC5323314.pdf
"https://doi.org/10.5217/ir.2017.15.1.97 • Intest Res 2017;15(1):97-102 99 www.irjournal.org When compared to prevalence of these infections in gen- eral population, the results were not statistically significant  (P=0.05, P=0.26, and P=0.31, respectively) (Fig.",OADS,/arxiv_data1/oa_pdf/6a/32/ir-15-97.PMC5323314.pdf
https://doi.org/10.5217/ir.2017.15.1.97 • Intest Res 2017;15(1):97-102 101 www.irjournal.org tions from southern states showing a very high prevalence  (>20%).15  Another finding of the current study was that HBV was  significantly more prevalent in patients with ITB (5.9%) than in those with IBD (2.4%) ( P=0.04).,Non-OADS,/arxiv_data1/oa_pdf/6a/32/ir-15-97.PMC5323314.pdf
"http://naco.gov.in/sites/default/files/National%20HIV%20Counselling%20%26%20Testing%20Services%20Guideline,%20Dec%202016.pdf.",Non-OADS,/arxiv_data1/oa_pdf/6a/32/ir-15-97.PMC5323314.pdf
http://www.ncdc.gov.in/writere-addata/linkimages/NewsLtr0103_20146480274026.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6a/32/ir-15-97.PMC5323314.pdf
"Management of biliary  strictures often involves endoscopy either for definite  treatment, as a bridge to surgery or for palliativ e Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1119 1119 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1119-1124  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) EDITORIAL Common controversies in management of biliary strictures Mansour A Parsi purposes.",Non-OADS,/arxiv_data1/oa_pdf/38/ff/WJG-23-1119.PMC5323437.pdf
"World J Gastroenterol 2017; 23(7): 1119-1124   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i7/1119.htm  DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1119 INTRODUCTION Preoperative biliary drainage in resectable malignant  strictures The rationale behind preoperative biliary drainage  is the belief that cholestasis is associated with  higher postoperative morbidity and mortality and that  preoperative biliary drainage may improve surgical  outcomes by improving the liver synthetic function,  increasing clearance of endotoxins and improving the  gastrointestinal mucosal barrier function which in turn  may reduce the risk of bacterial translocation[1].",Non-OADS,/arxiv_data1/oa_pdf/38/ff/WJG-23-1119.PMC5323437.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/38/ff/WJG-23-1119.PMC5323437.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscriptREVIEWSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1125 1125 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1125-1138  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/81/fb/WJG-23-1125.PMC5323438.pdf
World J Gastroenterol  2017; 23(7): 1125-1138   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i7/1125.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1125 INTRODUCTION Yīn-Chén-Hāo decoction (YCHD) was first described  in the “ Treatise on Febrile Diseases ” by Zhong-Jing  Zhang during the Eastern Han Dynasty (AD 25-220).,Non-OADS,/arxiv_data1/oa_pdf/81/fb/WJG-23-1125.PMC5323438.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/81/fb/WJG-23-1125.PMC5323438.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Koo Jeong Kang, MD, PhD,  Division of  Hepatobiliary and Pancreatic Surgery, Department of Surgery,   School of Medicine, Keimyung University Dong-san Medical  Center,  56 Dalseong-Ro, Jung-Gu, Daegu 41931,  South Korea.",Non-OADS,/arxiv_data1/oa_pdf/46/7a/WJG-23-1139.PMC5323439.pdf
"We also discuss the  potential pitfalls associated with this approach.MINIREVIEWSSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1139 1139 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1139-1146  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/46/7a/WJG-23-1139.PMC5323439.pdf
World J Gastroenterol  2017; 23(7): 1139-1146   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i7/1139.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1139 INTRODUCTION Primary liver cancer is the second leading cause  of cancer death worldwide[1].,Non-OADS,/arxiv_data1/oa_pdf/46/7a/WJG-23-1139.PMC5323439.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/46/7a/WJG-23-1139.PMC5323439.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscriptCorrespondence to: Suneela S Dhaneshwar, PhD, Professor,  Department of Pharmaceutical Chemistry, Poona College of  Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune,  Maharashtra 411038,  India.",Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
"Statistical significance  was assumed at P < 0.05, P < 0.01, P < 0.001 when  compared with disease controls using one-way and Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1147 1147 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1147-1162  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Investigation of mitigating effect of colon-specific prodrugs  of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid- induced colitis in Wistar rats: Design, kinetics and biological  evaluationBasic Study Ajinkya Sarkate, Suneela S Dhaneshwar",Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
World J Gastroenterol  2017;  23(7): 1147-1162  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
com/1007-9327/full/v23/i7/1147.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
Available from: URL: http://www.koliskoinstitute.,Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
"Available from:  URL: http://www.patentimages.storage.googleapis.com/pdfs/ US3988466.pdf 51 Lee JS , Jung YJ, Kim YM.",OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
"Available from: URL:  http://www.ajprd.com/downloadebooks_pdf/8.pdf‎ 54 Dhaneshwar S , Gautam H. Exploring novel colon-targeting Sarkate A et al.",Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/d3/db/WJG-23-1147.PMC5323440.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Dr. Tahereh Falsafi, Professor,   Department of Microbiology, Faculty of Biological Sciences,  Alzahra University, Vanak Village Street, Tehran 1993893973, Iran.",Non-OADS,/arxiv_data1/oa_pdf/b0/00/WJG-23-1163.PMC5323441.pdf
"Minimum bactericidal  1163 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comORIGINAL ARTICLE Effect of biofilm formation by clinical isolates of  Helicobacter pylori  on the efflux-mediated resistance to  commonly used antibioticsBasic Study Bahareh Attaran, Tahereh Falsafi, Nassim GhorbanmehrSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1163World J Gastroenterol   2017 February 21; 23(7): 1163-1170  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/b0/00/WJG-23-1163.PMC5323441.pdf
wjgnet.com/1007-9327/full/v23/i7/1163.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/00/WJG-23-1163.PMC5323441.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/b0/00/WJG-23-1163.PMC5323441.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Chih-Yang Huang, PhD,  Graduate  Institute of Chinese Medical Science, China Medical University,  No.",Non-OADS,/arxiv_data1/oa_pdf/72/1b/WJG-23-1171.PMC5323442.pdf
"91, Hsueh-Shih Road, Taichung 40402, Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1171 1171 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1171-1179   ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Thymoquinone suppresses migration of LoVo human colon  cancer cells by reducing prostaglandin E2 induced COX-2  activationBasic Study Hsi-Hsien Hsu, Ming-Cheng Chen, Cecilia Hsuan Day, Yueh-Min Lin, Shin-Yi Li, Chuan-Chou Tu,  Viswanadha Vijaya Padma, Hui-Nung Shih, Wei-Wen Kuo, Chih-Yang Huang",Non-OADS,/arxiv_data1/oa_pdf/72/1b/WJG-23-1171.PMC5323442.pdf
"World J  Gastroenterol  2017; 23(7): 1171-1179  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i7/1171.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1171 INTRODUCTION Colorectal cancer is one of the most universally diag­ nosed gastrointestinal cancers and among the main  causes of cancer ­related death in western developed  countries[1,2].",Non-OADS,/arxiv_data1/oa_pdf/72/1b/WJG-23-1171.PMC5323442.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/72/1b/WJG-23-1171.PMC5323442.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Zhi-Peng Tang, MD, PhD, Professor,  Director,  Institute of Digestive Diseases, Shanghai University  of Traditional Chinese Medicine, 725 Wanping Road, Shanghai  200032, China.",Non-OADS,/arxiv_data1/oa_pdf/60/c7/WJG-23-1180.PMC5323443.pdf
"On  day 14, the colon length was measured, the colorectal Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1180 1180 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1180-1188  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Jianpi Qingchang decoction alleviates ulcerative colitis by  inhibiting nuclear factor- κB activationBasic Study Lie Zheng, Ya-Li Zhang, Yan-Cheng Dai, Xuan Chen, De-Liang Chen, Yue-Ting Dai, Zhi-Peng Tang",Non-OADS,/arxiv_data1/oa_pdf/60/c7/WJG-23-1180.PMC5323443.pdf
wjgnet.com/1007-9327/full/v23/i7/1180.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/60/c7/WJG-23-1180.PMC5323443.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/60/c7/WJG-23-1180.PMC5323443.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/Manuscript source:  Unsolicited manuscript Correspondence to: Kang-Sheng Gu, PhD, Professor,  Department of Oncology, the First Affiliated Hospital of Anhui  Medical University, 218 Jixi Road, Hefei 230032, Anhui  Province, China.",Non-OADS,/arxiv_data1/oa_pdf/d1/e2/WJG-23-1189.PMC5323444.pdf
"A total of 1308 mRNAs  (578 up regulated and 730 downregulated) were Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1189 1189 February 21, 2017 |Volume 23 |Issue 7 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1189-1202  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Dysregulation of mRNA profile in cisplatin-resistant gastric  cancer cell line SGC7901Basic Study Xiao-Que Xie, Qi-Hong Zhao, Hua Wang, Kang-Sheng Gu",Non-OADS,/arxiv_data1/oa_pdf/d1/e2/WJG-23-1189.PMC5323444.pdf
"World J Gastroenterol  2017; 23(7): 1189-1202 Available from:  URL: http://www.wjgnet.com/1007-9327/full/v23/i7/1189.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1189 INTRODUCTION Gastric cancer is the fourth most common cancer  and the second leading cause of cancer death  globally[1], and more than two thirds of patients when  diagnosed with unresectable disease[2].",Non-OADS,/arxiv_data1/oa_pdf/d1/e2/WJG-23-1189.PMC5323444.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/d1/e2/WJG-23-1189.PMC5323444.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Shuang-Suo Dang, PhD, MD, Department  of Infectious Diseases, the Second Affiliated Hospital of Medical  School of Xi’an Jiaotong University, No.",Non-OADS,/arxiv_data1/oa_pdf/4b/ef/WJG-23-1203.PMC5323445.pdf
"CAPE increased the  antioxidant levels and the translocation of Nrf2 from Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1203 1203 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1203-1214  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Caffeic acid phenethyl ester up-regulates antioxidant levels  in hepatic stellate cell line T6 via an Nrf2-mediated mitogen  activated protein kinases pathwayBasic Study Ning Yang, Juan-Juan Shi, Feng-Ping Wu, Mei Li, Xin Zhang, Ya-Ping Li, Song Zhai, Xiao-Li Jia,  Shuang-Suo Dang",Non-OADS,/arxiv_data1/oa_pdf/4b/ef/WJG-23-1203.PMC5323445.pdf
wjgnet.com/1007-9327/full/v23/i7/1203.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/ef/WJG-23-1203.PMC5323445.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/4b/ef/WJG-23-1203.PMC5323445.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Daisuke Ichikawa, MD, PhD, Assistant  Professor,  Division of Digestive Surgery, Department of  Surgery, Kyoto Prefectural University of Medicine, Kajii-cho  465, Kamigyo-ku, Kyoto 602-8566,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"ichikawa@koto.kpu-m.ac.j p Telephone:  +81-75-251552 7 Fax:  +81-75-2515522 Received:  October 19, 2016 Peer-review started:  October 20, 2016 First decision:  November 9, 2016 Revised:  November 26, 2016 Accepted:  January 11, 2017 Article in press:  January 11, 2017 Published online: February 21, 2017Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1215 1215 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1215-1223  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Surgery for gastric cancer patients of age 85 and older:  Multicenter surveyRetrospective Cohort Study Hirotaka Konishi, Daisuke Ichikawa, Hiroshi Itoh, Kenichiro Fukuda, Naoki Kakihara, Manabu Takemura,  Kaori Okugawa, Kiyoshi Uchiyama, Masashi Nakata, Hiroshi Nishi, Toshiyuki Kosuga, Shuhei Komatsu,  Kazuma Okamoto, Eigo Otsuji",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"World  J Gastroenterol  2017; 23(7): 1215-1223  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i7/1215.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1215 INTRODUCTION The elderly population is increasing worldwide, and  life expectancy has also consistently increased in most  countries[1].",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"Available from: URL: http://www.mhlw.go.jp/toukei/ saikin/hw/life/life14/index.html 3 Extermann M , Overcash J, Lyman GH, Parr J, Balducci L.  Comorbidity and functional status are independent in older cancer  patients.",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"Available from: URL: http://www.gunma-cc.jp/ sarukihan/seizonritu/seizonritu2007c.html 23 Sun DS , Jeon EK, Won HS, Park JC, Shim BY, Park SY, Hong  YS, Kim HK, Ko YH.",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/50/d1/WJG-23-1215.PMC5323446.pdf
"Higher serum tacrolimus level was associated  with lower post-PTLD  surviva l in pediatric patients Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1224 1224 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1224-1232  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Post-transplant lymphoproliferative disorder after liver  transplantation: Incidence, long-term survival and impact  of serum tacrolimus levelRetrospective Study Ahad Eshraghian, Mohammad Hadi Imanieh, Seyed Mohsen Dehghani, Saman Nikeghbalian,  Alireza Shamsaeefar, Frouzan Barshans, Kourosh Kazemi, Bita Geramizadeh, Seyed Ali Malek-Hosseini",Non-OADS,/arxiv_data1/oa_pdf/03/81/WJG-23-1224.PMC5323447.pdf
World J Gastroenterol  2017;  23(7): 1224-1232  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/03/81/WJG-23-1224.PMC5323447.pdf
com/1007-9327/full/v23/i7/1224.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/03/81/WJG-23-1224.PMC5323447.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/03/81/WJG-23-1224.PMC5323447.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscriptCorrespondence to: Jin Gu, MD, FACS, Professor,  Department  of Colorectal Surgery, Peking University Cancer Hospital and  Institute, Beijing Cancer Hospital, No.",Non-OADS,/arxiv_data1/oa_pdf/8c/e9/WJG-23-1233.PMC5323448.pdf
"RESULTS Univariate analysis revealed that platelet-derived  1233 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comORIGINAL ARTICLE High levels of serum platelet-derived growth factor-AA and  human epidermal growth factor receptor-2 are predictors  of colorectal cancer liver metastasisRetrospective Study Hong-Da Pan, Yi-Fan Peng, Gang Xiao, Jin GuSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1233World J Gastroenterol   2017 February 21; 23(7): 1233-1240  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/8c/e9/WJG-23-1233.PMC5323448.pdf
World J Gastroenterol  2017; 23(7): 1233-1240  Available from:  UrL: http://www.wjgnet.com/1007-9327/full/v23/i7/1233.htm    DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1233 INTRODUCTION Liver metastasis occurs in almost 50% of patients with  colorectal cancer and it is the leading cause of death  from colorectal cancer[1].,Non-OADS,/arxiv_data1/oa_pdf/8c/e9/WJG-23-1233.PMC5323448.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/8c/e9/WJG-23-1233.PMC5323448.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscriptCorrespondence to: Francesca Romana  Ponziani, MD,   Internal Medicine, Gastroenterology and Hepatology, Agostino  Gemelli Hospital, Largo Agostino Gemelli 8, 00168 Rome,  Italy.",Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
"SIBO was con firmed in 12/39 (30.8%) patients  who also presented with a higher concentration of Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1241 1241 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1241-1249  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Subclinical atherosclerosis is linked to small intestinal  bacterial overgrowth via vitamin K2-dependent mechanismsObservational Study Francesca Romana Ponziani, Maurizio Pompili, Enrico Di Stasio, Maria Assunta Zocco, Antonio Gasbarrini,  Roberto Flore",Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
World J Gastroenterol  2017; 23(7): 1241-1249  Available from:  URL: http://www.wjgnet.com/1007-9327/full/v23/i7/1241.htm    DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1241 INTRODUCTION The presence of bacteria in the gastrointestinal tract  is crucial for maintaining host health.,Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
"Available from: URL:  http://epic.iarc.fr/about/background.php 24 Van Bortel LM , Balkestein EJ, van der Heijden-Spek JJ,  Vanmolkot FH, Staessen JA, Kragten JA, Vredeveld JW, Safar  ME, Struijker Boudier HA, Hoeks AP.",Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
"Available from: URL: http://www.R-project.org/2014 28 Vlachopoulos C , Xaplanteris P, Aboyans V , Brodmann M, Cífková  R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent  S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni  D, Schmidt-Trucksä ss A, Van Bortel L, Weber T, Yamashina A,  Zimlichman R, Boutouyrie P, Cockcroft J, O’Rourke M, Park  JB, Schillaci G, Sillesen H, Townsend RR.",Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/56/a1/WJG-23-1241.PMC5323449.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Georgică-Costinel Târtea, MD, PhD,  Department of Internal Medicine, University of Medicine and  Pharmacy of Craiova, Petru Rareș Street 2, 200349 Craiova,  Romania.",Non-OADS,/arxiv_data1/oa_pdf/8c/56/WJG-23-1250.PMC5323450.pdf
"METHODS In this study, we included forty-eight patients with  primary colorectal cancer and nine patients for control Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1250 1250 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1250-1261  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE B2 adrenergic receptors and morphological changes of the  enteric nervous system in colorectal adenocarcinomaObservational Study Raluca Niculina Ciurea, Ion Rogoveanu, Daniel Pirici, Georgică-Costinel Târtea, Costin Teodor Streba,  Cristina Florescu, Bogdan Cătălin, Ileana Puiu, Elena-Anca Târtea, Cristin Constantin Vere",Non-OADS,/arxiv_data1/oa_pdf/8c/56/WJG-23-1250.PMC5323450.pdf
wjgnet.com/1007-9327/full/v23/i7/1250.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8c/56/WJG-23-1250.PMC5323450.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/8c/56/WJG-23-1250.PMC5323450.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Won Young Kim, MD, PhD,  Department  of Emergency Medicine, University of Ulsan College of  Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa- gu, Seoul 05505, South Korea.",Non-OADS,/arxiv_data1/oa_pdf/be/5f/WJG-23-1262.PMC5323451.pdf
"Among the Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1262 1262 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1262-1267  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Predictors of poor outcomes in patients with wild  mushroom-induced acute liver injuryObservational Study Taerim Kim, Danbi Lee, Jae Ho Lee, Yoon-Seon Lee, Bum Jin Oh, Kyoung Soo Lim, Won Young Kim",Non-OADS,/arxiv_data1/oa_pdf/be/5f/WJG-23-1262.PMC5323451.pdf
"World  J Gastroenterol  2017; 23(7): 1262-1267  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i7/1262.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1262 INTRODUCTION Although mushroom poisoning is associated with  high morbidity and mortality rates[1], little is known  about the in-hospital prognosis of these patients  during treatment.",Non-OADS,/arxiv_data1/oa_pdf/be/5f/WJG-23-1262.PMC5323451.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/be/5f/WJG-23-1262.PMC5323451.pdf
Clinical trial registration statement:  This study is registered  at http://www.chictr.org.cn/usercenter.aspx .,Non-OADS,/arxiv_data1/oa_pdf/95/64/WJG-23-1268.PMC5323452.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscriptCorrespondence to: Dr. Hua Mao, Professor,  Department  of Digestive Diseases, Zhujiang Hospital of Southern Medical  University, No.",Non-OADS,/arxiv_data1/oa_pdf/95/64/WJG-23-1268.PMC5323452.pdf
"RESULTS Following treatment, changes in the gastric microvascular  network were statistically different between the  combination therapy group and th e monotherapy group Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1268 1268 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1268-1277  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Effects of hydrotalcite combined with esomeprazole on  gastric ulcer healing quality: A clinical observation studyObservational Study Rui-Qi Yang, Hua Mao, Li-Yun Huang, Pei-Zhu Su, Min Lu",Non-OADS,/arxiv_data1/oa_pdf/95/64/WJG-23-1268.PMC5323452.pdf
wjgnet.com/1007-9327/full/v23/i7/1268.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/95/64/WJG-23-1268.PMC5323452.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/95/64/WJG-23-1268.PMC5323452.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Harsha Moole, MD, Clinical Associate,  Department of Medicine, University of Illinois College of Medicine,  Peoria, IL 61637,  United States.",Non-OADS,/arxiv_data1/oa_pdf/1d/c2/WJG-23-1278.PMC5323453.pdf
"SYSTEMATIC REVIEWSSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1278 1278 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1278-1288  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/1d/c2/WJG-23-1278.PMC5323453.pdf
World J Gastroenterol  2017; 23(7): 1278-1288   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i7/1278.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.i7.1278 INTRODUCTION Cholangiocarcinoma is the primary cancer of bile ducts.,Non-OADS,/arxiv_data1/oa_pdf/1d/c2/WJG-23-1278.PMC5323453.pdf
Available from: URL: http://www.ohri.,Non-OADS,/arxiv_data1/oa_pdf/1d/c2/WJG-23-1278.PMC5323453.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/1d/c2/WJG-23-1278.PMC5323453.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Joan W Chen, MD, MS,  Department of  Gastroenterology and Hepatology, University of Michigan Health  Systems, 3912 Taubman Center, 1500 E. Medical Center Dr.,  SPC 5362, Ann Arbor, MI 48109,  United States.",Non-OADS,/arxiv_data1/oa_pdf/77/d2/WJG-23-1289.PMC5323454.pdf
"Future  studies using standardized FLIP protocol and balloon SYSTEMATIC REVIEWSSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1289 1289 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1289-1297  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/77/d2/WJG-23-1289.PMC5323454.pdf
World J  Gastroenterol  2017; 23(7): 1289 ­1297  Available from: URL:  http://www.wjgnet.com/1007 ­9327/full/v23/i7/1289.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1289 INTRODUCTION The role of the esophagus is to transport ingested  material from the mouth into the stomach via  complex neuromuscular activities during peristalsis.,Non-OADS,/arxiv_data1/oa_pdf/77/d2/WJG-23-1289.PMC5323454.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/77/d2/WJG-23-1289.PMC5323454.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Invited manuscript   Correspondence to: Simon R Knowles, PhD, Senior  Lecturer,  Department of Psychological Sciences, Swinburne  University of Technology, Hawthorn, Victoria 3122,  Australia.",Non-OADS,/arxiv_data1/oa_pdf/8e/0a/WJG-23-1298.PMC5323455.pdf
"SYSTEMATIC REVIEWSSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1298 1298 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1298-1309  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/8e/0a/WJG-23-1298.PMC5323455.pdf
World J  Gastroenterol  2017; 23(7): 1298 ­1309  Available from: URL:  http://www.wjgnet.com/1007 ­9327/full/v23/i7/1298.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1298 INTRODUCTION Gastroparesis is a gastrointestinal disorder involving  delayed gastric emptying in the absence of a  mechanical obstruction of the stomach[1].,Non-OADS,/arxiv_data1/oa_pdf/8e/0a/WJG-23-1298.PMC5323455.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/8e/0a/WJG-23-1298.PMC5323455.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Qing-Guang Zhang, MD,  Department  of Thoracic Surgery, Affiliated Hospital of Binzhou Medical  University, No.",Non-OADS,/arxiv_data1/oa_pdf/12/1d/WJG-23-1310.PMC5323456.pdf
"Prospective trials  are warranted.META-ANALYSISSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1310 1310 February 21, 2017 |Volume 23 |Issue 7| WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1310-1318  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/12/1d/WJG-23-1310.PMC5323456.pdf
World J  Gastroenterol  2017; 23(7): 1310-1318  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i7/1310.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1310 INTRODUCTION Esophageal cancer (EC) is the eighth most common  malignant tumor worldwide[1] and is the sixth leading  cause of cancer death[2].,Non-OADS,/arxiv_data1/oa_pdf/12/1d/WJG-23-1310.PMC5323456.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/12/1d/WJG-23-1310.PMC5323456.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/Manuscript source:  Unsolicited manuscript Correspondence to: Johan Bohr, MD, PhD,  Division of  Gastroenterology, Department of Medicine, Örebro University  Hospital, SE-70185 Örebro,  Sweden.",Non-OADS,/arxiv_data1/oa_pdf/7b/39/WJG-23-1319.PMC5323457.pdf
"Key words:  Faecal microbiota transplantation; Microbiota; CASE REPORTSubmit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i7.1319 1319 February 21, 2017 |Volume 23 |Issue 7 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 February 21; 23(7): 1319-1324  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/7b/39/WJG-23-1319.PMC5323457.pdf
"World J  Gastroenterol  2017; 23(7): 1319-1324  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i7/1319.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i7.1319 INTRODUCTION Microscopic colitis (MC) is a chronic inflammatory  disease of the colon, characterized clinically by  chronic watery diarrhea, abdominal pain and weight  loss[1].",Non-OADS,/arxiv_data1/oa_pdf/7b/39/WJG-23-1319.PMC5323457.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 450  7",Non-OADS,/arxiv_data1/oa_pdf/7b/39/WJG-23-1319.PMC5323457.pdf
"The IFA is integrated within the not ‑for‑profit  charitable organization iMERiT (International Medical Education and Research Initiative) under Belgian Law, and IFA website (http://www.fluidacademy.org) is an official SMACC (Social Media and Critical Care) affiliated site, based  on the philosophy of FOAM (Free Open Access Medical Education).",Non-OADS,/arxiv_data1/oa_pdf/d6/6a/134_2016_Article_4665.PMC5323492.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: PhenylketonuriaSapropterin dihydrochlorideBH 4 IntelligenceIQWhite matterDiffusion tensor imaging 1.,Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
http://dx.doi.org/10.1016/j.ymgmr.2017.01.013 2214-4269/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"99 (2010) S3 –S9,http://dx.doi.org/10.1016/j.ymgme.2009.10.005 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"109 (2) (2013) 125 –131, http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"White, Response monitoring in children with phenylketonuria, Neuropsychology 23 (1) (2009) 130, http://dx.doi.org/10.1037/a0013488 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"Levy, Phenylketonuria, Lancet 376 (9750) (2010) 1417 –1427, http://dx.doi.org/10.1016/S0140-6736(10)60961-0 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"99 (2010) S59 –S63, http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"3 (4) (2008) 286–300, http://dx.doi.org/10.1111/j.1745-6924.2008.00079.x .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"25 (1) (2014) 7 –29, http://dx.doi.org/10.1177/0956797613504966 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"217 (1) (2009) 27 –37,http://dx.doi.org/10.1027/0044-3409.217.1.27 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"99 (2010) S64 –S67, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"86 (2005) 86 –90,http://dx.doi.org/ 10.1016/j.ymgme.2005.05.013 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"107 (3) (2012)294–301, http://dx.doi.org/10.1016/j.ymgme.2012.09.021 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"114 (1) (2015) 19 –24,http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"111 (4) (2014) 445 –451, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"104 (1) (2011) 89 –92,http://dx.doi.org/10.1016/j.ymgme.",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"97 (3) (2009) 165 –171, http://dx.doi.org/10.1016/j.ymgme.2009.03.009 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"29 (4) (2007) 436–441, http://dx.doi.org/10.1080/13803390600745829 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"94 (3) (1957) 224–230, http://dx.doi.org/10.1001/archpedi.1957.04030040006002 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"28 (9) (2007) 831 –845, http://dx.doi.org/10.1002/humu.20526 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"22 (11) (2011) 1359 –1366, http://dx.doi.org/10.1177/0956797611417632 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"33 (6) (2010) 689 –695, http://dx.doi.org/10.1007/s10545-010-9224-1 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"99 (2010) S90 –S95, http://dx.doi.org/10.1016/j.ymgme.2009.10.008 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"23 (5) (2000) 487 –496, http://dx.doi.org/10.1023/A:1005664231017 .",Non-OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"110 (3) (2013) 213 –217, http://dx.doi.org/10.1016/j.ymgme.2013.07.010 .",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
"99 (2010) S1 –S2,http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/f1/05/main.PMC5323508.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
"Abbreviations: BEZ, Beza ﬁbrate; BG, blood glucose; ED, early onset of diabetes; EM, electron microscopy; HOMA-IR, homeostatic model assessment of insulin resistance; FA, fatty acid; LD, late onset of diabetes; NAFLD, non-alcoholic fatty liver disease; NEFA, non-esteri ﬁed fatty acid; PPAR, peroxisome proliferator-activated receptor; qNMR, quantitative nuclear magnetic resonance; RER, respiratory exchange ratios; SD, standard diet; T2D, type 2 diabetes; TG, triglyceride Received November 17, 2016 /C15Revision received December 8, 2016 /C15Accepted December 15, 2016 /C15Available online 6 January 2017 http://dx.doi.org/10.1016/j.molmet.2016.12.007 Original Article 256MOLECULAR METABOLISM 6 (2017) 256 e266/C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/00/14/main.PMC5323884.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
"Received December 9, 2016 /C15Revision received January 3, 2017 /C15Accepted January 5, 2017 /C15Available online 12 January 2017 http://dx.doi.org/10.1016/j.molmet.2017.01.001 Brief Communication 306MOLECULAR METABOLISM 6 (2017) 306 e312/C2112017 The Authors.",OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/a1/main.PMC5323886.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
"Received December 6, 2016 /C15Revision received December 27, 2016 /C15Accepted January 5, 2017 /C15Available online 12 January 2017 http://dx.doi.org/10.1016/j.molmet.2017.01.002 Brief Communication MOLECULAR METABOLISM 6 (2017) 267 e275/C2112017 Published by Elsevier GmbH.",OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/68/main.PMC5323887.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
"Received October 27, 2016 /C15Revision received December 20, 2016 /C15Accepted December 29, 2016 /C15Available online 4 January 2017 http://dx.doi.org/10.1016/j.molmet.2016.12.010 Brief Communication 276MOLECULAR METABOLISM 6 (2017) 276 e287/C2112017 The Authors.",OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c9/d1/main.PMC5323888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
"Received October 10, 2016 /C15Revision received November 22, 2016 /C15Accepted December 1, 2016 /C15Available online 8 December 2016 http://dx.doi.org/10.1016/j.molmet.2016.12.002 Brief Communication MOLECULAR METABOLISM 6 (2017) 295 e305/C2112016 The Authors.",OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
"ucsc.edu )[27,28] and pathogenicity was tested using in silico ana- lyses (SIFT [29], PROVEAN [30] (http://provean.jcvi.org ), Muta- tionAssesor ( http://mutationassessor.org )[31], CADD ( http://cadd.gs.",OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
"washington.edu/score )[32], and SNPs&GO ( http://snps.biofold.org ) [33].",OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/34/main.PMC5323889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
"Abbreviations: Cre, Cre recombinase; CreERT2, tamoxifen-inducible Cre recombinase-estrogen receptor fusion protein; CRISPR, clustered regularly interspaced short palindromic repeat; DAPI, 40,6-diamidino-2-phenylindole; ESC, embryonic stem cell; FACS, ﬂuorescence-activated cell sorting; GCG, glucagon; GLP1, glucagon-like peptide 1; IRES, internal ribosomal entry site; LSL, loxP-stop-loxP; gRNA, guide RNA; UTR, untranslated region; YFP, yellow ﬂuorescent protein Received December 27, 2016 /C15Revision received January 5, 2017 /C15Accepted January 9, 2017 /C15Available online 12 January 2017 http://dx.doi.org/10.1016/j.molmet.2017.01.003 Original Article 236MOLECULAR METABOLISM 6 (2017) 236 e244/C2112017 Published by Elsevier GmbH.",Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
"The In-Fusion HD Cloning Kit (Clontech, MountainView, CA, USA) was used to sub-clone the PCR-ampli ﬁed sequences into the pBS vector (Stratagene, La Jolla, CA, USA) that was linearized with XmaI and EcoRI, to generate the gene targeting vector.A guide RNA (gRNA) targeting the ATTATCGCAGTCACAACACC sequencein the Gcg 3 0UTR was cloned into the pX335 vector containing Cas9 ,following the CRISPR Genome Engineering Toolbox Target Sequence Cloning Protocol ( http://www.genome-engineering.org/crispr/ ).",Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/46/0c/main.PMC5323890.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/02/main.PMC5324012.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 1–6 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2016.11.001 1013-9052 /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/ea/02/main.PMC5324012.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/02/main.PMC5324012.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 24–28 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2016.10.002 1013-9052 /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/fb/87/main.PMC5324013.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fb/87/main.PMC5324013.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fb/87/main.PMC5324013.pdf
15. http://dx.doi.org/10.1111/ bjd.13613 .,Non-OADS,/arxiv_data1/oa_pdf/fb/87/main.PMC5324013.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/58/main.PMC5324014.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 36–40 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2016.10.001 1013-9052 /C2112016 The Author.",Non-OADS,/arxiv_data1/oa_pdf/d1/58/main.PMC5324014.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/58/main.PMC5324014.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5a/8a/main.PMC5324016.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 29–35 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2017.01.001 1013-9052 /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/5a/8a/main.PMC5324016.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5a/8a/main.PMC5324016.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 15–23 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2016.12.001 1013-9052 /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d1/bf/main.PMC5324017.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/bf/main.PMC5324017.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d1/bf/main.PMC5324017.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/dd/main.PMC5324018.pdf
"Production and hosting by ElsevierThe Saudi Dental Journal (2017) 29, 7–14 King Saud University The Saudi Dental Journal www.ksu.edu.sa www.sciencedirect.com http://dx.doi.org/10.1016/j.sdentj.2016.08.005 1013-9052 /C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a4/dd/main.PMC5324018.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/dd/main.PMC5324018.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
"Abbreviations: GIPR, GIP receptor; GFP, green ﬂuorescent protein; OGTT, oral glucose tolerance test; ITT, insulin tolerance test; CT, computerized tomography Received December 26, 2016 /C15Revision received January 11, 2017 /C15Accepted January 16, 2017 /C15Available online 19 January 2017 http://dx.doi.org/10.1016/j.molmet.2017.01.006 Brief Communication 288MOLECULAR METABOLISM 6 (2017) 288 e294/C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
Proceedings of theNational Academy of Sciences of the United States of America 96(26):14843 e 14847.. https://www.ncbi.nlm.nih.gov/pubmed/?term ¼Miyawaki%2C þGIP% 2CþPNAS .,OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/2b/main.PMC5324019.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
"Abbreviations: mTORC1, mechanistic target of rapamycin complex 1; 4E-BP1, eukaryotic translation initiation factor 4E (eIF4e)-binding protein 1; GLP-1, Glucago n-like peptide-1; AA, amino acid; LC-MS/MS, liquid chromatography triple quadrupole mass spectrometry; GLP-2R, GLP-2 receptor; S6K1, 70 kDa ribosomal pr otein S6 kinase 1; GLP-2, glucagon-like peptide-2; EECs, enteroendocrine cells; PGDP, proglucagon-derived peptides; EAA, essential amino acid; BBMV, brush border membrane vesicles; ENS, enteric nervous system Received January 6, 2017 /C15Accepted January 11, 2017 /C15Available online 17 January 2017 http://dx.doi.org/10.1016/j.molmet.2017.01.005 Original Article MOLECULAR METABOLISM 6 (2017) 245 e255/C2112017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
SUPPLEMENTARY DATA Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
http://dx.doi.org/10.1016/j.jpeds.2016.10.027 pii: S0022 e3476(16)31095-2.,OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
http://dx.doi.org/10.1111/ dom.12845 .,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
http://dx.doi.org/10.1007/s11695-016-2345-3 .,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/70/14/main.PMC5324020.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Niels Olsen Saraiva Camara, MD,  Department of Immunology, Institute of Biomedical Sciences,  University of São Paulo, 1730 Av.",Non-OADS,/arxiv_data1/oa_pdf/00/32/WJT-7-1.PMC5324024.pdf
"Key words:  Transplant immunology; Immune rejection;  Inflammation; Adaptive immunity; Innate immunity; Graft REVIEW  February 24, 207 |Volume 7 |Issue | WJT|www.wjgnet.comOld game, new players: Linking classical theories to new  trends in transplant immunologyWorld J Transplant   207 February 24; 7(): -25 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 0.5500/wjt.v7.i.World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/00/32/WJT-7-1.PMC5324024.pdf
"World J Transplant  2017; 7(1): 1-25  Available  from: URL: http://www.wjgnet.com/2220-3230/full/v7/i1/1.htm    DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.1 INTRODUCTION Although the first attempts at organ and tissue trans­ plantation date to many centuries ago, knowledge of  the underlying principles that orchestrate the immune  response to this surgical procedure only began to be  understood in the mid ­twentieth century.",Non-OADS,/arxiv_data1/oa_pdf/00/32/WJT-7-1.PMC5324024.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/00/32/WJT-7-1.PMC5324024.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Gerold Thölking, MD, Division of General  Internal Medicine, Nephrology and Rheumatology, Department of  Medicine D, University Hospital of Münster, Albert-Schweitzer- Campus 1, Gebäude A1, 48149 Münster,  Germany.",Non-OADS,/arxiv_data1/oa_pdf/d8/0e/WJT-7-26.PMC5324025.pdf
"The TAC MINIREVIEWS 26 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comInfluence of tacrolimus metabolism rate on renal function  after solid organ transplantationWorld J Transplant   2017 February 24; 7(1): 26-33 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.26World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/d8/0e/WJT-7-26.PMC5324025.pdf
World J Transplant  2017; 7(1): 26-33  Available  from: URL: http://www.wjgnet.com/2220-3230/full/v7/i1/26.htm    DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.26 INTRODUCTION The calcineurin inhibitor (CNI) tacrolimus (TAC) is a  cornerstone of the immunosuppressive regimen after  solid organ transplantation.,Non-OADS,/arxiv_data1/oa_pdf/d8/0e/WJT-7-26.PMC5324025.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/d8/0e/WJT-7-26.PMC5324025.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Michelle Willicombe, MA, MRCP, MD,   Imperial College Kidney and Transplant Centre, Hammersmith  Hospital, South Wharf Road, London W12 0HS,  United Kingdom.",Non-OADS,/arxiv_data1/oa_pdf/8a/50/WJT-7-34.PMC5324026.pdf
"On multivariate analysis,  risk factors for DGF were male recipients, recipients of  black ethnicity, circulatory death donation, preformed  DSA, increasing cold ischaemic time, older donor age and  dialysis vintage.ORIGINAL ARTICLE 34 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comRisk factors and outcomes of delayed graft function in  renal transplant recipients receiving a steroid sparing  immunosuppression protocolWorld J Transplant   2017 February 24; 7(1): 34-42 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.34World Journal of  Transplantation WJT Retrospective Cohort Study",Non-OADS,/arxiv_data1/oa_pdf/8a/50/WJT-7-34.PMC5324026.pdf
World J Transplant  2017; 7(1): 34­42   Available from: URL: http://www.wjgnet.com/2220 ­3230/full/v7/ i1/34.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.34 INTRODUCTION Delayed graft function (DGF) is associated with adverse  allograft and patient outcomes[1-6].,Non-OADS,/arxiv_data1/oa_pdf/8a/50/WJT-7-34.PMC5324026.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/8a/50/WJT-7-34.PMC5324026.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Giovanni Vennarecci, MD, Division of  Surgical Oncology and Liver Transplantation, San Camillo Hospital,  POIT San Camillo-INMI Lazzaro Spallanzani, Cir.ne Gianicolense  N° 187, 00149 Rome,  Italy.",Non-OADS,/arxiv_data1/oa_pdf/8d/16/WJT-7-43.PMC5324027.pdf
"CONCLUSION The cases that we presented show that the use of  biological mesh (Permacol ™, Covidien) in transplanted  patients may be safe and effective, being careful in the  management of perioperative immunosuppression and ORIGINAL ARTICLE 43 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comEffectiveness and versatility of biological prosthesis in  transplanted patientsWorld J Transplant   2017 February 24; 7(1): 43-48 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.43World Journal of  Transplantation WJT Retrospective Cohort Study",Non-OADS,/arxiv_data1/oa_pdf/8d/16/WJT-7-43.PMC5324027.pdf
World J Transplant  2017; 7(1): 43-48  Available from: URL: http:// www.wjgnet.com/2220-3230/full/v7/i1/43.htm   DOI: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8d/16/WJT-7-43.PMC5324027.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/8d/16/WJT-7-43.PMC5324027.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Evangelia Dounousi, MD, PhD, Department  of Medicine, School of Health Sciences, University of Ioannina,  Stavrou Niarchou Avenue, 45110 Ioannina,  Greece.",Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
"METHODS Two hundred and forty-two adult patients with a  functioning graft for at least three months and available ORIGINAL ARTICLE 49 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comCardiovascular disease: Risk factors and applicability of a  risk model in a Greek cohort of renal transplant recipientsWorld J Transplant   2017 February 24; 7(1): 49-56 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.49World Journal of  Transplantation WJT Retrospective Cohort Study",Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
World J Transplant   2017; 7(1): 49­56  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
"com/2220 ­3230/full/v7/i1/49.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.49 INTRODUCTION Renal transplantation is the treatment of choice for  patients with end stage renal disease (ESRD), as it  enhances survival and quality of life and is also cost- effective.",Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
The MACE risk was  calculated for all 242 participants (http://www.medsci.,Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/22/53/WJT-7-49.PMC5324028.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Bruno Gomes Rodrigues dos Santos, MD,  Kidney  Transplant Unit, Universitário Walter Cantídio, Hospital  Universidade Federal do Ceará, Rua Capitão Francisco Pedro, 1290  - Rodolfo Teófilo, Fortaleza, CE 60430-370,  Brazil.",Non-OADS,/arxiv_data1/oa_pdf/6f/2c/WJT-7-57.PMC5324029.pdf
"METHODS We retrospectively evaluated 11 renal transplant recipients ORIGINAL ARTICLE 57 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comDengue in renal transplant recipients: Clinical course and  impact on renal functionWorld J Transplant   2017 February 24; 7(1): 57-63 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.57World Journal of  Transplantation WJT Retrospective Study",Non-OADS,/arxiv_data1/oa_pdf/6f/2c/WJT-7-57.PMC5324029.pdf
World J Transplant  2017; 7(1): 57-63  Available from: URL: http:// www.wjgnet.com/2220-3230/full/v7/i1/57.htm   DOI: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6f/2c/WJT-7-57.PMC5324029.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/6f/2c/WJT-7-57.PMC5324029.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Dr. Vivek B Kute, MBBS, MD, FCPS,  DM Nephrology (Gold Medalist), FASN, Associate Professor,  Department of Nephrology and Clinical Transplantation, Institute  of Kidney Diseases and Research Center, Dr HL Trivedi Institute  of Transplantation Sciences (IKDRC-ITS), Civil Hospital  Campus, Asarwa, Ahmedabad 380016,  India.",Non-OADS,/arxiv_data1/oa_pdf/6c/55/WJT-7-64.PMC5324030.pdf
"The two donor recipient pairs had  negative lymphocyte cross ­matching, flow cross ­match ORIGINAL ARTICLE 64 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comInternational kidney paired donation transplantations to  increase kidney transplant of O group and highly sensitized  patient: First report from IndiaWorld J Transplant   2017 February 24; 7(1): 64-69 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.64World Journal of  Transplantation WJT Retrospective Study",Non-OADS,/arxiv_data1/oa_pdf/6c/55/WJT-7-64.PMC5324030.pdf
World J Transplant   2017; 7(1): 64-69  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/6c/55/WJT-7-64.PMC5324030.pdf
"com/2220-3230/full/v7/i1/64.htm   DOI: http://dx.doi.org/ 10.5500 / wjt.v7.i1.64 INTRODUCTION There is growing incidence of chronic kidney disease in  India and worldwide[1,2].",Non-OADS,/arxiv_data1/oa_pdf/6c/55/WJT-7-64.PMC5324030.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/6c/55/WJT-7-64.PMC5324030.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Michael Eberlein, MD, PhD, Division of  Pulmonary, Critical Care and Occupational Medicine, University  of Iowa Hospitals and Clinics, 200 Hawkins Drive, C 33 GH,  Iowa City, IA 52242, United States.",Non-OADS,/arxiv_data1/oa_pdf/64/fc/WJT-7-70.PMC5324031.pdf
"michael-eberlein@uiowa.edu Telephone: +1-319-3561265 Fax: +1-319-3536406  Received:  May 30, 2016 Peer-review started: June 3, 2016 First decision: July 5, 2016 Revised: December 2, 2016 Accepted: December 27, 2016 Article in press:  December 29, 2016 Published o nline:  February 24, 2017 Abstract AIM To systematically review reports on deceased-donor-lobar  lung transplantation (ddLLTx) and uniformly describe size SYSTEMATIC REVIEWS 70 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comLobar lung transplantation from deceased donors: A  systematic reviewWorld J Transplant   2017 February 24; 7(1): 70-80 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.70World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/64/fc/WJT-7-70.PMC5324031.pdf
World J Transplant  2017; 7(1): 70-80   Available from: URL: http://www.wjgnet.com/2220-3230/full/ v7/i1/70.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.70 INTRODUCTION Lung transplantation (LTx) is an established therapy  for appropriately selected patients suffering from end- stage lung disease.,Non-OADS,/arxiv_data1/oa_pdf/64/fc/WJT-7-70.PMC5324031.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/64/fc/WJT-7-70.PMC5324031.pdf
"See: http://creativecommons.org/ licenses/by ­ nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Kianoush B Kashani, MD, Assistant  Professor , Division of Nephrology and Hypertension, Department  of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MI  55905, United States.",Non-OADS,/arxiv_data1/oa_pdf/41/ee/WJT-7-81.PMC5324032.pdf
"However, data on the effects of CIAKI on long-term graft  function were limited.META-ANALYSIS 81 February 24, 2017 |Volume 7 |Issue 1 | WJT|www.wjgnet.comContrast-induced acute kidney injury in kidney transplant  recipients: A systematic review and meta-analysis World J Transplant   2017 February 24; 7(1): 81-87 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.81World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/41/ee/WJT-7-81.PMC5324032.pdf
"World J Transplant  2017; 7(1): 81­87  Available  from: URL: http://www.wjgnet.com/2220 ­ 3230/full/v7/i1/81.htm    DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.81 INTRODUCTION Contrast-induced acute kidney injury (CIAKI), or con - trast-induced nephropathy (CIN), is associated with a  significant increase in mortality and morbidity in patients  with native kidneys[1-7].",Non-OADS,/arxiv_data1/oa_pdf/41/ee/WJT-7-81.PMC5324032.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/41/ee/WJT-7-81.PMC5324032.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Lauren E Malinzak, MD, Transplant and  Hepatobiliary Surgery, Henry Ford Hospital, 2790 West Grand  Boulevard, Detroit, MI 48202, United States.",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/WJT-7-88.PMC5324033.pdf
"Key words:  Page kidney; Kidney transplantation; Trauma;  Subcapsular hematoma; Doppler ultrasoundCASE REPORT 88 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comAllograft loss from acute Page kidney secondary to trauma  after kidney transplantationWorld J Transplant   2017 February 24; 7(1): 88-93 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.88World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/WJT-7-88.PMC5324033.pdf
wjgnet.com/2220-3230/full/v7/i1/88.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a9/d6/WJT-7-88.PMC5324033.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/a9/d6/WJT-7-88.PMC5324033.pdf
See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Unsolicited manuscript Correspondence to: Dr .,Non-OADS,/arxiv_data1/oa_pdf/c7/c1/WJT-7-94.PMC5324034.pdf
"We reported how we CASE REPORT 94 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comRenoportal anastomosis in living donor liver transplantation  with prior proximal splenorenal shuntWorld J Transplant   2017 February 24; 7(1): 94-97 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.94World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/c7/c1/WJT-7-94.PMC5324034.pdf
wjgnet.com/2220-3230/full/v7/i1/94.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c7/c1/WJT-7-94.PMC5324034.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/c7/c1/WJT-7-94.PMC5324034.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Adam Testro, MBBS, FRACP, PhD,  Head of Intestinal Rehabilitation and Transplantation, Australian  Intestinal Transplant Service, Austin Health, 145 Studley Road,  Heidelberg, VIC 3084, Australia.",Non-OADS,/arxiv_data1/oa_pdf/17/fa/WJT-7-98.PMC5324035.pdf
"If  the native biopsy is abnormal, drug toxicity should be  considered as a differential diagnosis as it may show  overlapping features with ACR.CASE REPORT 98 February 24, 2017 |Volume 7 |Issue 1| WJT|www.wjgnet.comMycophenolate mofetil toxicity mimicking acute cellular  rejection in a small intestinal transplantWorld J Transplant   2017 February 24; 7(1): 98-102 ISSN 2220-3230 (online)Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.5500/wjt.v7.i1.98World Journal of  Transplantation WJT",Non-OADS,/arxiv_data1/oa_pdf/17/fa/WJT-7-98.PMC5324035.pdf
"World J Transplant  2017; 7(1): 98-102   Available from: URL: http://www.wjgnet.com/2220-3230/full/ v7/i1/98.htm   DOI: http://dx.doi.org/ 10.5500 /wjt.v7.i1.98 INTRODUCTION Mycophenolate mofetil (MMF) acts by inhibiting inosine- 5’-monophosphate dehydrogenase, leading to decreased  purine synthesis in T and B lymphocytes.",Non-OADS,/arxiv_data1/oa_pdf/17/fa/WJT-7-98.PMC5324035.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/17/fa/WJT-7-98.PMC5324035.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/de/05/umj0086-0001.PMC5324171.pdf
2 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/de/05/umj0086-0001.PMC5324171.pdf
"Making IT work: Harnessing the power of health information technology to improve care in England (Review of IT in NHS England led by Dr Bob Wachter), September 2016: https://www.gov.uk/government/publications/using-information-technology-to-improve-the-nhs  4.",Non-OADS,/arxiv_data1/oa_pdf/de/05/umj0086-0001.PMC5324171.pdf
"Health and wellbeing 2026: Delivering together (Ministerial response to the recommendations of the Expert Panel), October 2016: https://www.health-ni.gov.uk/publications/health-and-wellbeing-2026-delivering-together",Non-OADS,/arxiv_data1/oa_pdf/de/05/umj0086-0001.PMC5324171.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
4 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Cardiotoxicity Following Cancer Treatment5 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
6 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Cardiotoxicity Following Cancer Treatment7 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available online: http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/radiotherapy/about/what-radiotherapy-is Last accessed September 2016.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available online from: https://www.nice.org.uk/guidance/cg121.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available online from:  http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence#heading-Zero.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
8 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available  online from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094815.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available online: https://www.nice.org.uk/guidance/cg108.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Cardiotoxicity Following Cancer Treatment9 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT00858039.,Non-OADS,/arxiv_data1/oa_pdf/d4/c6/umj0086-0003.PMC5324172.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d7/d2/umj0086-0010.PMC5324173.pdf
An Assessment of Fetal Cerebral and Hepatic Perfusion in Normal Pregnancy   and Pre-Eclampsia Using Three-Dimensional Ultrasound11 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d7/d2/umj0086-0010.PMC5324173.pdf
12 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d7/d2/umj0086-0010.PMC5324173.pdf
An Assessment of Fetal Cerebral and Hepatic Perfusion in Normal Pregnancy   and Pre-Eclampsia Using Three-Dimensional Ultrasound13 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d7/d2/umj0086-0010.PMC5324173.pdf
14 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/d7/d2/umj0086-0010.PMC5324173.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/17/66/umj0086-0015.PMC5324174.pdf
16 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/17/66/umj0086-0015.PMC5324174.pdf
Outcome of primary rhegmatogenous retinal detachment surgery in a tertiary referral   centre in Northern Ireland – A regional study17 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/17/66/umj0086-0015.PMC5324174.pdf
18 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/17/66/umj0086-0015.PMC5324174.pdf
Outcome of primary rhegmatogenous retinal detachment surgery in a tertiary referral   centre in Northern Ireland – A regional study19 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/17/66/umj0086-0015.PMC5324174.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ce/8b/umj0086-0020.PMC5324175.pdf
Outcomes of Sacral Nerve Stimulation For Faecal Incontinence in Northern Ireland21 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ce/8b/umj0086-0020.PMC5324175.pdf
22 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ce/8b/umj0086-0020.PMC5324175.pdf
Outcomes of Sacral Nerve Stimulation For Faecal Incontinence in Northern Ireland23 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ce/8b/umj0086-0020.PMC5324175.pdf
24 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ce/8b/umj0086-0020.PMC5324175.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/92/8b/umj0086-0025.PMC5324176.pdf
26 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/92/8b/umj0086-0025.PMC5324176.pdf
Prevalence of Corneal Astigmatism in an NHS Cataract Surgery Practice in Northern Ireland27 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/92/8b/umj0086-0025.PMC5324176.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/47/ea/umj0086-0028.PMC5324177.pdf
A rare characteristic neuroimaging pattern in hyperammonaemia29 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/47/ea/umj0086-0028.PMC5324177.pdf
30 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/47/ea/umj0086-0028.PMC5324177.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
32 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
"Robert Collis (1900-1975), early champion of paediatrics33 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).",Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
34 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
"Robert Collis (1900-1975), early champion of paediatrics35 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).",Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
Availabe online from: http://munksroll.rcplondon.ac.uk/Biography/Details/953 Last accessed October 2016.13.,Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
Available online from:  http://www.igp-web.com/IGPArchives/ire/wicklow/photos/tombstones/1headstones/calary.txt Last accessed October 2016.,Non-OADS,/arxiv_data1/oa_pdf/a4/64/umj0086-0031.PMC5324178.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
Enhancing Feedback On Case Reports To Third Year Medical Students On Clinical Attachment37 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
38 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
Enhancing Feedback On Case Reports To Third Year Medical Students On Clinical Attachment39 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
40 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
Enhancing Feedback On Case Reports To Third Year Medical Students On Clinical Attachment41 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
Available online from: https://bmcmededuc.biomedcentral.,OADS,/arxiv_data1/oa_pdf/84/8b/umj0086-0036.PMC5324179.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/e8/53/umj0086-0042.PMC5324180.pdf
Letters43 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/a7/ba/umj0086-0043.PMC5324181.pdf
44 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/a7/ba/umj0086-0043.PMC5324181.pdf
"Available online from: http://niformulary.hscni.net/PrescribingNewsletters/PDF/NIMM_2015/NIMM_%20NewsletterspecialSupplement_Jan15.pdf Last accessed September 2016 INAPPROPRIATE ED ATTENDANCES IN  NORTHERN IRELAND: A REVIEW OF ATTENDANCES IN THE BELFAST HEALTH AND SOCIAL CARE TRUST Editor, Inappropriate attendances (IAs) at Emergency Departments  (EDs) may impact on patient safety and flow through the unscheduled care system.",Non-OADS,/arxiv_data1/oa_pdf/a7/ba/umj0086-0043.PMC5324181.pdf
44 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/94/89/umj0086-0044.PMC5324182.pdf
"Available online from: http://niformulary.hscni.net/PrescribingNewsletters/PDF/NIMM_2015/NIMM_%20NewsletterspecialSupplement_Jan15.pdf Last accessed September 2016 INAPPROPRIATE ED ATTENDANCES IN  NORTHERN IRELAND: A REVIEW OF ATTENDANCES IN THE BELFAST HEALTH AND SOCIAL CARE TRUST Editor, Inappropriate attendances (IAs) at Emergency Departments  (EDs) may impact on patient safety and flow through the unscheduled care system.",Non-OADS,/arxiv_data1/oa_pdf/94/89/umj0086-0044.PMC5324182.pdf
44 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/32/74/umj0086-0044a.PMC5324183.pdf
"Available online from: http://niformulary.hscni.net/PrescribingNewsletters/PDF/NIMM_2015/NIMM_%20NewsletterspecialSupplement_Jan15.pdf Last accessed September 2016 INAPPROPRIATE ED ATTENDANCES IN  NORTHERN IRELAND: A REVIEW OF ATTENDANCES IN THE BELFAST HEALTH AND SOCIAL CARE TRUST Editor, Inappropriate attendances (IAs) at Emergency Departments  (EDs) may impact on patient safety and flow through the unscheduled care system.",Non-OADS,/arxiv_data1/oa_pdf/32/74/umj0086-0044a.PMC5324183.pdf
Letters45 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/32/74/umj0086-0044a.PMC5324183.pdf
Letters45 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/c6/06/umj0086-0045.PMC5324184.pdf
46 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/c6/06/umj0086-0045.PMC5324184.pdf
46 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/93/47/umj0086-0046.PMC5324185.pdf
Letters47 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/93/47/umj0086-0046.PMC5324185.pdf
48 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/93/47/umj0086-0046.PMC5324185.pdf
Available online at: http://www.nrls.npsa.nhs.uk/resources/?EntryId45=94845 .,Non-OADS,/arxiv_data1/oa_pdf/93/47/umj0086-0046.PMC5324185.pdf
48 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/7a/16/umj0086-0048.PMC5324186.pdf
Available online at: http://www.nrls.npsa.nhs.uk/resources/?EntryId45=94845 .,Non-OADS,/arxiv_data1/oa_pdf/7a/16/umj0086-0048.PMC5324186.pdf
Letters49 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/7a/16/umj0086-0048.PMC5324186.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/cf/52/umj0086-0050.PMC5324187.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/8b/6f/umj0086-0051.PMC5324188.pdf
52 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/8b/6f/umj0086-0051.PMC5324188.pdf
Ulster Society of Internal Medicine 95th (Spring) Meeting53 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/8b/6f/umj0086-0051.PMC5324188.pdf
54 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/8b/6f/umj0086-0051.PMC5324188.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
56 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics57 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
58 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics59 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
60 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics61 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
62 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics63 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
64 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics65 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
66 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
19th Meeting of the Irish Society of Human Genetics67 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
68 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/58/00/umj0086-0055.PMC5324189.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
Please refer to ‘ Curiositas: Guidelines for contributors ’ http://www.ums.ac.uk/ curiositas.html  and email umj@qub.ac.uk with your ideas and submissions.,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
70 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
https://www.health-ni.gov.uk/publications/systems-not-structures-changing-health-and-social-care-full-report Accessed 29th Nov 2016 4.,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
2015; Available at: http://labtestsonline.org.uk/under - standing/analytes/platelet/tab/test/) .,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
Available: https://www.nice.org.uk/guidance/ng12/resources/suspected-cancer-recognition-and-referral-1837268071621.,Non-OADS,/arxiv_data1/oa_pdf/9e/cd/umj0086-0069.PMC5324190.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/7c/30/umj0086-0071.PMC5324191.pdf
72 The Ulster Medical Journal UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/7c/30/umj0086-0071.PMC5324191.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/c2/5e/umj0086-0073.PMC5324192.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/15/da/umj0086-0073a.PMC5324193.pdf
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ef/c1/umj0086-0074.PMC5324194.pdf
So you want to be an Acute Physician75 UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).,Non-OADS,/arxiv_data1/oa_pdf/ef/c1/umj0086-0074.PMC5324194.pdf
USEFUL WEBSITES https://www.jrcptb.org.uk/specialities/acute-medicine http://www.acutemedicine.org.uk/what-we-do/training-and- education/training-in-acute-medicine/  http://careers.bmj.com/careers/advice/view-article.,Non-OADS,/arxiv_data1/oa_pdf/ef/c1/umj0086-0074.PMC5324194.pdf
html?id=20022363  https://www.rcplondon.ac.uk/file/383/ download?token=wpfU3yC6,Non-OADS,/arxiv_data1/oa_pdf/ef/c1/umj0086-0074.PMC5324194.pdf
Bristol- Myers Squibb Australia Pty Ltd and Pfizer Pty Ltd; 2013.  http://www.bmsa.com .au/products/pages/Home.aspx.,Non-OADS,/arxiv_data1/oa_pdf/e9/ff/CCR-13-41.PMC5324317.pdf
"Resting‑state functional magnetic resonance imaging  data preprocessing Statistical Parametric Mapping 8 (SPM8) software (http:// www.fil.ion.ucl.ac.uk/spm/software/spm8/), Analysis of  Functional NeuroImage software  (http://afni.nimh.nih.",OADS,/arxiv_data1/oa_pdf/15/75/CMJ-130-414.PMC5324377.pdf
GIFT software (http://mialab.mrn.org/ software/gift/) was used to perform group independent  components (ICs).,OADS,/arxiv_data1/oa_pdf/15/75/CMJ-130-414.PMC5324377.pdf
"Statistical analysis Data analysis was performed using the statistical programs SPSS®version 21 (IBM, Armonk, New York, USA) and Confidence Interval Analysis (University of Southamp- ton; http://www.som.soton.ac.uk/research/sites/cia)16.T o determine the influence of method of administration of thequestionnaire (written, by e-mail or by telephone), the total mean GSRS score and the prevalence of food intolerance in the three groups were compared with the Kruskal–Wallisandχ 2test respectively.",OADS,/arxiv_data1/oa_pdf/24/e6/BJS-104-393.PMC5324533.pdf
https://doi.org/10.1002/dev.21484224| SIMONS ET AL.,Non-OADS,/arxiv_data1/oa_pdf/b0/ac/DEV-59-217.PMC5324537.pdf
lme4: Linear mixed-effects models using S4 classes Available at: http://CRAN.R-project.org/package=lme4.,Non-OADS,/arxiv_data1/oa_pdf/76/6a/DYS-23-42.PMC5324540.pdf
"R package version 1.4. http://CRAN.R-project.org/package=languageR Boeriis, M., & Holsanova, J.",Non-OADS,/arxiv_data1/oa_pdf/76/6a/DYS-23-42.PMC5324540.pdf
"Horizontal Visibility Observations We obtained raw, synoptic weather station records from the NOAA National Climatic Data Center Integrated Surface Database (https://catalog.data.gov/dataset/integrated-surface-global-hourly-data),which is composed of data from WMO-level surface stations provided by national meteorological agencies.",OADS,/arxiv_data1/oa_pdf/6b/92/GBC-31-24.PMC5324547.pdf
"FIRE DYNAMICS IN AMAZONIA (1973 –2014) 37Acknowledgments We would like to thank Enrico Dammers, Benjamin Aouizerats, and Douglas Morton for useful discussions.Furthermore, we acknowledge INPE formaking the PRODES publicly available (http://www.obt.inpe.br/prodes/index.",Non-OADS,/arxiv_data1/oa_pdf/6b/92/GBC-31-24.PMC5324547.pdf
GFED4s data is publicly availableat http://www.global ﬁredata.org/data.,OADS,/arxiv_data1/oa_pdf/6b/92/GBC-31-24.PMC5324547.pdf
Visibility observations were obtained from the NOAA National Climatic Data Center Integrated SurfaceDatabase (https://catalog.data.gov/dataset/integrated-surface-global- hourly-data).,OADS,/arxiv_data1/oa_pdf/6b/92/GBC-31-24.PMC5324547.pdf
Available at: http://plants.usda.gov (accessed 1 March 2015).,OADS,/arxiv_data1/oa_pdf/65/1b/GCB-23-1065.PMC5324548.pdf
"Werecently implemented a ‘one click’ submission mecha- nism from bioRxiv to all EMBO Press publica- tions.”“[ http://www.embl.de/training/events/stay- informed/newsletter/ 2016 /march/EMBOPress / }][EMBL, 2016].",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"Measuring Child Poverty Available: https://www.uni- cef-irc.org/publications/660/ Alberts B, Kirschner MW, Tilghman S, Varmus H. 2014.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.google.com/search?q 5Avent1R.11 The1 Third1Great1Wave.111 Special1report.11The1Economist%2 C1October 14th%2C 12013.1111 &ie5utf-8&oe 5utf-8&client 5 ﬁrefox-b.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
6. https://hbr.org/2015/10/a- new-way-to-deﬁne-value-in-drug-pricing.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://cos.io/ .,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"5November, 2015. http://cepr.net/blogs/beat-the-press/the-ratio-nale-for-high-drug-prices-incredibly-inefﬁcient-research?utm_source5twitterfeed&utm_medium 5twitter&utm_campaign 5 Feed%3A 1beat_the_press 1%28Beat 1the1Press%29.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
2015. https://www.cia.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
13 August 2016. http://www.econo- mist.com/news/leaders/21704791-science-getting-grips-ways-slow-ageing-rejoice-long-side-effects-can-be Citation Metrics.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://promarket.org/the-true-price-of-reduced-competition-in-health-care-hospital-monopolies-drasti- cally-drive-up-prices/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.nap.edu/read/10785/chapter/6.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.wsj.com/articles/a-defense-for-the-high-cost-of-many-scientiﬁc-journals- 1461000697.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://kingsreview.co.uk/magazine/blog/2014/02/24/how-academia-and- publishing-are-destroying-scientiﬁc-innovation-a-conversation- with-sydney-brenner/ .,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.economist.com/node/9339752.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.economist.com/news/brieﬁng/21695385- proﬁts-are-too-high-america-needs-giant-dose-competition-too- much-good-thing.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.embl.de/training/events/stay-informed/newsletter/2016/march/EMBOPress/18 TRIGGLE AND TRIGGLE Drug Dev.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Fair Access to Science and Technology Research Act of 2015. https://www.govtrack.us/congress/bills/114/s779/text Feldman R. 2014.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"Stanford Lawand Policy Review Online, 16-22. https://journals.law.stanford.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://ldi.upenn.edu/health-policysense.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
The Scientist 10: 11. http://www.the-sci- entist.com/?articles.view/articleNo/18038/title/The-Signiﬁcant- Scientiﬁc-Literature-Appears-In-A-Small-Core-Of-Journals/ Garﬁeld E. 2006.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.timeshighereducation.com/news/dec- laration-of-independence-from-journal-impact-factor/2003865.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://catalyst.nejm.org/is-value-based-drug-pricing-compatible-with-pharma-innovation/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.the-scientist.com/?articles.view/articleNo/45868/title/The-Zombie-Literature/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"Available: http://www.hbs.edu/faculty/conferences/2015-crisis-in- theory-of-ﬁrmﬁrm/Documents/Crisis%20in%20the%20Theory%20November%202015.pdf Helfond C. 2016, June 7.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Health Affairs Blog http://healthaffairs.org/blog/2015/12/01/how- might-proposed-payer-mergers-impact-state-insurance-markets/.Accessed 14 August 2016.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.latimes.com/business/hiltzik/la-ﬁ-hiltzik-university-busi-ness-20160602-snap-story.html.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.philly.com/philly/blogs/health-care/Its-not-just-Vertex-and-Shkreli-gouging-drug-prices.html.Accessed 14 August 2016.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://biorxiv.org/content/early/2015/10/22/029629.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
29 June 2006. http://blogs.nature.com/peer-to-peer/2006/06/quality_and_value_the_true_pur.html Jinha A.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.politico.com/story/2016/05/drug-prices-addiction-223192 Accessed 14 August 2016 Katz Y.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://bostonreview.net/editors-picks-books-ideas/yarden-katz-who-owns-molecular-biology.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.bloomberg.com/news/articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.vocativ.com/culture/science/ﬁve-corpora-tions-control-academic-publishing/ Krueger AO.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.forbes.com/sites/johnlamattina/2014/05/29/what-price-innovation-the-sovaldi-saga/#5f2aecc11ce1.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.bloomberg.com/news/articles/2016-02-02/shkreli-not-alone-in-drug-price-spikes-as-skin-gel-soars-1-860.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
bioRxiv doi: http://dx.doi.org/10.1101/062109.Accessed 14 August 2016.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.pharmaceutical-technology.com/features/featurepharma-mergers-big-business-bad-science-4467897/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"November 9, 2015. http://blogs.sciencemag.org/pipe-line/archives/2015/11/09/idiocy-on-drug-research-costs Lozano GA, Larivie `re V, Gingras Y.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.demos.org/publication/enough-make-you-sick-burden-medical-debt.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.nytimes.com/2016/07/19/health/zika-data-monkey-studies.html?_r 50.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Pﬁzer Chief Defends Merger With Allergan as Good for U.S.http://www.nytimes.com/2015/11/24/business/dealbook/pﬁzer-allergan-merger-inversion.html?_r 50.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"http://www.epi.org/publication/ceo-pay-has-grown-90-times-faster-than-typical-worker-pay-since-1978/.Accessed 24 August, 2016.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.nytimes.com/2015/10/04/business/valeants-high-price-drug-strategy.html.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"Center for Health Policy and Research, George Mason Univer- sity, Fairfax, VA. https://www.google.com/search?q 5What1pri- ce1should1we1pay1for1specialty 1drugs%3F 1&ie5utf- 8&oe5utf-8&client 5ﬁrefox-b.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.google.com/search?q 5Norris1J%2 C1Adelman 1C%2C1Spantchak 1Y%2C1Marano 1K.1Social 1and1Economic 1Impact1Review1on1Neglected 1Tropical 1 Diseases.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.the-scientist.com/?articles.view/articleNo/46126/title/Do-Patents-Promote-or-Stall-Innovation-/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Full article availableat http://dx.doi.org/10.1126/science.aac4716.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"https://www.openaire.eu/h2020openaccess/ Oreskes N, Conway EM.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
October 2013. https://www.google.com/search?q 5143.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://fortune.com/2016/05/17/high-drug-prices- mergers-pharma-competition/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.pnhp.org/news/2015/september/rent-seeking-by- drug-barons .,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
New York Times.http://www.nytimes.com/2016/02/05/business/drug-prices- valeant-martin-shkreli-congress.html.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.slate.com/articles/health_and_science/science/ 2013/06/supreme_court_patent_case_science_the_justices_mis-understand_molecular_biology.html.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
December 2015. https://www.google.com/ search?q 5Public1Citizen%2C 1TPP%3A 1Threats 1to1affor- dable1medicine.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Available: http://economix.blogs.nytimes.com/2010/08/13/health-care-uncertainty-and-morality/?_ r50.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Reviewing the literature on academic citations.http://blogs.lse.ac.uk/impactofsocialsciences/2014/04/23/academ- ic-papers-citation-rates-remler/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
com http://healthaffairs.org/blog/2016/01/13/how-much-does-congress-care-about-drug-pricesless-than-it-should/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.wwnorton.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.sci-encenews.org/article/bacteria-resistant-last-resort-antibiotic- appears-us.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://osp.od.nih.gov/sacghs-document-archive/gene-patents-and-licensing- practices-and-their-impact-patient-access-genetic-tests-report- secretarys.,OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
18876. http://www.nature.com/news/pirate-research-paper-sites- play-hide-and-seek-with-publishers-1.18876 Science Daily.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.sciencedaily.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
BMC Med 13:230. http://bmcmedicine.biomedcentral.com/articles/10.1186/ s12916-015-0469-2 Sherkow JS.,OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.slate.com/blogs/future_ tense/2013/06/13/myriad_dna_patenting_supreme_court_case_scalia_says_he_doesn_t_get_the_science.html.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
Avail- able: http://www.the-scientist.com/?articles.view/articleNo/ 46641/title/Opinion–A-Baseball-Analogy/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"Psychiatric Times March 5, 2010. http://www.psychiatrictimes.",Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
4. https://www.google.com/search?q 5 Turner1G.1Is1Global1Collapse 1Imminent.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
2016. http://www.nytimes.com/roomfordebate/2016/08/24/is-obamacare-sustainable/obamacare-is-an-unstable- economic-model.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.google.com/search?q 572.%09US 1 National 1Academy 1of1Sciences.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.brookings.edu/2016/03/15/gene-editing-new-challenges-old-lessons/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.ft.com/cms/s/0/6aad8ebe-e9c0-11e4-b863-00144feab7de.html#axzz4He5OvlaS.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.ft.com/cms/s/0/e8320ccc-0327-11e5-8333-00144feabdc0.html#axzz4He5OvlaS.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
2015. http://www.who.int/reproductivehealth/publications/ monitoring/maternal-mortality-2015/en/ .,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
https://www.google.com/search?q 5West1DM.1 What1Happens 1if1Robots1Take1the1Jobs%3F 11The1 impact1of1emerging 1technologies 1on1employment 1and1 public1policy.1The1Center1for1Technology 1Innovation%2 C1The1Brookings 1Institution.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.theatlantic.com/science/archive/2015/08/psychology- studies-reliability-reproducability-nosek/402466/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
http://www.wired.com/2015/10/battle- genome-editing-gets-science-wrong/.,Non-OADS,/arxiv_data1/oa_pdf/3b/9f/DDR-78-3.PMC5324562.pdf
"National Health and Nutrition Examina- tion Survey, 1988 –1994, NHANES III Linked Mortality Public use File (http://www.cdc.gov/ nchs/data/datalinkage/nh3_ﬁle_layout_pub- lic_2010.pdf).",OADS,/arxiv_data1/oa_pdf/ac/5e/JCPE-43-104.PMC5324563.pdf
"Then the X-ﬁle software(Rimm Laboratory at Yale University; http://www.tissuearray.org/rimmlab) 17was applied to divide the protein expression into two categories (low expression and high expression)here, the High expression is from 80 to 300 microscopicscore and Low expression is from 0 to 80 microscopic score,which were obtained from the microscopic IHC staining score of tumor cells collected from the patients.",OADS,/arxiv_data1/oa_pdf/b3/ec/IJC-140-1620.PMC5324565.pdf
Available at: https://www.rcog .org.uk/globalassets/documents/ guidelines/gtg-29.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ce/c2/BIRT-44-86.PMC5324579.pdf
Available at: http://www.scb.se/sv_/ Hitta-statistik/Artiklar/Finland-oc h-Irak-de-tva-vanligaste-fodel selanderna-bland-utrikes-fodda/2016.94 BIRTH 44:1 March 2017,Non-OADS,/arxiv_data1/oa_pdf/ce/c2/BIRT-44-86.PMC5324579.pdf
"http://www.cancer.org/cancer/skincancer-mela-noma/detailedguide/melanoma-skin-cancer-survival-rates-by-stage.Accessed January 21, 2016.",Non-OADS,/arxiv_data1/oa_pdf/10/e6/CNCR-123-617.PMC5324582.pdf
"Mean ambient T, °C 1.0 4.0 2.3 3.6 Standard deviation of daily mean ambient T,° C5.0 3.0 3.3 3.5 Number of periods with ambient T<−4 °C1 311 3 5 Number of periods with ambient T>10 °C81 0 1 3 9 All temperatures are ambient temperatures: in case of the study periods 2009–2013 down- loaded from the SMEAR database (http://avaa.tdata.ﬁ/web/smart/smear, Junninen et al.",OADS,/arxiv_data1/oa_pdf/6d/c3/PCE-38-2299.PMC5324583.pdf
"Subsequent func- tionalizations dramatically increase theDFofTRGO-T rz from 1:50to1:25after three runs(TableS2).TheDFvalues of TRGO-T rz1,TRGO-T rz2,andTRGO-T rz3that were calcu- lated onthebasis ofmass loss inthethermogravimetric analysis (TGA) diagrams at450 88Careingood agreement with theobtained elemental analysis results (TableS2and[*]A.Faghani, I.S.Donskyi, B.Ziem, Prof. Dr.R.Haag, Prof. Dr.M.Adeli Institut f/C252rChemie undBiochemie FreieUniversit /C228tBerlin Takustrasse 3,14195 Berlin (Germany) and Department ofChemist ry,Faculty ofScience Lorestan Universi ty,Khorram Abad (Iran) E-mail :haag@chemie .fu-berlin .de aadeli@fu-b erlin.de M.FardinGholami, Prof. J.P.Rabe Department ofPhysics &IRIS Adlershof Humbol dtUniversi t/C228tzuBerlin Newtonstr asse 15,12489 Berlin (Germany ) I.S.Donskyi, A.Lippitz, Dr.W.E.S.Unger BAM—F ederal Institute forMaterial Science andTesting Division ofSurface Analysis andInterfaci alChemist ry Unter denEichen 44–46, 12205 Berlin (Germa ny) Dr.C.Bçttcher Forschung szentrum f/C252rElektronen mikroskopie andCoreFacility BioSupraMol ,Institut f/C252rChemie undBiochemie FreieUniversit /C228tBerlin, Fabeckstrasse 36a, 14195 Berlin (Germany ) Supportin ginformation forthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016124 22.",Non-OADS,/arxiv_data1/oa_pdf/0d/31/ANIE-56-2675.PMC5324584.pdf
Available at http://www.rijksoverheid.,Non-OADS,/arxiv_data1/oa_pdf/9d/1c/EJP-21-520.PMC5324589.pdf
Available at: http://www.scm.com.,Non-OADS,/arxiv_data1/oa_pdf/ea/72/JCC-37-83.PMC5324590.pdf
"It was developed using Survey Monkey (http://www.sur- veymonkey.com) and included four sections; demo-graphics, stress, satisfaction and burnout.",OADS,/arxiv_data1/oa_pdf/58/99/JMIRO-61-146.PMC5324591.pdf
2012. http://www.who.int/mediacentre/ factsheets/fs318/en/.,Non-OADS,/arxiv_data1/oa_pdf/76/59/IDJ-67-59.PMC5324593.pdf
14. WHO Oral Health Country/Area Proﬁle Programme Caries Prevalence: DMFT and DMFS http://www.whocollab.od.mah.se/expl/orhdmft.html.,Non-OADS,/arxiv_data1/oa_pdf/76/59/IDJ-67-59.PMC5324593.pdf
Suppor ting informat ionforthisarticle isavailable ontheWWW under http://dx.doi.org /10.1002/anie.,Non-OADS,/arxiv_data1/oa_pdf/2d/fe/ANIE-54-5369.PMC5324602.pdf
jp Supportin ginforma tion andtheORCID identifica tion number(s) for theauthor(s) ofthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016119 74.,Non-OADS,/arxiv_data1/oa_pdf/e7/b2/ANIE-56-2482.PMC5324605.pdf
Available from:http://globocan.iarc.fr/Pages/fact_sheets_popula-tion.aspx.,Non-OADS,/arxiv_data1/oa_pdf/16/b5/BJH-176-743.PMC5324608.pdf
Available from: https://Ctep.cancer.,Non-OADS,/arxiv_data1/oa_pdf/16/b5/BJH-176-743.PMC5324608.pdf
Available from: https://www.nccn.org/professionals/physician_gls/ PDF/myeloma.pdf.,Non-OADS,/arxiv_data1/oa_pdf/16/b5/BJH-176-743.PMC5324608.pdf
"[*]Dr.J.M.Sarria Toro,C.Garc /C237a-Mor ales, M.Raducan ,E.S.Smirnova, Prof. A.M.Echavar ren Institute ofChemical Research ofCatalonia (ICIQ) Barcelona Institute ofScience andTechnology Av.Pa/C239sosCatalans 16,43007 Tarragona (Spain) E-mail :aechavarren @iciq.es Prof. A.M.Echavar ren Departame ntdeQu/C237mica Anal/C237ticaiQu/C237mica Org/C224nica Universit atRovira iVirgili C/Marce l·liDomingo s/n, 43007 Tarragona (Spain) Supportin ginforma tion andtheORCID identifica tion number(s) for theauthor(s) ofthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016117 05.",Non-OADS,/arxiv_data1/oa_pdf/ca/73/ANIE-56-1859.PMC5324612.pdf
conscientious 3The form can be found at http://www.nevdgp.org.au/info/immunisa- tion/conscientious-objection-form.pdf [Accessed 10 May 2016].,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://www.aph.gov.au/Parliamentary_Business/Bills_ Legislation/bd/bd1516a/6bd036.,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://www.polioeradication.org/Data- andmonitoring/Poliothisweek/Poliocasesworldwide.aspx [Accessed 1 Feb 2016].6T.,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://www.ohchr.org/Documents/Publica- tions/ConscientiousObjection_en.pdf [accessed 2 February 2016].,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://cpti.ws/cpti_docs/brett/ recruitment_and_co_A4.pdf [Accessed 1 February 2016]; United Nations.,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
"Advisory Committee on Conscientious Objectors, https://www.gov.uk/ government/organisations/advisory-committee-on-conscientious-objec- tors [Accessed 1 February 2016].",Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://academic.eb.com/EBchecked/topic/462675/plague [Accessed 1 February 2016].,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at http://www.ncsl.org/research/health/school-immuni- zation-exemption-state-laws.aspx [Accessed 2 February 2016].,Non-OADS,/arxiv_data1/oa_pdf/40/1d/BIOE-31-155.PMC5324623.pdf
Available at: http://grants.nih.gov/grants/guide/pa-files/PA-07-288.html.,Non-OADS,/arxiv_data1/oa_pdf/85/91/LIO2-2-04.PMC5324625.pdf
Available at: http://www.foodallergyawareness.org/(accessed 5 February 2016).,Non-OADS,/arxiv_data1/oa_pdf/d1/14/APT-45-777.PMC5324627.pdf
http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedi-calProducts/UCM135941.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/bd/NER-20-177.PMC5324639.pdf
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm375804.htm.,Non-OADS,/arxiv_data1/oa_pdf/cd/bd/NER-20-177.PMC5324639.pdf
"https://en.wikipedia.org/wiki/ Failure_mode_and_effects_analysis Accessed June 3, 2016.",Non-OADS,/arxiv_data1/oa_pdf/cd/bd/NER-20-177.PMC5324639.pdf
"https://www.ismp.org/newsletters/acutecare/articles/20040115.asp Accessed June 3, 2016.4.",Non-OADS,/arxiv_data1/oa_pdf/cd/bd/NER-20-177.PMC5324639.pdf
"17. http://www.drugs.com/drug-interactions/ciprofloxacin- index.html?filter =3&generic_only.AccessedMay18,2016.",Non-OADS,/arxiv_data1/oa_pdf/75/9e/JCPH-57-328.PMC5324641.pdf
"The objective function was minimized using the sto- chastic self organizing migrating algorithm (SOMA,http://www.ft.utb.cz/people/zelinka/soma/).",OADS,/arxiv_data1/oa_pdf/73/a1/MRM-77-1104.PMC5324642.pdf
"Variants iden- tiﬁed in this study have been submitted to the Alzheimer Disease & Frontotemporal Dementia Mutation Database (AD&FTDMDB, http://www.molgen.vib-ua.be/FTDMutations) and Locus Speciﬁc Database [Cruts et al., 2012].",OADS,/arxiv_data1/oa_pdf/f7/68/HUMU-38-297.PMC5324646.pdf
Acknowledgments The authors thank the personnel of the Neuromics Support Facility of the VIB Center for Molecular Neurology (http://www.vibgeneticservicefacility .be) and the Antwerp Biobank of the Institute Born-Bunge for their expert support.,Non-OADS,/arxiv_data1/oa_pdf/f7/68/HUMU-38-297.PMC5324646.pdf
"In order to quantitatively compare our results with pre- vious ﬁndings using standard BOLD fMRI, we computed the correlation between the BOLD unthresholded voice selective map obtained in this study and that made avail- able at http://neurovault.org/collections/33/ by Pernetet al.",OADS,/arxiv_data1/oa_pdf/64/8e/HBM-38-1140.PMC5324648.pdf
Available: http://www.fsis.usda.gov/wps/ portal/fsis/topics/regulatory-compliance/listeria[7October2015].,Non-OADS,/arxiv_data1/oa_pdf/75/4a/JSFA-97-1042.PMC5324655.pdf
Correspondence to: E. Heinzle Received 10 February 2016; Revision received 16 August 2016; Accepted 2 November2016Accepted manuscript online 2 November 2016; Article ﬁrst published online 21 November 2016 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/bit.26214/abstract).DOI 10.1002/bit.26214ARTICLE /C2232016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/14/BIT-114-785.PMC5324675.pdf
"Finally, we sys- temically and quantitatively analyze the data of the Allen Mouse Brain Connectivity Atlas (http://connectivity.brain- map.org/, RRID:SCR_008848), which contains injections covering the entire cortex and the claustrum from both w i l d - t y p ea n dC r ed r i v e rm i c ew i t ht h eG F P - e x p r e s s i n g adeno-associated virus (AAV) tracer (Harris et al., 2012;Oh et al., 2014).",Non-OADS,/arxiv_data1/oa_pdf/01/93/CNE-525-1317.PMC5324679.pdf
Histology and immunohistochemistry A detailed description of the histology and double immunohistochemistry (IHC) procedures can be found at the Allen Mouse Brain Connectivity Atlas documenta- tion page (http://help.brain-map.org//display/mouse- connectivity/Documentation).,Non-OADS,/arxiv_data1/oa_pdf/01/93/CNE-525-1317.PMC5324679.pdf
Tracer injection and brain imaging A detailed description for tracer injection and brain imaging can be found at the Allen Mouse Brain Connec- tivity Atlas documentation page (http://help.brain-map.,Non-OADS,/arxiv_data1/oa_pdf/01/93/CNE-525-1317.PMC5324679.pdf
"The nomenclature for cortical and subcortical structures was adapted from the Allen reference atlas (Dong, 2008), with modifications to higher visual areas (http://help.brain-map.org/down- load/attachments/2818171/MouseCCF.pdf; see also Abbreviations list).",Non-OADS,/arxiv_data1/oa_pdf/01/93/CNE-525-1317.PMC5324679.pdf
"DATA ACCESSIBILITY All connectivity, ISH, and reference data for the Allen Mouse Brain Connectivity Atlas are available through the data portal (http://mouse.brain-map.org).",OADS,/arxiv_data1/oa_pdf/01/93/CNE-525-1317.PMC5324679.pdf
Avail- able at: http://seer.cancer.gov/csr/ 1975_2013/ 2.,Non-OADS,/arxiv_data1/oa_pdf/16/fb/IJC-140-1609.PMC5324681.pdf
http://www.genet.sickkids.on.,Non-OADS,/arxiv_data1/oa_pdf/bf/8e/PPUL-52-E11.PMC5324682.pdf
Available: http://www.legislation.gov.uk/ ukpga/2005/9/contents.,Non-OADS,/arxiv_data1/oa_pdf/70/83/GPS-32-297.PMC5324689.pdf
http://www.ibtphem.org.uk (accessed 03/11/ 2016).,Non-OADS,/arxiv_data1/oa_pdf/ba/99/ANAE-72-379.PMC5324693.pdf
"London: Intensive Care Society, 2011. http://www.ics.ac.uk/ ICS/guidelines-and-standards.aspx (accessed 07/11/2016).",Non-OADS,/arxiv_data1/oa_pdf/ba/99/ANAE-72-379.PMC5324693.pdf
"Rec- ommendations for the safe transfer of patients with brain injury, 2006. https://www.aagbi.org/sites/default/files/braininjury.pdf (accessed 15/10/2015).",Non-OADS,/arxiv_data1/oa_pdf/ba/99/ANAE-72-379.PMC5324693.pdf
2002. http://www.near.edu/DataEntryForm2.PDF (accessed 03/09/2015).,OADS,/arxiv_data1/oa_pdf/ba/99/ANAE-72-379.PMC5324693.pdf
Emergency Medicine International 2012: 161630. http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/ba/99/ANAE-72-379.PMC5324693.pdf
"[a]Dr.V.Papaefthim iou,Dr.F.Paloukis ,Dr.T.Dintzer ,Dr.S.Zafeirato s Institut deChim ieetProc/C216d/C216spourl’Energie l’Envir onnem entetlaSant /C216(ICPEES), ECPM UMR 7515 CNRS-Univer sit/C216deStrasbourg 25,rueBecq uerel,67087 Strasb ourg Cede x02(France) E-mail :spiros .zafeiratos@ unistra.fr [b]D.K.Niakola s FORTH/ICE -HT 26504 Rion, Patra s(Greece ) Supp orting Infor mati onand theORCID identificati onnumber (s)forthe autho r(s)ofthisarticle canbefoundunde rhttp://dx.doi.org/ 10.1002 / cphc.2 01600948.",Non-OADS,/arxiv_data1/oa_pdf/13/e5/CPHC-18-164.PMC5324694.pdf
http://resus.org.,Non-OADS,/arxiv_data1/oa_pdf/88/b0/ANAE-72-289.PMC5324704.pdf
http://anzaag.com/Mgmt Resources.,Non-OADS,/arxiv_data1/oa_pdf/88/b0/ANAE-72-289.PMC5324704.pdf
"2, 188 –196 http://dx.doi.org/10.1080/15476286.2016.1270004",Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
ORCID Jagpreet S. Nanda http://orcid.org/0000-0001-5387-8683 Sarah E. Walker http://orcid.org/0000-0002-9983-2485 References 1.,Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
RNA 2002; 8:382-97; PMID:12008673; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Methods Enzymol 2007; 430:111-45; PMID:17913637; http://dx.doi.org/10.1016/S0076-6879(07)30006-2 3.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
RNA 2011; 17:925-32; PMID:21415142;http://dx.doi.org/10.1261/rna.2623711 4.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Arch Biochem Bio-phys 1956; 61:220-30; PMID:13292958; http://dx.doi.org/10.1016/0003-9861(56)90334-4 5.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Cold Spring Harb PerspectBiol 2012; 4:a011544-a; PMID:22815232; http://dx.doi.org/10.1101/ cshperspect.a011544 6.,Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Science 2013; 342:1240585-; PMID:24200810; http://dx.doi.org/10.1126/science.1240585 7.,Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Science 2010; 330:1203-9; PMID:21109664;http://dx.doi.org/10.1126/science.1194294 8.,Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
"RNA Biol 2010; 7:354-60; PMID:20404492; http://dx.doi.org/10.4161/rna.7.3.11648 1 0 .T r a u n e rA ,B e n n e t tM H ,W i l l i a m sH D .I s o l a t i o no fB a c t e r i a l Ribosomes with Monolith Chromatography.",Non-OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
PLoS ONE 2011; 6:e16273; PMID:21326610; http://dx.doi.org/10.1371/journal.pone.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
RNA 2007; 14:188-95; PMID:17998293; http://dx.doi.org/10.1261/ rna.692408 12.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Methods 2009; 48:306-10; PMID:19398006; http://dx.doi.org/10.1016/j.ymeth.2009.04.003 13.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
RNA 2013; 19:1449-59; PMID:23929938; http://dx.doi.org/ 10.1261/rna.038117.113 14.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
J Chromatogr A 2007; 1144:2-13; PMID:17174320; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
J Biol Chem 2006; 281:8469-75; PMID:16461768; http://dx.doi.org/10.1074/jbc.M600210200RNA BIOLOGY 195,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
J Biol Chem 2013; 288:5316-29; PMID:23293029; http://dx.doi.org/ 10.1074/jbc.M112.440693 17.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
RNA 2012; 19:191-207; PMID:23236192; http://dx.doi.org/10.1261/rna.035881.112 18.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
J Biol Chem 2013; 289:1704-22;PMID:24285537; http://dx.doi.org/10.1074/jbc.M113.529370 19.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Methods 2008; 44:81-6; PMID:18241790; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
J Mol Biol 2009; 385:491-506; PMID:18976658; http://dx.doi.org/10.1016/j.jmb.2008.10.029 21.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
Nat Meth 2012; 9:671-5; PMID:17913637; http://dx.doi.org/10.1038/nmeth.2089196 A. M. MUNOZ ET AL.,OADS,/arxiv_data1/oa_pdf/de/8f/krnb-14-02-1270004.PMC5324736.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"4, 367 –373 http://dx.doi.org/10.1080/15384101.2016.1269044",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"J Invest Dermatol 2014; 134:867-70; PMID:24025552; http://dx.doi.org/10.1038/jid.2013.377 [8] de Gruijl FR, Sterenborg HJ, Forbes PD, Davies RE, Cole C, K e l f k e n sG ,v a nW e e l d e nH ,S l a p e rH ,v a nd e rL e u nJ C .W a v e - length dependence of skin cancer induction by ultraviolet irradi- ation of albino hairless mice.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Pharm World Sci 2006; 28:159-62; http://dx.doi.org/10.1007/s11096-006-9030-x [10] Neudorfer M, Merimsky O, Lazar M, Geyer O. Cisplatin and doxoru- bicin for invasive basal cell carcinoma of the eyelids.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"J Invest Dermatol 2006; 126:1251- 5; PMID:16557235; http://dx.doi.org/10.1038/sj.jid.5700264 [12] Hunter RD, Pereira DT, Pointon RC.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"J Med Imaging Radiat Oncol 2008; 52:382-93;PMID:18811764; http://dx.doi.org/10.1111/j.1440-1673.2008.01974.x [15] Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Endocrinology 2005; 146:2864-71; PMID:15802494; http://dx.doi.org/10.1210/en.2005-0102 [19] Cody V, Davis PJ, Davis FB.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Steroids 2007; 72:165-70; PMID:17166537; http://dx.doi.org/10.1016/j.steroids.2006.11.008 [20] Hercbergs A, Davis PJ, Davis FB, Ciesielski MJ, Leith JT.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Cell Cycle 2009; 8:2586-91; PMID:19597333; http://dx.doi.org/10.4161/cc.8.16.9328 [21] Hercbergs AH, Lin HY, Davis FB, Davis PJ, Leith JT.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Cell Cycle2011; 10:352-7; PMID:21212737; http://dx.doi.org/10.4161/ cc.10.2.14641 [22] Cucinotta FA, Pluth JM, Anderson JA, Harper JV, O ’Neill P. Bio- chemical kinetics model of DSB repair and induction of gamma-H2AX foci by non-homologous end joining.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Radiat Res 2008; 169:214-22; PMID:18220463; http://dx.doi.org/10.1667/RR1035.1 [23] Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y. GammaH2AX and cancer.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Nat Rev Cancer2008; 8:957-67; PMID:19005492; http://dx.doi.org/10.1038/nrc2523 [24] Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, Barton O, Jeggo PA. gammaH2AX foci analysis for monitoringDNA double-strand break repair: strengths, limitations andoptimization.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Radiat Res 2013; 179:540-8;PMID:23560631; http://dx.doi.org/10.1667/RR3124.1 [26] Taleei R, Nikjoo H. The non-homologous end-joining (NHEJ) path- way for the repair of DNA double-strand breaks: I.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
Radiat Res 2013; 179:530-9; PMID:23560635; http://dx.doi.org/10.1667/RR3123.1 [27] Ryan JM.,OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Stem Cells 2009; 27:1847-57; PMID:19544431; http://dx.doi.org/10.1002/stem.128 [29] Kuhn H, Kopff C, Konrad J, Riedel A, Gessner C, Wirtz H. In ﬂuence of basic ﬁbroblast growth factor on the proliferation of non-small cell lung cancer cell lines.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Lung Cancer 2004; 44:167-74; PMID:15084381; http://dx.doi.org/10.1016/j.lungcan.2003.11.005 [30] Imokawa G, Kobayasi T, Miyagishi M. Intracellular signaling mecha- nisms leading to synergistic effects of endothelin-1 and stem cell fac-tor on proliferation of cultured human melanocytes.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"J Biol Chem 2000; 275:33321-8; PMID:10921922; http://dx.doi.org/10.1074/jbc.M004346200 [31] Brenner DJ, Hlatky LR, Hahnfeldt PJ, Huang Y, Sachs RK.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"PLoS Comput Biol 2011; 7:e1001073;PMID:21304935; http://dx.doi.org/10.1371/journal.pcbi.1001073 [35] Malaise EP, Fertil B, Deschavanne PJ, Chavaudra N, Brock WA.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"BMC Genomics 2012; 13:348; PMID:22846430;http://dx.doi.org/10.1186/1471-2164-13-348 [40] Saczko J, Gebarowska E, Zabel M. Immunocytochemical evaluation of reorganisation of keratinocyte cytoskeleton induced by change inCa2Cconcentration in culture medium.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Clin Cancer Res 2008; 14:5022-32; PMID:18698020; http://dx.doi.org/10.1158/1078-0432.CCR-07-4717 [42] Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Biochem Pharmacol 2007; 74:1702-12; PMID:17904532; http://dx.doi.org/10.1016/j.bcp.2007.08.025 [43] Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Membrane recep- tor for thyroid hormone: physiologic and pharmacologic implications.Annu Rev Pharmacol Toxicol 2011; 51:99-115; PMID:20868274; http://dx.doi.org/10.1146/annurev-pharmtox-010510-100512 [44] Davis PJ, Mousa SA, Cody V, Tang HY, Lin HY.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Horm Cancer 2013; 4:335-42; http://dx.doi.org/ 10.1007/s12672-013-0156-8 [45] Davis PJ, Goglia F, Leonard JL.",Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Nat Rev Endocrinol 2016; 12:111-21; PMID:26668118; http://dx.doi.org/10.1038/nrendo.2015.205 [46] Jane EP, Pollack IF.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells.Eur J Cancer 2010; 46:412-9; PMID:19913408; http://dx.doi.org/ 10.1016/j.ejca.2009.10.014[47] Kiefer J.,Non-OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"J Radiat Res 2013; 54:1161-3; PMID:23732771; http://dx.doi.org/10.1093/jrr/ rrt075 [49] Chadwick KH, Leenhouts HP.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Med Phys 1998; 25:2071-3; PMID:9800717; http://dx.doi.org/10.1118/1.598431 [51] Ohnishi T, Mori E, Takahashi A. DNA double-strand breaks: Their production, recognition, and repair in eukaryotes.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Mutat Res 2009; 669:8-12; PMID:19576233; http://dx.doi.org/10.1016/j.mrfmmm.2009.06.010 [52] Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Biochem Cell Biol 2003; 81:123-9;PMID:12897845; http://dx.doi.org/10.1139/o03-042 [53] Boker W, Iliakis G. Computational methods for analysis of foci: Vali- dation for radiation-induced gamma-H2AX foci in human cells.",OADS,/arxiv_data1/oa_pdf/5b/e2/kccy-16-04-1269044.PMC5324738.pdf
"Published with license by Taylor & Francis Group, LLC © Emiko Noro, Masaru Mori, Gakuto Makino, Yuki Takai, Sumiko Ohnuma, Asako Sato, Masaru Tomita, K enji Nakahigashi, and Akio Kanai This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
"2, 206 –218 http://dx.doi.org/10.1080/15476286.2016.1270001",Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
"The MS/ MS scan was performed under the following conditions: iso-lation width, 2; normalized collision energy, 35 V; activationQ, 0.25; activation time, 30 s. The mass spectrum data generated with nanoLC/ESI-MS/ MS were screened against UniProtKB/Swiss-Prot entries(http://www.uniprot.org/ ) with the Mascot program (Matrix Science, UK), under the following conditions: taxonomy, E. coli K-12; peptide ion tolerance, 3 ppm; product ion tolerance, 0.8 Da; enzyme, trypsin; missed coverage, 2; ﬁxed modi ﬁcation, carbamidomethylation at Cys; variable modi ﬁcation, oxidation at Met.",OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
The target sites locatedwithin the mRNAs were selected based on information from theBioCyc Database Collection ( http://biocyc.org/ ).,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
ORCID Masaru Mori http://orcid.org/0000-0002-7687-7429 Akio Kanai http://orcid.org/0000-0002-6362-2419 References 1.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Adv Genet 2015; 90:133-208; PMID:26296935; http://dx.doi.org/10.1016/bs.adgen.2015.05.001 2.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Trends Genet 2015; 31:613-26; PMID:26453491; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nat Rev Genet 2016; 17:47-62; PMID:26666209; http://dx.doi.org/10.1038/nrg.2015.10 4.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Mol Cell 2011; 43:880-91; PMID:21925377; http://dx.doi.org/10.1016/j.molcel.2011.08.022 5.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
FEMS Microbiol Rev2015; 39:316-30; PMID:25934118; http://dx.doi.org/10.1093/femsre/ fuv007 6.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Genome Res 2011; 21:1487-97; PMID:21665928; http://dx.doi.org/10.1101/gr.119370.110 7.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
RNA Biol 2014; 11:484-93; PMID:24755959; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
BMC Genomics 2011; 12:428; PMID:21864382; http://dx.doi.org/10.1186/1471-2164-12-428 9.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Int J Med Microbiol 2013; 303:217-29;PMID:23660175; http://dx.doi.org/10.1016/j.ijmm.2013.04.002 10.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
PLoS Genet 2015; 11:e1004957; PMID:25643072; http://dx.doi.org/10.1371/journal.pgen.1004957 11.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Mol Cell 2016; 61:352-63; PMID:26805574; http://dx.doi.org/ 10.1016/j.molcel.2015.12.023 12.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Mol Microbiol 2016; 99:254-73; PMID:26411266; http://dx.doi.org/10.1111/mmi.13230 13.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
RNA Biol 2015; 12:186-96; PMID:25826569; http://dx.doi.org/10.1080/ 15476286.2015.1017211 14.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
PLoS One 2014; 9:e90763; PMID:24637842; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
RNA 2014; 20:994-1003; PMID:24865611; http://dx.doi.org/10.1261/rna.043133.113 16.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Genome Biol Evol 2012; 4:330-45; PMID:22223756; http://dx.doi.org/10.1093/gbe/evs001 17.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Trends Genet 2015; 31:150-6; PMID:25708284; http://dx.doi.org/10.1016/j.tig.2015.01.005 18.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Biochimie 2015; 117:100-9;PMID:26143008; http://dx.doi.org/10.1016/j.biochi.2015.06.028 19.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
RNA 2015; 21:1790-806; PMID:26276802;http://dx.doi.org/10.1261/rna.052712.115 20.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
FEBS J 2015; 282:3230-42; PMID:25661987; http://dx.doi.org/ 10.1111/febs.13226 21.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nat Rev Mol Cell Biol 2009; 10:410-22; PMID:19461664; http://dx.doi.org/10.1038/nrm2698 22.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
ACS Synth Biol 2012; 1:6-13; PMID:23651005; http://dx.doi.org/ 10.1021/sb200001q 23.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Mol Cell 2011; 43:915-26; PMID:21925380; http://dx.doi.org/10.1016/j.molcel.2011.08.023 24.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Proc Natl Acad Sci U S A 1984; 81:7525-8; PMID:6438637; http://dx.doi.org/ 10.1073/pnas.81.23.7525 26.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Cell 1984; 37:429-36; PMID:6202422; http://dx.doi.org/ 10.1016/0092-8674(84)90373-8 27.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nucleic Acids Res 2011; 39:e50; PMID:21296758; http://dx.doi.org/10.1093/nar/gkr03428.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Science 2014; 346:1258096;PMID:25430774; http://dx.doi.org/10.1126/science.1258096 29.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Mol Cell 2014; 54:234-44; PMID:24766887; http://dx.doi.org/10.1016/j.molcel.2014.03.011 30.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
J Biochem 2011; 150:289-94; PMID:21546360; http://dx.doi.org/10.1093/jb/mvr055 31.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
J Bacteriol 2001; 183:1277- 83; PMID:11157940; http://dx.doi.org/10.1128/JB.183.4.1277-1283.2001 32.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nucleic Acids Res 2014; 42: W124-9; PMID:24753424; http://dx.doi.org/10.1093/nar/gku317 33.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Biosci Rep 2014; 34:e00166; PMID:25299745; http://dx.doi.org/10.1042/BSR20140113 36.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nucleic Acids Res 2003; 31:1813-20;PMID:12654996; http://dx.doi.org/10.1093/nar/gkg297 37.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Nucleic Acids Res 2010; 38:6637-51;PMID:20525796; http://dx.doi.org/10.1093/nar/gkq454 38.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
J Biol Chem 2005; 280:7901-8;PMID:15618228; http://dx.doi.org/10.1074/jbc.M413071200 39.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
J Bacteriol 2013; 195:4804-15; PMID:23873911; http://dx.doi.org/10.1128/JB.00722-13 40.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
J Bacteriol 2001; 183:1997-2005; PMID:11222598; http://dx.doi.org/10.1128/JB.183.6.1997-2005.2001 42.,Non-OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
Methods Mol Biol 2012; 905:235-44; PMID:22736008; http://dx.doi.org/10.1007/978-1-61779- 949-5_15218 E. NORO ET AL.,OADS,/arxiv_data1/oa_pdf/57/3d/krnb-14-02-1270001.PMC5324740.pdf
"2, 245 –258 http://dx.doi.org/10.1080/15476286.2016.1270005",Non-OADS,/arxiv_data1/oa_pdf/46/93/krnb-14-02-1270005.PMC5324750.pdf
ORCID Camelia Quek http://orcid.org/0000-0002-1244-961X Chol-Hee Jung http://orcid.org/0000-0002-2992-3162 Andrew F. Hill http://orcid.org/0000-0001-5581-2354 References 1.,Non-OADS,/arxiv_data1/oa_pdf/46/93/krnb-14-02-1270005.PMC5324750.pdf
Nat Rev Genet 2001; 2:919-929; PMID:11733745; http://dx.doi.org/ 10.1038/35103511 2.,Non-OADS,/arxiv_data1/oa_pdf/46/93/krnb-14-02-1270005.PMC5324750.pdf
Hum Mol Genet 2006; 15 (Spec No 1):R17-29; PMID:16651366; http://dx.doi.org/10.1093/hmg/ ddl046 3.,OADS,/arxiv_data1/oa_pdf/46/93/krnb-14-02-1270005.PMC5324750.pdf
